{"pages":[{"Granule":{"Synonym":"Granule Soma Quality","SuperCategory":"Soma Shape","Id":"nlx_414","Definition":" Small, generally round or drop-like shape that is densely packed together with many other cells"}},{"Granule Cell Morphology":{"Comment":"small numerous cell","SuperCategory":"Cell Morphological Quality","Id":"sao6934064108"}},{"Graph":{"CurationStatus":"uncurated","SuperCategory":"Image","Id":"IAO_0000038","Keywords":"Resource:CINERGI","DefiningCitation":"http://purl.obolibrary.org/obo/IAO_0000038","Definition":"A diagram that presents one or more tuples of information by mapping those tuples in to a two dimensional space in a non arbitrary way."}},{"Graph resource":{"Synonym":"Chart resource","CurationStatus":"uncurated","SuperCategory":"Image","Id":"nlx_157905","Definition":"A resource that is a diagram that presents one or more tuples of information by mapping those tuples in to a two dimensional space in a non arbitrary way. (Adapted from IAO, IAO_0000038)"}},{"Graphic Annotation Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0001","SuperCategory":"DICOM term","Id":"nlx_150068","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A sequence of Items each of which represents a group of annotations composed of graphics or text or both. One or more Items shall be present."}},{"Graphic Annotation Units":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0005","SuperCategory":"DICOM term","Id":"nlx_150069","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Units of measure for the axes of the graphic annotation."}},{"Graphic Coordinates Data Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0318","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150070","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"TBD."}},{"Graphic Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0022","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150071","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FL","Definition":"Coordinates that specify this graphic annotation."}},{"Graphic Dimensions":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0020","SuperCategory":"DICOM term","Id":"nlx_150072","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"The dimensions of the graphic."}},{"Graphic Filled":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0024","SuperCategory":"DICOM term","Id":"nlx_150073","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Whether or not the closed graphics element is displayed as filled (in some unspecified manner that shall be distinguishable from an outline) or as an outline. "}},{"Graphic Layer":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0002","SuperCategory":"DICOM term","Id":"nlx_150074","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The layer defined in the Graphic Layer Module in which the graphics or text is to be rendered."}},{"Graphic Layer Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0068","SuperCategory":"DICOM term","Id":"nlx_150075","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"A free text description of the contents of this layer."}},{"Graphic Layer Order":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0062","SuperCategory":"DICOM term","Id":"nlx_150076","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"An integer indicating the order in which it is recommended that the layer be rendered, if the display is capable of distinguishing. Lower numbered layers are to be rendered first."}},{"Graphic Layer Recommended Display Grayscale Value":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0066","SuperCategory":"DICOM term","Id":"nlx_150077","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"A default single gray unsigned value in which it is recommended that the layer be rendered on a monochrome display. The units are specified in P-Values from a minimum of 0000H (black) up to a maximum of FFFFH (white)."}},{"Graphic Layer Recommended Display RGB Value":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0067","SuperCategory":"DICOM term","Id":"nlx_150078","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"A triplet of unsigned RGB values in which it is recommended that the layer be rendered on a color display. The minimum intensity displayable is specified as 0000H0000H0000H (black) and the maximum intensity displayable as  FFFFHFFFFHFFFFH (white)."}},{"Graphic Layer Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0060","SuperCategory":"DICOM term","Id":"nlx_150079","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A sequence of Items each of which represents a single layer in which overlays, curves, graphics or text may be rendered. An Item is required for each layer referenced from the Graphic Annotation Module or the Overlay/Curve Activation Module."}},{"Graphic Object Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0009","SuperCategory":"DICOM term","Id":"nlx_150080","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that describes a graphic annotation. One or more Items may be present. Either one or both of Text Object Sequence (0070,0008) or Graphic Object Sequence (0070,0009) are required if the Sequence Item is present."}},{"Graphic Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0023","SuperCategory":"DICOM term","Id":"nlx_150081","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The shape of graphic that is to be drawn."}},{"Graphical pipeline construction software":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Workflow software","Id":"birnlex_2322"}},{"Grasping task":{"Created":"4/27/2011 15:34","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00750","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Grasping_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145972","Definition":"Subjects grasped or gripped a presented stimulus with their hand or mimicked grasping one that was not physically presented (i.e., was imaginary or presented as a picture or video)."}},{"Gravity sensitive Johnston organ neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-11-03T11:46:28Z","Synonym":"gravity sensitive Johnston''s organ neuron","Contributor":"sr544","SuperCategory":"Johnston organ neuron tonically activated by arista deflection","Comment":["This neuron remains active as long as aristal deflection is maintained","as determined electrophysiologically and with intracellular calcium sensors (Kamikouchi et al.","2009). Evidence for role in gravitaxis behaviour comes from silencing of subsets of JO neurons using targeted expression of tetanus toxin (Kamikouchi et al."],"Id":"nlx_148422","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100003","Definition":"Johnston's organ neuron (JON) that is tonically activated by aristal deflection and is necessary for normal gravitaxis behaviour. These neurons form a broad 'ring' in the medial and outer layers of the JON array (Kamikouchi et al., 2009)."}},{"Gravity-driven liquid chromotography instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Liquid chromotography instrument","Id":"birnlex_2403"}},{"Gray hermit crab":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998259","SuperCategory":"Pagurus","Id":"birnlex_576"}},{"Gray Lookup Table Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1200","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150082","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":["US, SS"],"Definition":"TBD (retired)."}},{"Gray Lookup Table Descriptor":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1100","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150083","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US or SS","Definition":"TBD (retired)."}},{"Gray matter":{"CurationStatus":"uncurated","SuperCategory":"Regional part of nervous system","Id":"UBERON:0002020","Definition":"Constitutional part of central nervous system characterized by high concentrations of cell bodies and/or processes, giving the structure a gray appearance in gross preparations."}},{"Gray oral reading test - 4":{"Created":"5/16/2011 11:23","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00828","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Gray_oral_reading_test_-_4","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146050","Definition":"measures growth in oral reading and aids in the diagnosis of oral reading difficulties. Five scores provide information on oral reading skills in terms of: Rate, accuracy, fluency, comprehension, overall reading ability, and comprehension. The test consists of two parallel forms, each containing 14 developmentally sequenced reading passages with five comprehension questions following each passage."}},{"Gray Scale":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1080","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150084","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Greasy":{"SuperCategory":"Coating","Id":"PATO_0001606"}},{"Great commissural interneuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-01-06T06:53:45Z","SuperCategory":"Interneuron (FBbt Term)","Id":"nlx_148108","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007407","Fasciculates_with":"great commissure","Definition":"Any interneuron (FBbt_00005125) that fasciculates with some great commissure (FBbt_00007080)."}},{"Greater bulldog bat":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1043149","SuperCategory":"Noctilio","Id":"birnlex_321"}},{"Greater horseshoe bat":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1021558","SuperCategory":"Rhinolophus","Id":"birnlex_277"}},{"Greek General Secretariat of Research and Technology":{"Synonym":["General Secretariat for Research and Technology (GSRT)"],"CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_151781","DefiningCitation":"http://www.startupgreece.gov.gr/content/general-secretariat-research-and-technology-gsrt","Abbrev":"GSRT"}},{"Green":{"SuperCategory":"Color","Id":"PATO_0000320","Definition":"A color hue with medium-wavelength of that portion of the visible spectrum lying between yellow and blue, evoked in the human observer by radiant energy with wavelengths of approximately 490 to 570 nanometers."}},{"Green fluorescent protein":{"CurationStatus":"uncurated","SuperCategory":"Fluorescent protein","Id":"nlx_mol_20090609","Abbrev":"GFP","Definition":"A naturally occuring fluorescent protein of 238 amino acids (26.9 kDa), originally isolated from the jellyfish Aequorea victoria that fluoresces green when exposed to blue light.  The GFP from A. victoria has a major excitation peak at a wavelength of 395 nm and a minor one at 475 nm. Its emission peak is at 509 nm which is in the lower green portion of the visible spectrum. The GFP from the sea pansy (Renilla reniformis) has a single major excitation peak at 498 nm. In cell and molecular biology, the GFP gene is frequently used as a reporter of expression. In modified forms it has been used to make biosensors, and many animals have been created that express GFP as a proof-of-concept that a gene can be expressed throughout a given organism. (Adapted from Wikipedia)"}},{"Green Palette Color Lookup Table Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1202","SuperCategory":"DICOM term","Id":"nlx_150085","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"OW","Definition":"Data Green Palette Color Lookup Table Data. Required if Photometric Interpretation (0028,0004) has a value of PALETTE COLOR or Pixel Presentation (0008,9205) at the image level equals COLOR or MIXED."}},{"Green Palette Color Lookup Table Descriptor":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1102","SuperCategory":"DICOM term","Id":"nlx_150086","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US or SS","Definition":"Specifies the format of the Green Palette Color Lookup Table Data (0028,1202) Required if Photometric Interpretation (0028,0004) has a value of PALETTE COLOR or Pixel Presentation (0008,9205) at the image level equals COLOR or MIXED."}},{"Gremicambarus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1686425","SuperCategory":"Orconectes","Id":"birnlex_483"}},{"Grepafloxacin":{"RelatedTo":["DNA gyrase subunit A"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00365","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00365","Definition":"Grepafloxacin hydrochloride (Raxar, Glaxo Wellcome) is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn in the United States due to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death. (Wikipedia) Pharmacology: Grepafloxacin has in vitro activity against a wide range of gram-positive and gram-negative aerobic microorganisms, as well as some atypical microorganisms. Mechanism of action: Grepafloxacin exerts its antibacterial activity by inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, essential enzymes for duplication, transcription, and repair of bacterial DNA. Drug type: Approved. Small Molecule. Withdrawn. Drug category: Anti-Bacterial Agents. Anti-Infectives. Antibiotics. Quinolones"}},{"Grey":{"SuperCategory":"Color","Id":"PATO_0000950","Definition":"A color between white and black colors."}},{"Grid":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1166","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150087","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Identify the grid. Only a single value shall be present."}},{"Grid Absorbing Material":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_7040","SuperCategory":"DICOM term","Id":"nlx_150088","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"The X-Ray absorbing material used in the grid."}},{"Grid Aspect Ratio":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_7046","SuperCategory":"DICOM term","Id":"nlx_150089","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Ratio of the vertical spacing and horizontal spacing of the X-Ray absorbing material used in the grid. Specified by a pair of integer values where the first value is the vertical size, and the second value is the horizontal size."}},{"Grid cell":{"Located in":["Entorhinal cortex"],"CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_144209","Has role":"Principal neuron role","Species":["Mouse","Adult rat"],"SpeciesPMID":"18683845","DefinitionPMID":"15965463","Definition":"a neuron which fires when an animal is in any point of space which corresponds to a vertex of its triangular grid firing field. "}},{"GRID computing software":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Systems interoperability software","Id":"birnlex_2324"}},{"Grid electrode recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Electrical recording protocol","Id":"birnlex_2277","Has role":"Electrophysiology concept"}},{"Grid Focal Distance":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_704C","SuperCategory":"DICOM term","Id":"nlx_150090","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Focal distance in mm of a FOCUSED grid."}},{"Grid Frame Offset Vector":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3004_000C","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150091","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"An array which contains the z coordinates (in mm) of the image frames in a multiframe dose. Required if multi-frame pixel data are present and Frame Increment Pointer (0028,0009) points to Grid Frame Offset Vector (3004,000C). "}},{"Grid Period":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_7048","SuperCategory":"DICOM term","Id":"nlx_150092","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Period in mSec of reciprocation cycle. Only meaningful if Grid (0018,1166) is RECIPROCATING."}},{"Grid Pitch":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_7044","SuperCategory":"DICOM term","Id":"nlx_150093","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The pitch in mm of the X-Ray absorbing material used in the grid."}},{"Grid Spacing Material":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_7041","SuperCategory":"DICOM term","Id":"nlx_150094","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"The spacing material used in the grid."}},{"Grid Thickness":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_7042","SuperCategory":"DICOM term","Id":"nlx_150095","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The thickness in mm of the X-Ray absorbing material used in the grid."}},{"Gridded numeric data":{"CurationStatus":"uncurated","SuperCategory":"Numeric dataset","Id":"nlx_158021","Keywords":"Resource:CINERGI","Definition":"Arrays of numeric values that quantify some variable(s) such that the values can be mapped to a corresponding location in a metric space."}},{"Griseofulvin":{"RelatedTo":["Tubulin beta chain"],"Synonym":["Griseofulvina (INN-Spanish)","Griseofulvine (INN-French)","Griseofulvinum (INN-Latin)","Amudane","Biogrisin-fp","Curling factor","Delmofulvina","Fulcin","Fulcine","Fulvican grisactin","Fulvicin","Fulvicin P/G","Fulvicin U/F","Fulvicin-P/G","Fulvicin-U/F","Fulvina","Fulvinil","Fulvistatin","Fungivin","Greosin","Gresfeed","Gricin","Grifulin","Grifulvin","Grifulvin V","Gris-PEG","Grisactin","Grisactin Ultra","Griscofulvin","Grisefuline","Griseo","Griseofulvin forte","Griseofulvin-forte","Griseomix","Grisetin","Grisofulvin","Grisovin","Grisovin FP","Grizeofulvin","Grysio","Guservin","Lamoryl","Likuden","Likunden","Murfulvin","Neo-Fulcin","Neocid","Poncyl","Spirofulvin","Sporostatin","Sporostatin xan"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27779","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00400","Definition":"An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. (PubChem) Pharmacology: Griseofulvin is a mycotoxic metabolic product of Penicillium spp. It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. Mechanism of action: Griseofulvin is fungistatic, however the exact mechanism by which it inhibits the growth of dermatophytes is not clear. It is thought to inhibit fungal cell mitosis and nuclear acid synthesis. It also binds to and interferes with the function of spindle and cytoplasmic microtubules by binding to alpha and beta tubulin. Drug type: Approved. Small Molecule. Drug category: Antibacterial Agents. Antibiotics, Antifungal"}},{"Gross anatomical parts of the cerebellum":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Regional part of cerebellum","Id":"birnlex_996"}},{"Gross dissection":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Tissue dissection","Id":"birnlex_2160"}},{"Ground state depletion microscopy":{"EditorialNote":"Trying to consolidate the assay and protocol branch, as it leads to unnecessary duplication.  Decided to go with protocol","CurationStatus":"graph position temporary","SuperCategory":"Optical imaging protocol","Curator":["Maryann Martone"],"Id":"nlx_158015","Has role":"Super-resolution microscopy","Abbrev":"GSD","Definition":"A type of microscopy that uses the triplet state of a fluorophore as the off-state and the singlet state as the on-state, whereby an excitation laser is used to drive the fluorophores at the periphery of the singlet state molecule to the triplet state. (adapted from Wikipedia:  http://en.wikipedia.org/wiki/Super-resolution_microscopy#Ground_state_depletion_.28GSD.29)"}},{"Group":{"CurationStatus":"uncurated","SuperCategory":"People resource","Id":"nlx_152625","Definition":"Collection of individuals interested in or working towards a common purpose, e.g., working group, special interest group"}},{"Group author":{"Synonym":"collaborative author","Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Author","Id":"birnlex_2384"}},{"Growth Factor":{"SuperCategory":"Molecule role","Id":"sao1671627152","Definition":"Signal molecules that are involved in the control of cell growth and differentiation (MSH)."}},{"Growth hormone-releasing hormone":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5139"}},{"Growth quality of occurrent":{"Synonym":"growth timing quality","SuperCategory":"Quality of a single process","Id":"PATO_0001433","Definition":"Quality of occurrent which distributes the growth of an organism, structure, or group of organisms."}},{"Growth rate":{"SuperCategory":"Rate","Id":"PATO_0001492"}},{"Grumose foamy spheroid body":{"PMID":"PMID: 7477732","CurationStatus":"uncurated","Pages":"238-45.","PublicationDate":"1995","JournalVolume":"21","SuperCategory":"Supra Cellular Structure","PublicationName":"Neuropathol Appl Neurobiol. ","Id":"nlx_subcell_100203","JournalNumber":"3","Authors":["Arai"],"Title":"Grumose or foamy spheroid bodies involving astrocytes in the human brain","Definition":"Grumose foamy spheroid body is a spheroidal supracellular structure with a foamy appearance in haematoxylin and eosin stains that vary from 10 to 50 microns in diameter and contain amorphous debris-like material found in the brains in certain neurodegenerative conditions."}},{"Gryllidae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0018288","SuperCategory":"Grylloidea","Id":"birnlex_451"}},{"Gryllinae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1054662","SuperCategory":"Gryllidae","Id":"birnlex_333"}},{"Grylloidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1028300","SuperCategory":"Ensifera","Id":"birnlex_446"}},{"Gryllus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998383","SuperCategory":"Gryllinae","Id":"birnlex_370"}},{"Gryllus rubens":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1090190","SuperCategory":"Gryllus","Id":"birnlex_382"}},{"Gs":{"Synonym":"G-protein s","SuperCategory":"G-Protein","Id":"PR_000002202"}},{"Guaifenesin":{"Synonym":["Glycerin guaiacolate","Glycerin monoguaiacol ether","Glycero-guaiacol ether","Glycerol guaiacolate","Glyceryl guaiacol","Glyceryl guaiacol ether","Glyceryl guaiacolate","Glyceryl guaiacolate ether","Glyceryl guaiacyl ether","Glyceryl guaicolate","Glyceryl guiacolate","Guiaphenesin","Metfenossidiolo","Methoxypropanediol","Methphenoxydiol","Metossipropandiolo","o-Methoxyphenyl glyceryl ether","Actifed-C","Aeronesin","Amonidren","Amonidrin","Anti-Tuss","Aresol","Balminil Expectorant","Benylin-E","Breonesin","Bronchol","Calmipan","Calmylin Expectorant","Colrex expectorant","Cortussin","Creson","Diabetic Tussin EX","Dilyn","Dorassin","Equicol","Fenesin","Flartussin","Gaiamar","Gee-Gee","Genatuss","Glycodex","Glycotuss","Glytuss","Gnaifenesin","Guaia-rom","Guaiacol glycerin ether","Guaiacol glycerol ether","Guaiacol glyceryl ether","Guaiacolglicerinetere","Guaiacuran","Guaiacurane","Guaiacyl glyceryl ether","Guaiamar","Guaianesin","Guaicol glycerine ether","Guaicol glyceryl ether","Guaiphenesin","Guaiphenesine","Guaiphesin","Guajacol-glycerinaether","Guajacuran","Guajamar","Guanar","Guayanesin","Guiatuss","Gvaja","Halotussin","Humibid L,A","Humibid Sprinkle","Hustodil","Hustosil","Hytuss","Hytuss-2X","Mintosyl","Miocaina","Miocurin","Miorelax","Mucinex","Mucostop","Muskurelax","Myocain","Myocaine","Myorelax","Myoscain","Myoscaine","Naldecon Senior EX","Neuroton","Neurotone","Oresol","Oreson","Organidin NR","Pneumomist","Propanosedyl","Reduton","Relaxil G","Relaxyl-G","Reorganin","Resil","Respenyl","Respil","Resyl","Ritussin","Robitussin","Scot-tussin Expectorant","Sinumist-SR","Sirotol","Tenntus","Tenntuss","Tolseron","Tolyn","Touro EX","Tulyl","Tulyn"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00874","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00874","Definition":"An expectorant that also has some muscle relaxing action. It is used in many cough preparations. (PubChem) Pharmacology: Guaifenesin is an expectorant which increases the output of phlegm (sputum) and bronchial secretions by reducing adhesiveness and surface tension. The increased flow of less viscous secretions promotes ciliary action and changes a dry, unproductive cough to one that is more productive and less frequent. By reducing the viscosity and adhesiveness of secretions, guaifenesin increases the efficacy of the mucociliary mechanism in removing accumulated secretions from the upper and lower airway. Mechanism of action: Guaifenesin may act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that cause glandular exocytosis of a less viscous mucus mixture. Cough may be provoked. This combination may flush tenacious, congealed mucopurulent material from obstructed small airways and lead to a temporary improvement in dyspnea or the work of breathing. Drug type: Approved. Small Molecule. Drug category: Expectorants"}},{"Guanabenz":{"RelatedTo":"Alpha-2A adrenergic receptor","Synonym":[", GBZ","Guanabenz Acetate","Guanabenz (USAN:INN)","Guanabenz(USAN)","Guanabenzo (INN-Spanish)","Guanabenzum (INN-Latin)","Wy 8678 base"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00629","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00629","Definition":"An alpha-2 selective adrenergic agonist used as an antihypertensive agent. (PubChem) Pharmacology: Guanabenz, a centrally acting -2 adrenergic agonist, is indicated for treatment of hypertension. Mechanism of action: Guanabenz's antihypertensive effect is thought to be due to central alpha-adrenergic stimulation, which results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature in addition to a decreased systolic and diastolic blood pressure and a slight slowing of pulse rate. Chronic administration of guanabenz also causes a decrease in peripheral vascular resistance. Drug type: Approved. Small Molecule. Drug category: Adrenergic alpha-Agonists. Antihypertensive Agents. Sympatholytics"}},{"Guanadrel Sulfate":{"RelatedTo":["Alpha-2A adrenergic receptor","Alpha-2C adrenergic receptor","Sodium-dependent noradrenaline transporter","Alpha-1A adrenergic receptor","Alpha-2B adrenergic receptor","Alpha-1B adrenergic receptor"],"Synonym":["Guanadrelum (INN-Latin)","Guanadrel"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5556","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00226","Definition":"Guanadrel is a postganglionic adrenergic blocking agent. Uptake of guanadrel and storage in sympathetic neurons occurs via the norepinephrine pump or transporter. Pharmacology: High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled. Guanadrel works by controlling nerve impulses along certain nerve pathways. As a result, it relaxes the blood vessels so that blood passes through them more easily. This helps to lower blood pressure. Mechanism of action: Guanadrel is a postganglionic adrenergic blocking agent. Uptake of guanadrel and storage in sympathetic neurons occurs via the norepinephrine pump or transporter. Guanadrel slowly displaces norepinephrine from its storage in nerve endings and thereby blocks the release of norepinephrine normally produced by nerve stimulation. The reduction in neurotransmitter release in response to sympathetic nerve stimulation, as a result of catecholamine depletion, leads to reduced arteriolar vasoconstriction, especially the reflex increase in sympathetic tone that occurs with a change in position. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents"}},{"Guanethidine":{"RelatedTo":["Alpha-2A adrenergic receptor","Alpha-2C adrenergic receptor","Sodium-dependent noradrenaline transporter","Alpha-1A adrenergic receptor","Alpha-2B adrenergic receptor","Alpha-1B adrenergic receptor"],"Synonym":["Guanethidine Monosulfate","Guanethidine Sulphae","Abapresin","Apo-Guanethidine","Eutensol","Ismelin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5557","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01170","Definition":"An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. (PubChem) Pharmacology: High blood pressure can cause the heart and arteries to not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled. Guanethidine works by decreasing the heart rate and relaxing the blood vessels so that blood can flow more easily through the body, thereby reducing these risks. It is a postganglionic sympathetic nerve terminal blocker that prevents the release of norepinephrine from nerve terminals. Mechanism of action: Guanethidine acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. In contrast to ganglionic blocking agents, Guanethidine suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, Guanethidine lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more. Drug type: Approved. Small Molecule. Drug category: Adrenergic Agents. Antihypertensive Agents. Sympatholytics"}},{"Guanfacine":{"RelatedTo":["Alpha-2A adrenergic receptor"],"Synonym":["Guanfacina (INN-Spanish)","Guanfacine HCl","Guanfacine Hydrochloride","Guanfacinum (INN-Latin)","SPD 503","guanfacine","Estulic","Intuniv"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01018","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01018","Definition":"A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. (PubChem) Pharmacology: Similar to clonidine, guanfacine is a centrally-acting, alpha(2)-adrenergic receptor agonist used alone or in combination with other drugs for the treatment of hypertension. Mechanism of action: Guanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic nervous system outflow, reduction of peripheral and renal vascular resistance, and lowering of blood pressure and heart rate. Drug type: Approved. Investigational. Small Molecule. Drug category: Adrenergic alpha-Agonists. Antihypertensive Agents. Sympatholytics"}},{"Guanidine":{"RelatedTo":["Aldehyde dehydrogenase","mitochondrial","DNA","Lysozyme","Ribonuclease pancreatic","Discs large homolog 4","Argininosuccinate synthase","Guanidinoacetate N-methyltransferase","Divalent-cation tolerance protein cutA"],"Synonym":["Aminomethanamidine","Carbamamidine","Carbamidine","Guanidin","Guanidine Hydrochloride","Guanidinium Chloride","Guanidinium Sulfate","Imidourea","Iminourea"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:42820","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00536","Definition":"A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC. (PubChem) Pharmacology: Guanidine apparently acts by enhancing the release of acetylcholine following a nerve impulse. It also appears to slow the rates of depolarization and repolarization of muscle cell membranes. Mechanism of action: Not Available Drug type: Approved. Small Molecule. Drug category: Parasympathomimetics"}},{"Guanosine":{"Created":"2007-09-19","SuperCategory":"Purine Nucleoside","Id":"nifext_5186"}},{"Guanosine 3',5'-cyclic monophosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5200","DefiningCitation":["Thomas M. Jessell","Eric R. Kandel","James H. Schwartz","Essentials of Neuroscience and Behavior,Appleton & Lange","Norwalk","CT","1995"],"Definition":" A nucleotide synthesized by the enzyme guanylyl cyclase. This nucleotide acts to modify proteins in two ways. By binding directly to proteins such as cGMP-sensitive cation channels in the retina, and by protein phosphorylation through the cGMP-dependent protein kinase."}},{"Guanosine 5'-diphosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5201"}},{"Guanosine 5'-monophosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5199"}},{"Guanosine 5'-triphosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5202"}},{"Guenon":{"Created":"2006-10-07","EditorialNote":"This class is not intended to present a normative,          comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of          the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","CurationStatus":"uncurated","Umlscui":"C0007753","SuperCategory":"Cercopithecinae","Id":"birnlex_129"}},{"Guillain-Barre Syndrome":{"Synonym":["Acute Inflammatory Polyradiculoneuropathy","Guillaine-Barre Syndrome","Acute Autoimmune Neuropathy","Acute Inflammatory Polyneuropathy","Landry-Guillain-Barre Syndrome"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Polyradiculoneuropathy","Id":"birnlex_12554","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur (MeSH)."}},{"Guinea pig":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":["Cavia cobaya"],"Created":"2007-08-06","CurationStatus":"raw_import","Umlscui":"C0999699","SuperCategory":"Cavia","Id":"birnlex_297"}},{"Gustatory areas layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Gustatory areas  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153638","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Gustatory areas layer 4 of ABA 2009":{"PartiallyOverlapsWith":"Gustatory areas  layer 4","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152982","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Gustatory areas layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Gustatory areas  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152903","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Gustatory areas layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Gustatory areas  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153544","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Gustatory areas layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Gustatory areas  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153584","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Gustatory areas of ABA 2009":{"PartiallyOverlapsWith":"Gustatory areas","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153282","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Gustatory epithelium (nifext 12)":{"Created":"2007-09-05","CurationStatus":"pending final vetting","SuperCategory":"Regional part of tongue","Id":"nifext_12","Is part of":"Somatic peripheral nervous system"}},{"Gustatory learning":{"Created":"8/15/2011 10:06","CurationStatus":"uncurated","Contributor":"Tyler Davis","CAO_Id":"CAO_00321","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Gustatory_learning","SuperCategory":"Learning","Id":"nlx_145534","Definition":"The formation of a knowledge representation that contains information about gustatory percepts."}},{"Gustatory memory":{"Created":"2/25/2011 9:42","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00322","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Gustatory_memory","SuperCategory":"Sensory memory","Id":"nlx_145535","Has role":"Cognitive Atlas Concept","Definition":"the cognitive capacity of storing and retrieving information related to taste."}},{"Gustatory modality":{"EditorialNote":"I think stimulus role needs to be separated from modality","CurationStatus":"uncurated","SuperCategory":"Stimulus modality","Curator":["Jessica Turner"],"Id":"COGPO:00123","Definition":"The gustatory modality is the sensory modality pertaining to the sense of taste or flavor. It usually but not always arises through stimulation of the gustatory system (e.g., tastebuds, nasal receptors)."}},{"Gustatory receptor neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"GRN","SuperCategory":"Chemosensory neuron","Id":"nlx_147910","Is part of":"Peripheral nervous system (FBbt Term)","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00005927","Definition":"Any neuron (FBbt_00005106) that functions in (some) detection of chemical stimulus involved in sensory perception of taste (GO:0050912)."}},{"Gustatory receptor neuron of terminal organ":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-04-15T10:42:35Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148505","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100144","Definition":"Gustatory receptor neuron associated with the terminal organ."}},{"Gustatory receptor neuron of the dorsal organ":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-04-15T10:51:20Z","Contributor":"sr544","SomaLocation":"dorsal organ ganglion","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148506","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100145","Definition":"Gustatory receptor neuron that innervates the dorsal organ. Projections from at least some of these neurons innervate `subesophageal ganglion area 3` (FBbt_00100141) (Colomb et al., 2007)."}},{"Gustatory receptor neuron of the epiphysis":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-04-15T11:12:14Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148508","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100147","Definition":"Gustatory receptor that innervates the epiphysis."}},{"Gustatory receptor neuron of the hypopharyngeal sense organ":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-04-15T11:19:26Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148510","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100149","Definition":"Gustatory receptor organ that innervates hypopharyngeal sense organ."}},{"Gustatory receptor neuron of the hypophysis":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-04-15T11:16:06Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148509","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100148","Definition":"Gustatory receptor neuron that innervates the hypophysis."}},{"Gustatory receptor neuron of the ventral organ":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-04-15T10:57:33Z","Contributor":"sr544","SuperCategory":"Gustatory receptor neuron","Id":"nlx_148507","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100146","Definition":"Gustatory receptor neuron that innervates the ventral organ."}},{"Gustatory stimulus transduction":{"Synonym":["sensory detection of taste stimulus","sensory detection of gustatory stimulus"],"Created":"2008-03-13","CurationStatus":"graph_position_temporary","Umlscui":"C1327496","SuperCategory":"Chemical stimulus transduction","Id":"birnlex_15006","Definition":"The series of events in which a sensory chemical stimulus is received and converted into a molecular signal. (GO:ai) (GO)"}},{"Gustatory system":{"RelatedTo":"Gustatory system function","CurationStatus":"uncurated","SuperCategory":"Sensory system","Id":"nlx_anat_090803","Definition":"The sensory system for the sense of taste."}},{"Gustatory system function":{"RelatedTo":"Gustatory system","Created":"2007-08-25","EditorialNote":"Though the definition given refers to a disposition toward sensing and processing (which will exist separately in BIRNLex as an occurent), this is the closest definition that captures the sense of a function part of the nervous system.   The several other definitions relate more specifically only to the direct sensation component of overall auditory system function.","Synonym":"Taste system function","CurationStatus":"uncurated","Umlscui":"C0039336","SuperCategory":"Sensory system function","Id":"birnlex_2512"}},{"Gymnosomata":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C0998110","SuperCategory":"Opisthobranchia","Id":"birnlex_7227"}},{"Gyrus rectus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"straight gyrus","SynonymPMID":"21789500","CurationStatus":"uncurated","NeuronamesID":"76","Umlscui":"C0152300","SuperCategory":"Regional part of brain","Id":"birnlex_1103","Is part of":"Frontal lobe","Species":"Human","Abbrev":"RG"}},{"H minus":{"SuperCategory":"Schizosaccharomyces pombe mating type","Id":"PATO_0001345","Definition":"A S. pombe mating type determined by the mat1-Mc and mat1-Mi on the mat1 locus."}},{"H plus":{"SuperCategory":"Schizosaccharomyces pombe mating type","Id":"PATO_0001346","Definition":"A S. pombe mating type determined by mat1-Pc and mat1-Pi on the mat1 locus."}},{"H-reflex":{"Synonym":"Hoffman reflex","CurationStatus":"uncurated","Comment":["I'm not sure whether H-reflex refers to all motor reflexes;  from the definition provided","I think so.  I am wondering whether motor reflex is a synonym for H-reflex.  Wikipedia","however"],"SuperCategory":"Reflex","Id":"nlx_34312","Definition":"A motor reflex consisting of a reflectory reaction of muscles after electrical stimulation of sensory fibers (Ia afferents stemming from muscle spindles) in their innervating nerves (for example, those located behind the knee). The H-reflex test is performed using an electric stimulator, which gives usually a square-wave current of short duration and small amplitude (higher stimulations might involve alpha fibers, causing a M-wave, compromising the results), and an EMG set, to record the muscle response. That response is usually a clear wave, called H-wave, 50 ms after the stimulus, not to be confused with M-wave at 25-30 ms, which might appear in too intense stimulations. (adapted from Wikipedia)"}},{"H1 receptor":{"Created":"2007-09-19","Synonym":"H1; Histamine H1 receptor","CurationStatus":"uncurated","SuperCategory":"Histamine receptor","Id":"nifext_6333"}},{"H2 receptor":{"Created":"2007-09-19","Synonym":"H2; Gastric receptor I; H2R; Histamine H2 receptor","CurationStatus":"uncurated","SuperCategory":"Histamine receptor","Id":"nifext_6491"}},{"H3 receptor":{"Created":"2007-09-19","Synonym":"H3; G-protein coupled receptor 97; HH3R; Histamine H3 receptor","CurationStatus":"uncurated","SuperCategory":"Histamine receptor","Id":"nifext_7328"}},{"H4 receptor":{"Created":"2007-09-19","Synonym":"H4; AXOR35; G-protein coupled receptor 105; GPCR105; GPRv53; HH4R; SP9144; Histamine H4 receptor","CurationStatus":"uncurated","SuperCategory":"Histamine receptor","Id":"nifext_6783"}},{"Habenula":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":["habenular nucleus"],"NeuronamesID":"277","CurationStatus":"uncurated","Umlscui":"C0152362","SuperCategory":"Regional part of brain","Id":"birnlex_1611","Is part of":"Epithalamus,","Abbrev":"Hb"}},{"Habenular commissure":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-07","Synonym":"commissura habenularum","CurationStatus":"uncurated","NeuronamesID":"282","Umlscui":"C0152363","SuperCategory":"Commissure","Id":"birnlex_1609","Is part of":["Epithalamus"],"Abbrev":"hbc"}},{"Habenulo-interpeduncular tract of diencephalon":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-03","NeuronamesID":"444","CurationStatus":"uncurated","Umlscui":"C0228391","SuperCategory":"Regional part of brain","Id":"birnlex_1176","Is part of":["Diencephalon"]}},{"Habenulo-interpeduncular tract of midbrain":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"439377875","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_895","Is part of":["Midbrain tegmentum"],"Abbrev":"hipm"}},{"Habituation":{"CurationStatus":"uncurated","ISBN":"0582227089","SuperCategory":"Learning","Id":"ERO_0001344","Definition":"A decrease in a behavioral response to a repeated stimulus. This is exemplified by the failure of a person to show a startle response to a loud noise that has been repeatedly presented. (source: ISBN:0582227089)"}},{"Hackathon":{"SuperCategory":"Workshop","Id":"nlx_355","Definition":"A resource that provides an event where programmers meet to do collaborative computer programming in a field that can be related back to neuroscience.  A hackathon refers not simply to one time hacks, but to a specific time when many people come together to hack on what they want to, how they want to - with little to no restrictions on direction or goal of the programming."}},{"Hadjikhani et al. (1998) Visuotopic area V1d":{"Created":"2008-03-04","CurationStatus":"uncurated","Comment":["We should reverse the order of the name in order to conform with the other named regions","i.e."],"SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4053","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":"Human,","DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V1d"}},{"Hadjikhani et al. (1998) Visuotopic area V1v":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4054","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V1v"}},{"Hadjikhani et al. (1998) Visuotopic area V2d":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4055","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V2d"}},{"Hadjikhani et al. (1998) Visuotopic area V2v":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4056","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V2v"}},{"Hadjikhani et al. (1998) Visuotopic area V3":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4057","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V3"}},{"Hadjikhani et al. (1998) Visuotopic area V3A":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4058","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V3A"}},{"Hadjikhani et al. (1998) Visuotopic area V4v":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4060","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V4v"}},{"Hadjikhani et al. (1998) Visuotopic area V8":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4061","ParcellationScheme":"Hadjikhani_et_al._(1998)_visuotopic_partition_scheme","DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"V8"}},{"Hadjikhani et al. (1998) Visuotopic area VP":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":"Hadjikhani et al. (1998) visuotopic partition scheme region","Id":"birnlex_4059","ParcellationScheme":"Hadjikhani et al. (1998) visuotopic partition scheme","Species":["Human"],"DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh       and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in       human visual cortical area V8. Nat. Neurosci.","v1 n3"],"Abbrev":"VP"}},{"Hadjikhani et al. (1998) visuotopic partition scheme":{"CurationStatus":"uncurated","Pages":"235-41","JournalVolume":"1","Authors":["Hadjikhani N","Liu AK","Dale AM","Cavanagh P"],"RetrievedOn":"Pub Med","Title":"Retinotopy and color sensitivity in human visual cortical area V8","PMID":"10195149","PublicationDate":"1998","SuperCategory":"Cortical parcellation scheme","PublicationName":"Nature Neuroscience","Id":"nlx_94454","JournalNumber":"3","DefiningCitation":"Hadjikhani et al. (1998)","Definition":"Partitioning of visual cortex of human unctional magnetic resonance imaging (fMRI)"}},{"Hadjikhani et al. (1998) visuotopic partition scheme region":{"PMID":"10195149","Created":"2008-03-04","Synonym":["Hadjikhani visuotopic partition scheme","Hadjikhani visuotopic parcellation scheme"],"CurationStatus":"uncurated","SuperCategory":"Parcellation scheme parcel","Id":"birnlex_4052","Is part of":"Hadjikhani_et_al._(1998)_visuotopic_partition_scheme","DefiningCitation":["Nouchine Hadjikhani","Arthur K. Liu","Anders M. Dale","Patrick Cavanagh and Roger B. H. Tootell (1998) Retinotopy and color sensitivity in human visual cortical area V8. Nat. Neurosci.","v1 n3"],"DefinitionPMID":"10195149"}},{"Hairy":{"SuperCategory":"Pilosity","Id":"PATO_0000454"}},{"Halazepam":{"RelatedTo":["Translocator protein"],"Synonym":["Halazepamum (INN-Latin)","Pacinone"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00801","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00801","Definition":"Halazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a trifluoromethyl derivative of nordazepam. While its structure may be similar to chlordiazepoxide and diazepam, it has both less toxicity and less tendency to cause paradoxical hostility and aggression than either of them. (Wikipedia) Pharmacology: Not Available Mechanism of action: Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug type: Approved. Illicit. Small Molecule. Drug category: Anti-anxiety Agents. Benzodiazepines. Muscle Relaxants. Sedative"}},{"Half brother":{"Created":"2008-03-14","CurationStatus":"definition_incomplete","Umlscui":"C0337531","SuperCategory":"Brother","Id":"birnlex_7397","Definition":"A half brother is a brother with one shared biological or adoptive parent (Wikipedia)."}},{"Half Life":{"SuperCategory":"Measurement","Id":"sao124571525","Definition":"Measure of turnover."}},{"Half sister":{"Created":"2008-03-14","CurationStatus":"definition_incomplete","Umlscui":"C0337518","SuperCategory":"Sister","Id":"birnlex_7404","Definition":"A half sister is a sister with one shared biological or adoptive parent (Wikipedia)."}},{"Half Value Layer":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0314","SuperCategory":"DICOM term","Id":"nlx_150096","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The thickness of Aluminum in mm required to reduce the X-Ray Output (0040,0312) by a factor of two. Note: This value may be a calibrated value rather than measured during the exposure."}},{"Hallucination assessment":{"Synonym":"hallucination","Created":"2008-03-14","CurationStatus":"graph_position_temporary","Umlscui":"C0018524","SuperCategory":"Mental state assessment","Id":"birnlex_3027","Definition":"An assessment of  a hallucination, a false sensory perception in the absence of an external stimulus, as distinct from an illusion which is a misperception of an external stimulus. (from Wikipedia) (NCI); An assessment of hallucinations, subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS. (MSH); An assessment of hallucinations, subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real; may be of organic origin, drug induced, or associated with a mental disorder. (CSP)"}},{"Hallucinogen":{"CurationStatus":"uncurated","SuperCategory":"Drug","Id":"nlx_143651"}},{"Halobetasol Propionate":{"RelatedTo":["Corticosteroid-binding globulin"],"Synonym":[", Halobetasol","Ulobetasol Propionate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00596","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00596","Definition":"Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Pharmacology: Not Available Mechanism of action: Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents. Vasoconstrictor Agents"}},{"Halofantrine":{"RelatedTo":["Potassium voltage-gated channel subfamily H member 2","Vacuolar ATP synthase catalytic subunit A"],"Synonym":["Halofantrina (INN-Spanish)","Halofantrine (Usan)","Halofantrinum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01218","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01218","Definition":"Halofantrine is a drug used to treat malaria. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme \"heme polymerase\"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity. Pharmacology: Halofantrine is a synthetic antimalarial which acts as a blood schizonticide. It is effective against multi drug resistant (including mefloquine resistant) P. falciparum malaria. Mechanism of action: The mechanism of action of Halofantrine may be similar to that of chloroquine, quinine, and mefloquine; by forming toxic complexes with ferritoporphyrin IX that damage the membrane of the parasite. Drug type: Approved. Small Molecule. Drug category: Antimalarials. Antiprotozoals"}},{"Haloperidol":{"RelatedTo":["D(1A) dopamine receptor","Glutamate (NMDA) receptor subunit epsilon-2"],"Synonym":[", ALDO","Aloperidin","Aloperidol","Aloperidolo","Aloperidon","Apo-Haloperidol","Bioperidolo","Brotopon","Dozic","Dozix","Einalon S","Eukystol","Galoperidol","Haldol","Haldol Decanoate","Haldol La","Haldol Solutab","Halidol","Halojust","Halol","Halopal","Haloperido","Haloperidol Decanoate","Haloperidol Intensol","Haloperidol Lactate","Halopidol","Halopoidol","Halosten","Keselan","Lealgin Compositum","Linton","Mixidol","Novo-Peridol","Pekuces","Peluces","Peridol","Pernox","Pms Haloperidol","Serenace","Serenase","Serenelfi","Sernas","Sernel","Sigaperidol","Ulcolind","Uliolind"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5613","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00502","Definition":"A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279) Pharmacology: Haloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Mechanism of action: The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known. Its effect on the central nervous system is thought to be associated with the competitive blockade of postsynaptic dopamine D2 receptors in the mesolimbic dopaminergic system and an increased turnover rate of brain dopamine. Drug type: Approved. Small Molecule. Drug category: Anti-Dyskinesia Agents. Antidyskinetics. Antiemetics. Antipsychotic Agents. Antipsychotics. Butyrophenones. Dopamine Antagonists"}},{"Haloprogin":{"Synonym":[", Aloprogen","Haloprogin (USAN:INN:JAN)","Haloprogina (INN-Spanish)","Haloprogine (INN-French)","Haloproginum (INN-Latin)","Halotex","Mycanden","Mycilan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00793","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00793","Definition":"Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but also presumed to interfere with yeast membrane structure and function. Pharmacology: Used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Mechanism of action: Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but also presumed to interfere with yeast membrane structure and function. There is a higher incidence of cutaneous side effects with haloprogin, including irritation, burning, vesiculation (blisters), scaling, and itching. It is generally used when the infection is unresponsive to other antifungals. Drug type: Approved. Small Molecule. Drug category: Anti-fungal Agents"}},{"Halothane":{"RelatedTo":["Calcium-transporting ATPase type 2C member 1","Intermediate conductance calcium-activated potassium channel protein 4","Glycine receptor subunit alpha-1","Potassium large conductance calcium-activated channel","subfamily M","alpha member 1","ATP synthase delta chain","mitochondrial","NADH-ubiquinone oxidoreductase chain 1","Serum albumin","Glutamate receptor 1","Gamma-aminobutyric-acid receptor subunit alpha-1","Neuropeptide S receptor","G protein-activated inward rectifier potassium channel 1","G protein-activated inward rectifier potassium channel 2","Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit"],"Synonym":["Alotano (Dcit)","Bromchlortrifluoraethanum","Bromochlorotrifluoroethane","Cf3chclbr","Fluorotane","Fluorothane","Freon 123b1","Ftorotan (Russian)","Ftuorotan","Halotano (INN-Spanish)","Halothan","Halothanum (INN-Latin)","Narcotann Ne-Spofa (Russian)","Anestan","Chalothane","Fluktan","Fluothane","Halan","Halotan","Halothane","Halsan","Narcotan","Narcotane","Narkotan","Phthorothanum"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5615","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01159","Definition":"A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) Pharmacology: Halothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It reduces the blood pressure and frequently decreases the pulse rate and depresses respiration. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. Mechanism of action: Halothane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Halothane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Halothane also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor and the glycine receptor. Drug type: Approved. Small Molecule. Drug category: Anesthetics. Anesthetics, Inhalation. General Anesthetics"}},{"Hammersmith functional motor scale":{"RelatedTo":"Spinal Muscular Atrophies of Childhood","Related disease":["Spinal muscular atrophy"],"CurationStatus":"uncurated","SuperCategory":"Rating scale","Id":"12865054","Has role":"Functional motor assessment","Species":"Human","DefiningCitation":["Main","M. et al.","The Hammersmith Functional Motor Scale for Children with Spinal Muscular Atrophy: a Scale to Test Ability and Monitor Progress in Children with Limited Ambulation European Journal of Paediatric Neurology (2003) 7"],"Abbrev":"HFMS","DefinitionPMID":"12865054","Definition":"Rating scale used to assess functional motor abilities in children with neuromuscular disorders, particularly spinal muscular atrophy.  It was developed for children with limited ambulation to assess their functional abilities, monitor the progression of function and provide a tool for accurate classification of SMA.  It includes measures for both upper and lower limb function."}},{"Hand":{"CurationStatus":"uncurated","SuperCategory":"Regional part of body","Id":"FMAID: 9712"}},{"Handedness assessment":{"Created":"2008-03-14","CurationStatus":"graph_position_temporary","Umlscui":"C1286612","SuperCategory":"Behavioral assessment","Id":"birnlex_3028","Definition":"Assessment of behavioral manifestations of cerebral dominance in which there is preferential use and superior functioning of either the left or the right side, as in the preferred use of the right hand or right foot. (MSH); Assessment of learned or spontaneous differential dexterity with and tendency to use one hand rather than the other. (PSY); Assessment of the preferential use of the hand of one side in voluntary motor acts. (CSP)"}},{"Haplodiploid":{"SuperCategory":"Diploid","Id":"PATO_0001395","Definition":"A diploidy quality inhering in a bearer in which one of the sexes has haploid cells and the other has diploid cells."}},{"Haploid":{"SuperCategory":"Euploid","Id":"PATO_0001375","Definition":"A ploidy quality inhering in a bearer by virtue of containing a single set of homologous chromosomes."}},{"Haplorrhini":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","SuperCategory":"Primate","Id":"birnlex_457"}},{"Haptic illusion task":{"Created":"4/15/2011 11:19","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00948","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Haptic_illusion_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146173","Definition":"No definition submitted yet."}},{"Hard":{"Synonym":["tough"],"SuperCategory":"Hardness","Id":"PATO_0000386","Definition":"A hardness quality of being rigid and resistant to pressure."}},{"Hardcopy Creation Device":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1011","SuperCategory":"DICOM term","Id":"nlx_150097","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User defined identification of the device that created this Hardcopy Image."}},{"Hardcopy Device Manfuacturers Model Name":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_101B","SuperCategory":"DICOM term","Id":"nlx_150098","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Manufacturer's model number of the device that created this Hardcopy Image."}},{"Hardcopy Device Manufacturer":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1017","SuperCategory":"DICOM term","Id":"nlx_150099","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Manufacturer of the device that created this Hardcopy Image."}},{"Hardcopy Device Software Version":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_101A","SuperCategory":"DICOM term","Id":"nlx_150100","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Manufacturer's designation of the software of the device that created this Hardcopy Image."}},{"Hardness":{"Synonym":["toughness"],"SuperCategory":"Quality of a solid","Id":"PATO_0000048","Definition":"A physical quality inhering in a bearer by virtue of its capability of being turned, bowed, or twisted without breaking ."}},{"Has extra parts of type":{"Synonym":["having supernumerary physical parts","has increased number of","having extra physical parts","increased number of"],"Comment":["In polydactyly","the bearer of the quality is the hand","and the entity type being counted is 'finger'. In EQ syntax"],"SuperCategory":"Has number of","Id":"PATO_0002002","Definition":"The bearer of this quality has part > n of the indicated entity type, where n is the normal amount for a comparable organism.  Note that the bearer of the quality is the whole, not the part."}},{"Has fewer parts of type":{"Synonym":["has decreased number of","decreased number of"],"Comment":"Example: (E","SuperCategory":"Lacks parts or has fewer parts of type","Id":"PATO_0002001","Definition":"The bearer of this quality has part < n AND has part > 0 of the indicated entity type, where n is the normal amount for a comparable organism.  Note that the bearer of the quality is the whole, not the part.  Formally: if a bearer entity e has fewer parts of type X at time t, then the number of instances x of X at t such that x part of e is < n, where n is either the normal number for comparable entities, or n is stated explicitly."}},{"Has normal numbers of parts of type":{"Synonym":"having physical part","SuperCategory":"Has number of","Id":"PATO_0001905","Definition":"The bearer of this quality has part"}},{"Has number of":{"Synonym":["number","has or lacks parts of type","extra or missing physical or functional parts","cardinality"],"CurationStatus":"uncurated","SuperCategory":"Quality of related physical entities","Id":"PATO_0001555","Definition":"The number of parts of a particular type that the bearer entity has.  This is a relational quality, and thus holds between two entities: the bearer of the quality, and the type of parts."}},{"Having decreased function":{"SuperCategory":"Extra or missing physical and functional parts","Id":"PATO_0001624"}},{"Having decreased physical parts":{"SuperCategory":"Extra or missing physical and functional parts","Id":"PATO_0001569"}},{"Having decreased processual parts":{"SuperCategory":"Extra or missing processual parts","Id":"PATO_0001570","Definition":"A relational quality of occurrent inhering in a bearer by virtue of having fewer processual parts."}},{"Having extra function":{"Synonym":"Having supernumerary functions","SuperCategory":"Functionality","Id":"PATO_0001559","Definition":"A functionality quality which is an ability to perform additional or different tasks."}},{"Having extra physical parts":{"SuperCategory":"Extra or missing physical and functional parts","Id":"PATO_0002002"}},{"Having extra processual parts":{"Synonym":"having supernumerary processual parts","SuperCategory":"Extra or missing processual parts","Id":"PATO_0001561","Definition":"A relational quality of occurrent inhering in a bearer by virtue of having additional processual parts."}},{"Hayling sentence completion test":{"Created":"6/27/2011 13:47","CurationStatus":"uncurated","Contributor":"Carinna Torgerson","CAO_Id":"CAO_00950","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Hayling_sentence_completion_test","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146175","Definition":"Participants are given the beginnings of sentences to complete. The sentences appear to have expected answers. In the first condition, participants must complete the sentence with a-the word that makes sense. In the second condition, participants are asked to complete sentences by saying semantically unrelated words, thereby making the sentence nonsensical."}},{"HCN1":{"Synonym":["HAC2"],"Created":"2007-09-06","SuperCategory":"Hyperpolarization and cyclic-nucleotide gated channel","Id":"nifext_3061"}},{"HCN2":{"Synonym":["BCNG2"],"Created":"2007-09-06","SuperCategory":"Hyperpolarization and cyclic-nucleotide gated channel","Id":"nifext_3065"}},{"HCN3":{"Synonym":["HAC3"],"Created":"2007-09-06","SuperCategory":"Hyperpolarization and cyclic-nucleotide gated channel","Id":"nifext_3069"}},{"HCN4":{"Synonym":["BCNG3"],"Created":"2007-09-06","SuperCategory":"Hyperpolarization and cyclic-nucleotide gated channel","Id":"nifext_3073"}},{"Head":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C0018670","SuperCategory":"Regional part of body","Id":"birnlex_1230","Definition":"Cardinal body part, which consists of a maximal set of diverse subclasses of organ and organ part spatially associated with the skull, it is partially surrounded by skin of head."}},{"Head direction cell":{"Located in":["Postsubiculum","Anterior Thalamus"],"EditorialNote":"Need to check whether anterior thalamus is a general part of the thalamus, i.e., the anterior part of the thalamus, or whether it means the Anterior_nuclear_group or the anterior nucleus of the thalamus","Synonym":"Head-direction cell","CurationStatus":"graph position temporary","LocatedInPMID":["2303851","7823153"],"SuperCategory":"Neuron","Id":"nlx_144208","Has role":"Principal neuron role","Species":["Mouse"],"DefinitionPMID":"2303851","Definition":"Neurons which fire when an animal's head is facing in a particular direction of horizontal plane, regardless of location, behavior or position of body"}},{"Head of caudate nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","NeuronamesID":"209","CurationStatus":"uncurated","Umlscui":"C0152336","SuperCategory":"Regional part of brain","Id":"birnlex_1212","Is part of":"Caudate nucleus","Definition":"Largest part of the caudate nucleus lying lateral to and protruding into the anterior of the lateral ventricle"}},{"Health Canada":{"tweets.color":"#605C4F","tweets.background":"#F6F6F6","count":"5","CurationStatus":"uncurated","shell.background":"#013C41","SuperCategory":"Government granting agency","Id":"nlx_152114","Is part of":"Government of Canada","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http://www.hc-sc.gc.ca","tweets.links":"#013C41","Abbrev":"Health Canada"}},{"Health Care Organization":{"Synonym":"Healthcare Organization","CurationStatus":"uncurated","SuperCategory":"Institution","Id":"C43960","DefiningCitation":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C43960","Abbrev":"HCO","Definition":"An organization that provides healthcare services or that is involved in the provision of health care activities. Groupings or subdivisions of an organization, such as departments, may also be considered as organizations where there is a need to identify them."}},{"Health Resources and Services Administration":{"SuperCategory":"Government granting agency","Id":"nlx_inv_1005077","Is part of":"U.S. Department of Health and Human Services","Abbrev":"HRSA","Definition":"http://www.hrsa.gov/grants/default.htm"}},{"Heart Rate":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1088","SuperCategory":"DICOM term","Id":"nlx_150101","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Beats per minute."}},{"Heart shaped":{"Synonym":["Cordiform"],"SuperCategory":"Concave 3-D shape","Id":"PATO_0000948","Definition":"With a sinus or rounded lobe at the base; having the shape of a heart."}},{"Heat conduction":{"Synonym":"thermal conduction","SuperCategory":"Conduction","Id":"PATO_0001756","Definition":"The spontaneous transfer of thermal energy through matter, from a region of higher temperature to a region of lower temperature."}},{"Heat sensitization-adaptation":{"Created":"8/25/2011 7:56","CurationStatus":"uncurated","Contributor":"Birgit Nierula","CAO_Id":"CAO_00970","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Heat_sensitization-adaptation","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146195","Definition":"A long (~ 30 seconds or more) heat stimulus is applied to the skin and the participant rates the experienced sensation continuously on a visual analogue scale"}},{"Heat stimulation":{"Created":"8/25/2011 10:32","CurationStatus":"uncurated","Contributor":"Birgit Nierula","CAO_Id":"CAO_00969","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Heat_stimulation","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146194","Definition":"A heat stimulus is applied to the skin and the participant rates the experienced sensation on a visual analogue scale"}},{"Heavy staining density":{"Synonym":["Heavy staining","Strong staining","Heavily dense staining","Intense staining"],"CurationStatus":"uncurated","SuperCategory":"Staining density","Id":"nlx_qual_1010008","Has role":"NIF annotation standard for expression level"}},{"Hebb synapse":{"RelatedTo":"Long term potentiation","Synonym":["Hebbian synapse"],"CurationStatus":"uncurated","SuperCategory":"Electrophysiology theory","Id":"oen_0001206","Definition":"\"When an axon of cell A is near enough to excite a cell B and repeatedly or persistently takes part in firing it, some growth process or metabolic change takes place in one or both cells such that A's efficiency, as one of the cells firing B is increased.\""}},{"Height":{"SuperCategory":"1-D extent","Id":"PATO_0000119","Definition":"A 1-D extent quality which is equal to the vertical dimension of extension."}},{"Helicidae":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C0323955","SuperCategory":"Helicoidea","Id":"birnlex_7239"}},{"Helicoidea":{"Synonym":"Helicacea","Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1038801","SuperCategory":"Sigmurethra","Id":"birnlex_7238"}},{"Helisoma":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1001739","SuperCategory":"Planorbidae","Id":"birnlex_7232"}},{"Helisoma anceps":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1214481","SuperCategory":"Helisoma","Id":"birnlex_7235"}},{"Helisoma duryi":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1062641","SuperCategory":"Helisoma","Id":"birnlex_7234"}},{"Helisoma trivolvis":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1001740","SuperCategory":"Helisoma","Id":"birnlex_7233"}},{"Helix":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C0018882","SuperCategory":"Helicidae","Id":"birnlex_7240","Definition":"A genus of chiefly Eurasian and African land snails including the principal edible snails as well as several pests of cultivated plants. (MSH)"}},{"Helix aspersa":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C0553251","SuperCategory":"Helix","Id":"birnlex_7241"}},{"Helmholtz Center Munich":{"Synonym":["Helmholtz Zentrum Munchen German Research Center for Environmental Health","Helmholtz Zentrum Munchen-German Research Center for Environmental Health"],"CurationStatus":"uncurated","SuperCategory":"Lead institution","Id":"nlx_152050","Is part of":"Federal Republic of Germany","DefiningCitation":"http://www.helmholtz-muenchen.de/en/index.html","Abbrev":"Helmholtz Center Munich","Definition":"Lead research institution of the Federal Republic of Germany and the Free State of Bavaria with the research mission of increasing the understanding of disease mechanisms which affect human beings and essential parts of their environment. The Center is developing the fundamental principles for the medicine of the future and for a personalized medicine focused on addressing the causes of disease. It is divided into 28 research institutes and independent research units, which are interlinked and cooperate on various topics and in various research programs. The center has diverse technology platforms which function as central service units. To ensure rapid and efficient transfer of findings from basic research into medical applications, scientists of Helmholtz Zentrum Munchen work closely in translational centers and clinical cooperation groups together with medical partners in the universities and hospitals in Munich. The successful research record of Helmholtz Zentrum Munchen in the field of Environmental Health rests on two pillars: (1) a culture of excellence in science and with regard to education, training and research infrastructure and (2) interdisciplinary and cooperative research endeavors. On this basis, we are developing new approaches to combat respiratory, metabolic and neurological diseases. Translational research and technology transfer at Helmholtz Zentrum Munchen enable rapid utilization of research results to benefit society."}},{"Hematopoietic stem cell":{"CurationStatus":"uncurated","Comment":"Umls Cui: C0018956","SuperCategory":"Somatic stem cell","Id":"418318001"}},{"Hemisphere of cerebral cortex":{"Created":"2007-10-09","Synonym":"Cerebral hemisphere","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1796"}},{"Hemispheric Lobule II":{"Synonym":["Alar Central Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081202","Is part of":"Anterior lobe of the cerebellum"}},{"Hemispheric Lobule III":{"Synonym":["Alar Central Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081203","Is part of":"Anterior lobe of the cerebellum"}},{"Hemispheric Lobule IV":{"Synonym":["Lobulus Quadrangularis Anterior","Lobulus Anterior","Quadrangular Lobule","Anterior Quadrangular Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081204","Is part of":"Anterior lobe of the cerebellum"}},{"Hemispheric Lobule IX":{"Synonym":["Tonsilla","Paraflocculus","Cerebellar Tonsil"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081212","Is part of":"Flocculonodular lobe,"}},{"Hemispheric Lobule V":{"Synonym":["Lobulus Quadrangularis Anterior","Lobulus Anterior","Quadrangular Lobule","Anterior Quadrangular Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081205","Is part of":"Anterior lobe of the cerebellum"}},{"Hemispheric Lobule VI":{"Synonym":["Lobulus Quadrangularis Posterior","Lobulus Simplex","Simplex Lobule","Simple Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081206","Is part of":"Posterior lobe of the cerebellum,","Abbrev":"Sim"}},{"Hemispheric Lobule VII":{"SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081207"}},{"Hemispheric Lobule VIIA":{"Synonym":["Lobulus Semilunaris Superior","Lobulus Ansiform Crus I","Superior Semilunar Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_anat_20081208","Is part of":"Hemispheric Lobule VII"}},{"Hemispheric Lobule VIIBi":{"Synonym":["Lobulus Semilunaris Inferior","Lobulus Ansiform Crus II","Inferior Semilunar Lobule"],"CurationStatus":"uncurated","SuperCategory":"Hemispheric Lobule VII","Id":"nlx_anat_20081209","Is part of":"Posterior lobe of the cerebellum,"}},{"Hemispheric Lobule VIIBii":{"Synonym":["Lobulus Gracilis","Lobulus Paramedianus","Gracile Lobule","Paramedian 1 (HVII)"],"CurationStatus":"uncurated","SuperCategory":"Hemispheric Lobule VII","Id":"nlx_anat_20081210","Is part of":"Posterior lobe of the cerebellum,"}},{"Hemispheric lobule VIII":{"Synonym":["Lobulus Biventer","Paraflocculus Dorsalis","Biventral Lobule"],"CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081211","Is part of":"Posterior lobe of the cerebellum,"}},{"Hemispheric Lobule X":{"Synonym":"Flocculus","CurationStatus":"uncurated","SuperCategory":"Regional Parts of the Hemisphere Lobules","Id":"nlx_anat_20081213","Is part of":"Flocculonodular lobe,"}},{"Hemispheric part of the anterior lobe of the cerebellum":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Hemispheric parts of the cerebellar cortex","Id":"birnlex_1339"}},{"Hemispheric part of the flocculonodular lobe of the cerebellum":{"SuperCategory":"Hemispheric parts of the cerebellar cortex","Id":"nlx_anat_20081260"}},{"Hemispheric part of the posterior lobe of the cerebellum":{"SuperCategory":"Hemispheric parts of the cerebellar cortex","Id":"nlx_anat_20081261"}},{"Hemispheric parts of the cerebellar cortex":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Regional part of a lobe of the cerebellum","Id":"birnlex_1334"}},{"Hemispheric regions of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Cerebellar hemisphere","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153057","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebellar cortex of ABA 2009","Species":"Mouse"}},{"Hemorrhagic":{"CurationStatus":"uncurated","SuperCategory":"Structure","Id":"PATO_0002105","Definition":"A structural quality inhering in a bearer by virtue of the bearer's exhibiting excessive discharge of blood from the blood vessels."}},{"Hemostat":{"SuperCategory":"Surgical Instrument","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","Id":"nlx_92780","Has role":"Instrument role","Definition":"Hemostats are used to stop the flow of blood. They have ring handles and a locking mechanism known as a ratchet. The ratchet secures the device and stops blood flow."}},{"Heparin":{"RelatedTo":["Prothrombin","Coagulation factor X","Antithrombin-III","Coagulation factor IX","Heparanase"],"Synonym":["Alpha-Heparin","Heparin sodium","Heparin sodium preservative Free","Heparin sodium salt","Heparin sulfate","Heparinate","Heparinic acid","Low molecular weight heparin sodium","Sodium heparin","heparin","liquid","oral","Ariven","Arteven","Bemiparin","Calcilean","Calciparine","Certoparin","Clexane","Clivarin","Clivarine","Dalteparin","Depo-Heparin","Eparina (DCIT)","Fluxum","Fragmin A","Fragmin B","Fraxiparin","Hed-Heparin","Hepalean","Heparin Cy 216","Heparin Leo","Heparin Lock Flush","Hepathrom","Leparan","Lipo-Hepin","Liquaemin","Liquaemin Sodium","Liquemin","Multiparin","Novoheparin","Pabyrin","Parnaparin","Parvoparin","Pularin","Reviparin","Sandoparin","Sublingula","Thromboliquine","Vetren"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28304","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01109","Definition":"Heparin, a highly sulfated glycosaminoglycan is widely used as an injectable anticoagulant. It has the highest negative charge density of any known biological molecule. Heparin acts as an anticoagulant, preventing the formation of clots and extension of existing clots within the blood. While heparin does not break down clots that have already formed, it allows the body's natural clot lysis mechanisms to work normally to break down clots that have already formed. Heparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, heparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so heparin  s inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Pharmacology: Heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Heparin is a well known and commonly used anticoagulant which has antithrombotic properties. Heparin is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Heparin acts at multiple sites in the normal coagulation system. Small amounts of Heparin in combination with antithrombin III (Heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Mechanism of action: The mechanism of action of heparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Heparin interacts with antithrombin III, prothrombin and factor X. Drug type: Approved. Investigational. Small Molecule. Drug category: Anticoagulants. Fibrinolytic Agents. Heparins"}},{"Hepatitis C virus":{"CurationStatus":"uncurated","SuperCategory":"Virus","Id":"nlx_26670","Abbrev":"HCV"}},{"Heptachlor":{"Synonym":["1,4,5,6,7,8,8-Heptachlorotetrahydro-4,7-methanoindene","3,4,5,6,7,8,8-Heptachlorodicyclopentadiene","3,4,5,6,7,8,8a-Heptachlorodicyclopentadiene","3-Chlorochlordene","Aahepta","Agroceres","Arbinex 30TN","Basaklor","Caswell No. 474","3,4,5,6,7,8","8a-Heptachloro-Dicyclopentadiene","Drinox","Drinox H-34","Eptacloro","GPKH","Gold Crest H-60","Termide","Hepta","Hepta klor","Heptachloor","Heptachlor (technical grade)","Heptachlor and metabolites","Heptachlor solution","Heptachlorane","Heptachlore","Heptachlorotetrahydro-4,7-methanoindene","Heptagran","Heptagranox","Heptaklor","Heptamak","Heptamul","Heptasol","Heptox","Latka 104","Rhodiachlor","Soleptax","Technical heptachlor","Tetrahydro","Velsicol 104","Velsicol heptachlor"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0034","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0034","Abbrev":"C10H5Cl7","Definition":"Organic Compound;Pesticide;Organochloride; Heptachlor is a manufactured cyclodiene organochlorine insecticide. As it is a persistant organic pollutant, heptachlor use is banned or limited in most areas."}},{"Heptachlor epoxide":{"Synonym":["Epoxyheptachlor","HCE","Heptachlore epoxide","Velsicol 53-CS-17"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0046","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0046","Abbrev":"C10H5Cl7O","Definition":"Organic Compound;Pesticide;Organochloride; Heptachlor epoxide is a chemical produced when heptachlor is broken down by bacteria and animals. Heptachlor is a manufactured cyclodiene organochlorine insecticide. As it is a persistant organic pollutant, heptachlor use is banned or limited in most areas. The epoxide is more likely to be found in the environment than heptachlor."}},{"Hereditary Central Nervous System Demyelinating Diseases":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Demyelinating disease","Id":"birnlex_12526"}},{"Hereditary Sensory and Autonomic Neuropathies":{"Synonym":["Congenital Insensitivity to Pain with Anhidrosis"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Polyradiculoneuropathy","Id":"birnlex_12556","DefiningCitation":["Joynt","Clinical Neurology","1995","Ch51"],"Definition":"A group of inherited disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and clinically by loss of sensation and autonomic dysfunction. There are five subtypes. Type I features autosomal dominant inheritance and distal sensory involvement. Type II is characterized by autosomal inheritance and distal and proximal sensory loss. Type III is DYSAUTONOMIA, FAMILIAL. Type IV features insensitivity to pain, heat intolerance, and mental deficiency. Type V is characterized by a selective loss of pain with intact light touch and vibratory sensation (MeSH)."}},{"Hereditary Sensory Autonomic Neuropathy, Type 1":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Hereditary Sensory and Autonomic Neuropathies","Id":"birnlex_12557","Abbrev":["HSAN Type I"]}},{"Hereditary Sensory Autonomic Neuropathy, Type 2":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Hereditary Sensory and Autonomic Neuropathies","Id":"birnlex_12558","Abbrev":["HSAN Type II"]}},{"Hereditary Sensory Autonomic Neuropathy, Type 4":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Hereditary Sensory and Autonomic Neuropathies","Id":"birnlex_12559","Abbrev":["HSAN Type IV"]}},{"Hereditary Sensory Autonomic Neuropathy, Type 5":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Hereditary Sensory and Autonomic Neuropathies","Id":"birnlex_12560","Abbrev":["HSN Type V"]}},{"Hermaphrodite":{"Synonym":"intersex","SuperCategory":"Phenotypic sex","Id":"PATO_0001340","Definition":"A biological sex quality inhering in an individual or population with both male and female sex organs in one individual."}},{"Hermissenda":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C0596695","SuperCategory":"Facelinidae","Id":"birnlex_7247","Definition":"* A genus of marine sea slugs in the family Glaucidae, superorder GASTROPODA, found on the Pacific coast of North America. They are used in behavioral and neurological laboratory studies. (MSH) * soft-bodied shell-less gastropods with simple nervous systems; used in neurobiological studies of learning and memory. (CSP)"}},{"Hermissenda crassicornis":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1484186","SuperCategory":"Hermissenda","Id":"birnlex_7248"}},{"Herniated":{"SuperCategory":"Protruding","Id":"PATO_0000643","Definition":"Of or relating to a bodily structure that has protruded through an abnormal opening in the wall that contains it."}},{"Heroin":{"Synonym":["diacetyl-morphine","Diacetylmorphine","diacetylmorphine-HCl","Diacetylmorphine Hydrochloride"],"CurationStatus":"uncurated","Umlscui":"C0011892","SuperCategory":"Molecular entity","Id":"CHEBI:27808","Has role":"Drug of abuse role","DefiningCitation":"MeSH","Definition":"A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed)"}},{"Heroin dependence":{"Synonym":"Heroin addiction","CurationStatus":"uncurated","SuperCategory":"Heroin-Related Disorder","Id":"nlx_89410"}},{"Heroin-Related Disorder":{"Synonym":["Heroin Usage"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Opioid-Related Disorder","Id":"birnlex_12714","Definition":"Disorders related or resulting from abuse or mis-use of heroin."}},{"Herpes simplex virus I":{"CurationStatus":"uncurated","SuperCategory":"Virus","Id":"nlx_152235","Has role":["Transneuronal tracing role","Retrograde tracing role"],"HasRolePMID":"1690933","Abbrev":"HSV1"}},{"Hesperetin":{"RelatedTo":["Sterol O-acyltransferase 2","Sterol O-acyltransferase 1"],"Synonym":["Cyanidanon 4'-Methyl Ether 1626","Hesperitin","YSO2"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28230","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01094","Definition":"Hesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside hesperidin, is the predominant flavonoid in lemons and oranges. Pharmacology: Hesperetin is a cholesterol lowering flavanoid found in a number of citrus juices. It appears to reduce cholesteryl ester mass and inhibit apoB secretion by up to 80%. Hesperetin may have antioxidant, anti-inflammatory, anti-allergic, hypolipidemic, vasoprotective and anticarcinogenic actions. Mechanism of action: Hesperetin reduces or inhibits the activity of acyl-coenzyme A:cholesterol acyltransferase genes (ACAT1 and ACAT2) and it reduces microsomal triglyceride transfer protein (MTP) activity. Hesperetin also seems to upregulate the LDL receptor. This leads to the reduced assembly and secretion of apoB-containing lipoproteins and enhanced reuptake of those lipoproteins, thereby lowering cholesterol levels. Drug type: Approved. Small Molecule. Drug category: Anticholesteremic Agents"}},{"Hessian Ministry for Science and Art":{"Synonym":["Hessisches Ministerium fr Wissenschaft und Kunst"],"CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_151481","DefiningCitation":"http://www.hmwk.hessen.de/irj/HMWK_Internet?cid","Abbrev":"HMWK"}},{"Hetacillin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":[", Hetacillin potassium","Versapen"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5683","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00739","Definition":"Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \"penicillin\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Pharmacology: Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \"penicillin\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Mechanism of action: Hetacillin is a semisynthetic penicillin prodrug which itself has no antibacterial activity, but is converted in the body to ampicillin and has actions and uses similar to those of ampicillin. Hetacillin is prepared by reacting ampicillin with acetone. Ampicillin rapidly decomposes because of the intramolecular attack of the side chain amino group on the lactam ring. Hetacillin locks up the offending amino group and prevents the decompolsition Hetacillin, once hydrolyzed to ampicillin (and acetone) binds to the penicillin binding proteins found in susceptible bacteria. This inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Penicillins"}},{"Heterobranchia":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1228789","SuperCategory":"Apogastropoda","Id":"birnlex_616"}},{"Heterochronic":{"SuperCategory":"Occurrence quality","Id":"PATO_0000692","Definition":"A quality inhering in a bearer by virtue of its origin or development at an unusual time or out of the regular sequence."}},{"Heterochronic growth":{"SuperCategory":"Growth quality of occurrent","Id":"PATO_0001490","Definition":"Growth quality of occurrent in which the growth of an organisms, structure, or group of organisms has a reduced or increased outcome."}},{"Heteroneura":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","SuperCategory":"Neolepidoptera","Id":"birnlex_620"}},{"Heterophilic":{"SuperCategory":"Cellular adhesivity","Id":"PATO_0001441","Definition":"A cellular adhesivity quality inhering in a molecule in one cell by virtue of its attachment to a nonidentical molecule in an adjacent cell."}},{"Heterotremata":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1055831","SuperCategory":"Heterotremata/Thoracotremata group","Id":"birnlex_487"}},{"Heterotrimeric G proteins":{"Synonym":"G12/13","SuperCategory":"G-Protein","Id":"nlx_146"}},{"Hexachlorobutadiene":{"Synonym":["1,1,2,3,4,4-hexachloro-1,3-Butadiene","1,1,2,3,4,4-Hexachloro-buta-1,3-diene","1,1,2,3,4,4-hexachloro-1,3-butadiene (ACD/Name 4.0)","1,1,2,3,4,4-hexachlorobuta-1,3-diene","Hexachloro-1,3-Butadiene","1,3-Hexachlorobutadiene","Dolen-pur","HCB","HCBD","Hexachlorobutadiene13","Hexachlor-1,3-butadien","Hexachloro-1,3-butadiene","Hexachlorobuta-1,3-diene","Hexachlorobutadiene [UN2279]","Hexachlorobutadiene-(1,3)","Perchloro-1,3-butadiene","Perchlorobutadiene"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0022","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0022","Abbrev":"C4Cl6","Definition":"Organic Compound;Solvent;Organochloride; Hexachlorobutadiene is a man-made chemical primarily produced as a by-product in the production of carbon tetrachloride and tetrachloroethene. It is also used to make rubber compounds, lubricants, in gyroscopes, as a heat transfer liquid, as a hydraulic fluid, and as a solvent."}},{"Hexachlorocyclohexane, beta-":{"Synonym":["(1R,2R,3R,4R,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1R,2R,3S,4S,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2R,3S,4r,5R,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2R,3S,4s,5R,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2c,3c,4t,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2c,3t,4t,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2r,3r,4r,5r,6r)-1,2,3,4,5,6-hexachlorocyclohexane","(1s,2R,3R,4s,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","1,2,3,4,5,6-Hexachlorocyclohexane","1,2,3,4,5,6-Hexachlorocyclohexane (all stereo isomers)","1,2,3,4,5,6-Hexachlorocyclohexane (mixture of isomers)","1,2,3,4,5,6-Hexachlorocyclohexane gamma isomer","1,2,3,4,5,6-hexachlorocyclohexane alpha isomer","1a,2a,3b,4a,5b,6b-hexachlorocyclohexane","1a,2b,3a,4b,5a,6b-hexachlorocyclohexane","Aalindan","Aficide","Agrocide","Agrocide III","Agrocide WP Agronexit","Alpha-BHC","Alpha-HCH","Alpha-HCH solution","Alpha-benzenehexachloride","Alpha-hexachloran","Alpha-hexachlorane","Alpha-hexachlorocyclohexane","Alpha-lindane","Ameisenatod","Ameisenmittel merck","Ameisentod","Aparasin","Aphtiria","Aphtitria","Aplidal","Arbitex","Arcotal s","BBH","BCH","BHC","BHC (alpha-","beta-","gamma-)","BHC b","BHC insecticide","BHC-b isomer","Ben-hex","Benhexachlor","Benhexol","Benzanex","Benzene hexachloride","Benzene hexachloride all isomers","Benzene hexachloride-alpha-isomer","Benzene hexachloride-gamma isomer","Benzene hexachloride-gamma-isomer","Benzene-1,2,3,4,5,6-hexachloride","Benzene-cis-hexachloride","Benzene-trans-hexachloride","Benzenehexachloride mixed isomers","Benzenehexachloride-alpha-isomer","Benzex","Beta-BHC","Beta-HCH","Beta-HCH solution","Beta-benzene hexachloride","Beta-hexachlorocyclohexane","Beta-hexachloran","Beta-hexachlorobenzene","Beta-lindane","Bexol","Borer spray","CPD with unspecified stereochemistry","Caswell No. 079","Caswell No. 527","Celanex","Chinoin brand of lindane","Chloresene","Codechine","1,2,3,4,5,6-hexachloro-Cyclohexane","1,2,3,4,5,6-hexachloro-Cyclohexane (mixed isomers)","alpha-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane alpha-isomer","b-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane b-isomer","1,2,3,4,5,6-Hexachloro-Cyclohexane beta-isomer","delta-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane delta-isomer","gamma-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane gamma-isomer","trans-1,2,3,4,5,6-Hexachloro-Cyclohexane","DBH","Delitex","Delta-BHC","Delta-HCH","Delta-benzenehexachloride","Delta-hexachlorocyclohexane","Delta-lindane","Detmol extract","Detmol-extrakt","Devoran","Dol granule","Dolmix","Drilltox-spezial aglukon","Entomoxan","Epsilon-HCH","Epsilon-benzenehexachloride","Epsilon-hexachlorocyclohexane","Esoderm","Exagama","Fenoform forte","Forlin","Forst-nexen","Gallogama","GamAcid","GamAcide","GamAcide 20","Gamacarbatox","Gamaphex","Gamene","Gamiso","Gamma 666","Gamma BHC","Gamma benzene hexachloride","Gamma hexachlor","Gamma hexachlorocyclohexane","Gamma-666","Gamma-:hexachlorocyclohexane","Gamma-BHC","Gamma-BHC (lindane)","Gamma-BHC benhexachlor","Gamma-HCH","Gamma-benzenehexachloride","Gamma-benzohexachloride","Gamma-col","Gamma-hexachlorane","Gamma-hexachlorcyclohexanum","Gamma-hexachlorobenzene","Gamma-hexachlorocyclohexane","Gamma-lindane","Gamma-mean 400","Gamma666","Gammahexa","Gammahexane","Gammalin","Gammaterr","Gammex","Gammexane","Gammopaz","Gamtox","Geobilan","Gexane","Gyben","H.c.h","HC b","HCC","HCCH","HCH","HCH","technical grade [hexachlorocyclohexanes]","HCH-b","HEXA","HGI","Heclotox","Hecoltox","Hexablanc","Hexachlor","Hexachloran","Hexachlorane","Hexachlorcyclohexan","Hexachloride","benzene","Hexachloride","gamma-benzene","Hexachlorocyclohexane","Hexachlorocyclohexane (all isomers)","Hexachlorocyclohexane (mixed isomers)","Hexachlorocyclohexane (mixture)","Hexachlorocyclohexane (technical grade)","alpha-Hexachlorocyclohexane","beta-Hexachlorocyclohexane","delta-Hexachlorocyclohexane","Hexachlorocyclohexane gamma isomer","gamma-Hexachlorocyclohexane","Hexachlorocyclohexane gamma-isomer","Hexachlorocyclohexane technical","Hexachlorocyclohexane technical grade","Hexachlorocyclohexane-alpha","Hexachlorocyclohexane-beta","Hexachlorzyklohexan","Hexamul","Hexapoudre","Hexatox","Hexaverm","Hexcidum","Hexicide","Hexit Shampoo 1.0%","Hexit lotion","Hexyclan","Hilbeech","Hortex","Inexit","Infectopharm brand of lindane","Insecticide","BHC","Isatox","Isotox","Jacutin","Kokotine","Kwell","Kwell-r","Laccohilin","Lasochron","Latka 666","Lendine","Lentox","Lidenal","Lindafor","Lindagam","Lindagrain","Lindagranox","Lindalo","Lindamul","Lindane (benzene hexachloroide-gamma isomer)","Lindane (gamma-HCH)","Lindano","Lindanum","Lindapoudre","Lindaterra","Lindatox","Lindex","Lindosep","Lintox","Linvur","Lorexane","Mglawikl","Mixture name","Mszycol","Neo-scabicidol","Nexen FB","Nexi t-stark","Nexit","Nexit-stark","Nexol-e","Nicochloran","Novigam","Novigan","Omnitox","Ovadziak","Owadziak","PLK","PMS lindane","Pedraczak","Pflanzol","Pharmascience brand of lindane","Pms-Lindane Lot 1%","Pms-Lindane Shp 1%","Pmslindane","Quellada","Sang gamma","Scabecid","Scabene","Scabisan","Silvanol","Spritz-rapidin","Spritzlindane","Spruehpflanzol","Stiefel brand of lindane","Streunex","Submar","T-HCH","TBH","TRI-6","Technical HCH","Technical hexachlorocyclohexane","Tetocid","Trans-a-benzenehexachloride","Trans-alpha-benzenehexachloride","Trives-t","Verindal ultra Viton","agrisol g-20","agrocide 2","agrocide 6g","agrocide 7","alpha-1,2,3,4,5,6-Hexachlorocyclohexane","b,1,2,3,4,5,6-Hexachlorocyclohexane","b-BHC","b-HCH","b-benzene hexachloride","b-hexachlorocyclohexane","b-lindane","bentox 10","beta-1,2,3,4,5,6-Hexachlorocyclohexane","delta-(Aeeeee)-1,2,3,4,5,6-hexachlorocyclohexane","delta-1,2,3,4,5,6-Hexachlorocyclohexane","detox 25","gamma-1,2,3,4,5,6-Hexachlorocyclohexane","gammalin 20","geolin g 3","hungaria l7"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0036","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0036","Abbrev":"C6H6Cl6","Definition":"Organic Compound;Pesticide;Organochloride; Hexachlorocyclohexane, Beta- is one of eight isoforms of the commercially manufactured chemical hexachlorocyclohexane. It is used as an insecticide on fruit, vegetables, and forest crops and is also available as a prescription (lotion, cream, or shampoo) to treat head and body lice, and scabies."}},{"Hexachlorocyclohexane, delta-":{"Synonym":["delta,1,2,3,4,5,6-Hexachlorocyclohexane,delta-BHC","delta-HCH","delta-benzene hexachloride","delta-hexachlorocyclohexane","(1R,2R,3R,4R,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1R,2R,3S,4S,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2R,3S,4r,5R,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2R,3S,4s,5R,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2c,3c,4t,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2c,3t,4t,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2r,3r,4r,5r,6r)-1,2,3,4,5,6-hexachlorocyclohexane","(1s,2R,3R,4s,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","1,2,3,4,5,6-Hexachlorocyclohexane","1,2,3,4,5,6-Hexachlorocyclohexane (all stereo isomers)","1,2,3,4,5,6-Hexachlorocyclohexane (mixture of isomers)","1,2,3,4,5,6-Hexachlorocyclohexane gamma isomer","1,2,3,4,5,6-Hexachlorohexane(b-bhc)","1,2,3,4,5,6-hexachlorocyclohexane alpha isomer","1a,2a,3b,4a,5b,6b-hexachlorocyclohexane","1a,2b,3a,4b,5a,6b-hexachlorocyclohexane","Aalindan","Aficide","Agrocide","Agrocide III","Agrocide WP","Agronexit","Alpha- BHC","Alpha-BHC","Alpha-HCH","Alpha-HCH solution","Alpha-benzenehexachloride","Alpha-hexachloran","Alpha-hexachlorane","Alpha-hexachlorocyclohexane","Alpha-lindane","Ameisenatod","Ameisenmittel merck","Ameisentod","Aparasin","Aphtiria","Aphtitria","Aplidal","Arbitex","Arcotal s","BBH","BCH","BHC","BHC delta","BHC (alpha-","beta-","gamma-)","BHC insecticide","BHC-delta isomer","Ben-hex","Benhexachlor","Benhexol","Benzanex","Benzene hexachloride","Benzene hexachloride (ambiguous)","Benzene hexachloride","all isomers","Benzene hexachloride-alpha-isomer","Benzene hexachloride-gamma-isomer","Benzene-1,2,3,4,5,6-hexachloride","Benzene-cis-hexachloride","Benzene-trans-hexachloride","Benzenehexachloride mixed isomers","Benzenehexachloride-alpha-isomer","Benzex","Beta-BHC","Beta-HCH","Beta-HCH solution","Beta-benzene hexachloride","Beta-hexachloran","Beta-hexachlorobenzene","Beta-hexachlorocyclohexane","Beta-isomer","eta-","Bexol","Borer spray","CPD with unspecified stereochemistry","Celanex","Chinoin brand of lindane","Chloresene","Codechine","delta,1,2,3,4,5,6-hexachloro-Cyclohexane","1,2,3,4,5,6-hexachloro-Cyclohexane","delta-1,2,3,4,5,6-hexachloro-Cyclohexane","1,2,3,4,5,6-hexachloro-Cyclohexane (mixed isomers)","beta-1,2,3,4,5,6-Hexachloro-Cyclohexane","delta-1,2,3,4,5,6-Hexachloro-Cyclohexane","DBH","Delitex","Delta-BHC","Delta-HCH","Delta-benzenehexachloride","Delta-hexachlorocyclohexane","Delta-lindane","Detmol extract","Detmol-extrakt","Devoran","Dol granule","Dolmix","Drilltox-spezial aglukon","Entomoxan","Epsilon HCH","Epsilon-HCH","Epsilon-","Epsilon-hexachlorocyclohexane","Esoderm","Exagama","Fenoform forte","Forlin","Forst-nexen","G-BHC-delta","Gallogama","GamAcid","GamAcide","GamAcide 20","Gamacarbatox","Gamaphex","Gamene","Gamiso","Gamma 666","Gamma BHC","Gamma benzene hexachloride","Gamma hexachlor","Gamma hexachlorocyclohexane","Gamma-666","Gamma-BHC","Gamma-BHC benhexachlor","Gamma-HCH","Gamma-benzenehexachloride","Gamma-benzohexachloride","Gamma-col","Gamma-hexachlorane","Gamma-hexachlorcyclohexanum","Gamma-hexachlorobenzene","Gamma-hexachlorocyclohexane","Gamma-lindane","Gamma-mean 400","Gamma666","Gammahexa","Gammahexane","Gammalin","Gammaterr","Gammex","Gammexane","Gammopaz","Gamtox","Geobilan","Gexane","Gyben","HCC","HCCH","HCH","HCH (alpha)","HCH (beta)","HCH technical grade [hexachlorocyclohexanes]","HCH-delta","HCH-d","HEXA","HGI","Heclotox","Hecoltox","Hexablanc","Hexachlor","Hexachloran","Hexachlorane","Hexachlorcyclohexan","Hexachloride","benzene","Hexachloride","gamma-benzene","Hexachlorocyclohexane (all isomers)","Hexachlorocyclohexane (mixed isomers)","Hexachlorocyclohexane (mixture)","Hexachlorocyclohexane (technical grade)","Hexachlorocyclohexane technical","Hexachlorocyclohexane technical grade","Hexachlorocyclohexane-alpha","Hexachlorocyclohexane-beta","Hexachlorzyklohexan","Hexamul","Hexapoudre","Hexatox","Hexaverm","Hexcidum","Hexicide","Hexit Shampoo 1.0%","Hexit lotion","Hexyclan","Hilbeech","Hortex","Inexit","Infectopharm brand of lindane","Insecticide","BHC","Isatox","Isotox","Jacutin","Kokotine","Kwell","Kwell-r","Lacco hi lin","Lasochron","Latka 666","Lendine","Lentox","Lidenal","Lindafor","Lindagam","Lindagrain","Lindagranox","Lindalo","Lindamul","Lindane (benzene hexachloroide-gamma isomer)","Lindane (gamma-HCH)","Lindano","Lindanum","Lindapoudre","Lindaterra","Lindatox","Lindex","Lindosep","Lintox","Linvur","Lorexane","Mglawik l","Mixture name","Mszycol","Neo-scabicidol","Nexen FB","Nexen-FB","Nexit","Nexit-stark","Nexol-e","Nicochloran","Novigam","Novigan","Omnitox","Ovadziak","Owadziak","PLK","PMS-lindane","Pedraczak","Pflanzol","Pharmascience brand of lindane","Pms-Lindane Lot 1%","Pms-Lindane Shp 1%","Pmslindane","Quellada","Sang gamma","Scabecid","Scabene","Scabisan","Silvanol","Spritz-rapidin","Spritzlindane","Spruehpflanzol","Stiefel brand of lindane","Streunex","Submar","T-HCH","TBH","Technical HCH","Technical hexachlorocyclohexane","Tetocid","Trans-alpha-benzenehexachloride","Tri-6","Trives-t","Verindal ultra","Viton","agrisol g-20","agrocide 2","agrocide 6g","agrocide 7","alpha-1,2,3,4,5,6-Hexachlorocyclohexane","bentox 10","beta-1,2,3,4,5,6-Hexachlorocyclohexane","delta-(Aeeeee)-1,2,3,4,5,6-hexachlorocyclohexane","delta-1,2,3,4,5,6-Hexachlorocyclohexane","detox 25","gamma-1,2,3,4,5,6-Hexachlorocyclohexane","gammalin 20","geolin g 3","hungaria l7"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0043","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0043","Abbrev":"C6H6Cl6","Definition":"Organic Compound;Pesticide;Organochloride; Hexachlorocyclohexane, Delta- is one of eight isoforms of the commercially manufactured chemical hexachlorocyclohexane. It is used as an insecticide on fruit, vegetables, and forest crops and is also available as a prescription (lotion, cream, or shampoo) to treat head and body lice, and scabies."}},{"Hexachlorocyclohexane, gamma-":{"Synonym":["gamma-BHC","gamma-HCH","gamma-benzene hexachloride","gamma-hexachloran","gamma-hexachlorane","gamma-hexachlorobenzene","gamma-hexachlorocyclohexane","gamma-lindane","gamma1,2,3,4,5,6-Hexachlorocyclohexane","(1R,2R,3R,4R,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1R,2R,3S,4S,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2R,3S,4s,5R,6S)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2c,3c,4t,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2c,3t,4t,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane","(1r,2r,3r,4r,5r,6r)-1,2,3,4,5,6-hexachlorocyclohexane","(1s,2R,3R,4s,5S,6S)-1,2,3,4,5,6-hexachlorocyclohexane","1,2,3,4,5,6-gamma-Hexachlorocyclohexane","1,2,3,4,5,6-Hexachlorocyclohexane","1,2,3,4,5,6-Hexachlorocyclohexane (gamma)","1,2,3,4,5,6-Hexachlorocyclohexane gamma isomer","1,2,3,4,5,6-hexachlorocyclohexane alpha isomer","1a,2a,3b,4a,5b,6b-hexachlorocyclohexane","1a,2b,3a,4b,5a,6b-hexachlorocyclohexane","Aalindan","Aficide","Agrocide","Agrocide III","Agrocide WP","Agronexit","Alpha- BHC","Alpha-BHC","Alpha-HCH","Alpha-HCH solution","Alpha-benzenehexachloride","Alpha-hexachloran","Alpha-hexachlorane","Alpha-hexachlorocyclohexane","Alpha-lindane","Ameisenatod","Ameisenmittel merck","Ameisentod","Aparasin","Aphtiria","Aphtitria","Aplidal","Arbitex","Arcotal s,Atlas steward","BBH","BCH","BHC","BHC (alpha-","beta-","gamma-)","BHC insecticide","BHC(gamma)","Ben-hex","Benhexachlor","Benhexol","Bentox 10","Benzanex","Benzene hexachloride","Benzene hexachloride gamma","Benzene hexachloride all isomers","Benzene-1,2,3,4,5,6-hexachloride","Benzene-cis-hexachloride","Benzene-trans-hexachloride","Benzex","Beta-BHC","Beta-HCH","Beta-HCH solution","Beta-benzene hexachloride","Beta-hexac hlorocyclohexane","Beta-hexachloran","Beta-hexachlorobenzene","Beta-hexachlorocyclohexane","Beta-hexachlorocyclohexanes","Beta-lindane","Bexol","Borer spray","CPD with unspecified stereochemistry","Caswell No. 079","Caswell No. 527","Celanex","Chinoin brand of lindane","Chloresene","Codechine","1,2,3,4,5,6-Hexachloro-Cyclohexane","gamma-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane","alpha-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane alpha-isomer","1,2,3,4,5,6-Hexachloro-Cyclohexane beta-isomer","delta-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane delta-isomer","gamma-1,2,3,4,5,6-Hexachloro-Cyclohexane","1,2,3,4,5,6-Hexachloro-Cyclohexane gamma-isomer","beta-1,2,3,4,5,6-Hexachloro-Cyclohexane","DBH","Delitex","Delta-BHC","Delta-HCH","Delta-benzenehexachloride","Delta-hexachlorocyclohexane","Delta-lindane","Detmol extract","Detmol-extrakt","Devoran","Dol granule","Dolmix","Drilltox-spezial aglukon","Entomoxan","Epsilon HCH","Epsilon-hexachlorocyclohexane","Esoderm","Exagama","Fenoform forte","Forlin","Forst-nexen","Fumite lindane","Gallogama","GamAcid","GamAcide","GamAcide 20","Gamacarbatox","Gamaphex","Gamene","Gamiso","Gamma 666","Gamma BHC","Gamma benzene hexachloride","Gamma hexachlor","Gamma hexachlorocyclohexane","Gamma-666","Gamma-:hexachlorocyclohexane","Gamma-BHC","Gamma-BHC (lindane)","Gamma-BHC benhexachlor","Gamma-BHC dust","Gamma-HCH","Gamma-HCH [hexachlorocyclohexanes]","Gamma-HCH dust","Gamma-benzene hexachloride","Gamma-benzenehexachloride","Gamma-benzohexachloride","Gamma-col","Gamma-hexachlorane","Gamma-hexachlorcyclohexanum","Gamma-hexachlorobenzene","Gamma-hexachlorocyclohexane","Gamma-lindane","Gamma-mean 400","Gamma666","Gammahexa","Gammahexane","Gammalin","Gammalin 20","Gammasan","Gammaterr","Gammex","Gammexane","Gammopaz","Gamtox","Geobilan","Gexane","Gyben","HCC","HCCH","HCH","HCH technical grade [hexachlorocyclohexanes]","HEXA","HGI","Heclotox","Hecoltox","Hexablanc","Hexachlor","Hexachloran","Hexachlorane","Hexachlorcyclohexan","Benzene Hexachloride","gamma-Benzene Hexachloride","Hexachlorocyclohexane","Hexachlorocyclohexane (all isomers)","Hexachlorocyclohexane (mixed isomers)","Hexachlorocyclohexane (mixture)","Hexachlorocyclohexane (technical grade)","alpha-Hexachlorocyclohexane","beta-Hexachlorocyclohexane","delta-Hexachlorocyclohexane","Hexachlorocyclohexane gamma isomer","gamma-Hexachlorocyclohexane","Hexachlorocyclohexane gamma-isomer","Hexachlorocyclohexane technical","Hexachlorocyclohexane technical grade","Hexachlorocyclohexane gamma-isomer","Hexachlorocyclohexane-alpha","Hexachlorocyclohexane-beta","Hexachlorocyclohexanes","Hexachlorzyklohexan","Hexamul","Hexapoudre","Hexatox","Hexaverm","Hexcidum","Hexicide","Hexit Shampoo 1.0%","Hexit lotion","Hexyclan","Hilbeech","Hortex","Inexit","Infectopharm brand of lindane","Insecticide","BHC","Isatox","Isotox","Jacutin","Kokotine","Kwell","Kwell-r","Lacco hi lin","Lasochron","Latka 666","Lendine","Lentox","Lidenal","Lindafor","Lindagam","Lindagrain","Lindagranox","Lindalo","Lindamul","Lindane (benzene hexachloroide-gamma isomer)","Lindane (g-BHC)","Lindane (gamma-HCH)","Lindane [hexachlorocyclohexanes]","Lindano","Lindanum","Lindapoudre","Lindaterra","Lindatox","Lindex","Lindosep","Lintox","Linvur","Lorexane","Mglawik l","Milbol 49","Mixture name","Mszycol","Murfume grain store smoke","Neo-scabicidol","New kotol","Nexen FB","Nexen-FB","Nexit","Nexit-stark","Nexol-e","Nicochloran","Novigam","Novigan,. Omnitox","Ovadziak","Owadziak","PLK","PMS lindane","Pedraczak","Pflanzol","Pharmascience brand of lindane","Pms-Lindane Lot 1%","Pms-Lindane Shp 1%","Pmslindane","Quellada","Sang gamma","Sang-gamma","Scabecid","Scabene","Scabene lotion","Scabisan","Silvanol","Spritz-rapidin","Spritzlindane","Spruehpflanzol","Stiefel brand of lindane","Streunex","Submar","T-HCH","TBH","Technical HCH","Technical hexachlorocyclohexane","Tetocid","Trans-alpha-benzenehexachloride","Tri-6","Trives-t","Verindal ultra","Viton","agrisol g-20","agrocide 2","agrocide 6g","agrocide 7","alpha-1,2,3,4,5,6-Hexachlorocyclohexane","beta-1,2,3,4,5,6-Hexachlorocyclohexane","delta-(Aeeeee)-1,2,3,4,5,6-hexachlorocyclohexane","delta-1,2,3,4,5,6-Hexachlorocyclohexane","detox 25","g-1,2,3,4,5,6-Hexachlorocyclohexane","gamma-1,2,3,4,5,6-Hexachlorocyclohexane"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0032","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0032","Abbrev":"C6H6Cl6","Definition":"Organic Compound;Pesticide;Organochloride; Hexachlorocyclohexane, Gamma- is one of eight isoforms of the commercially manufactured chemical hexachlorocyclohexane. It is used as an insecticide on fruit, vegetables, and forest crops and is also available as a prescription (lotion, cream, or shampoo) to treat head and body lice, and scabies."}},{"Hexachlorophene":{"RelatedTo":"D-lactate dehydrogenase","Synonym":[", AT-7","Acigena","Almederm","Bilevon","Bivelon","Compound G-11","Cotofilm","Dermadex","Dial","Distodin","E-Z Scrub","Eleven","Exofene","Fascol","Fesia-Sin","Fomac","Fostril","G-Eleven","G-II","Gamophen","Gamophene","Germa-Medica","HCP","Hexa-Germ","Hexabalm","Hexachlorofen","Hexachlorophane","Hexachlorophen","Hexachlorophene","Pharma","Hexafen","Hexascrub","Hexazinone","Hexide","Hexophene","Hexosan","Isobac","Isobac 20","Nabac","Nabac 25 Ec","Neosept V","Phiso-Scrub","Phisodan","Phisohex","Pre-Op","Rcra Waste Number U132","Ritosept","Scrubteam Surgical Spongebrush","Septi-Soft","Septisol","Septofen","Soy-Dome","Ster-Zac","Steral","Steraskin","Surgi-Cen","Surgi-Cin","Surofene","Tersaseptic","Trichlorophene"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00756","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00756","Definition":"A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797) Pharmacology: Hexachlorophene, a detergent cleanser, is an antibacterial sudsing emulsion for topical administration. It is a bacteriostatic cleansing agent. It cleanses the skin thoroughly and has bacteriostatic action against staphylococci and other gram-positive bacteria. Cumulative antibacterial action develops with repeated use. Cleansing with alcohol or soaps containing alcohol removes the antibacterial residue. Mechanism of action: The primary mechanism of action of hexachlorophene, based on studies with Bacillus megatherium, is to inhibit the membrane-bound part of the electron transport chain, respiratory D-lactate dehydrogenase. It induces leakage, causes protoplast lysis, and inhibits respiration. Drug type: Approved. Small Molecule. Drug category: Anti-Infective Agents, Local. Anti-Infectives"}},{"Hexafluronium bromide":{"RelatedTo":"Cholinesterase","Synonym":["Hexafluorenium","Hexafluorenium bromide","Milaxen"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00941","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00941","Definition":"Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases. Pharmacology: Hexafluronium bromide is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudocholinesterase, a plasma cholinesterase. The prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions, then in profound relaxation. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. There are two types of cholinesterase acetylcholinesterase and pseuodocholinesterase. The first hydrolyses acetylcholine more quickly; the latter hydrolyses butyrylcholine and succinylcholine more quickly. An absence or mutation of the pseudocholinesterase enzyme leads to a medical condition known simply as pseudocholinesterase deficiency. This is a silent condition that only manifests itself when people who have the deficiency receive the muscle relaxants succinylcholine or mivacurium during a surgery. Mechanism of action: Hexafluronium bromide is a non-competitive reversible inhibitor of human plasma cholinesterase or pseudocholinesterase. Drug type: Approved. Small Molecule. Drug category: Muscle Relaxants"}},{"Hexaploid":{"SuperCategory":"Polyploid","Id":"PATO_0001384","Definition":"A polyploidy quality inhering in a bearer by virtue of containing four homologous sets of chromosomes."}},{"Hexapoda":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1095852","SuperCategory":"Pancrustacea","Id":"birnlex_565"}},{"Hexobarbital":{"RelatedTo":["Gamma-aminobutyric-acid receptor subunit alpha-1"],"Synonym":["5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid","Hexobarbitone","Methexenyl","Methylhexabital","Barbidorm","Citopan","Cyclopal","Cyclopan","Evipal","Evipan","Noctivane","Sombucaps","Sombulex"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5706","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01355","Definition":"A barbiturate that is effective as a hypnotic and sedative. (PubChem) Pharmacology: Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s-1950s as an agent for inducing anesthesia for surgery and has a relatively fast onset of effects and short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days. Mechanism of action: Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Drug type: Approved. Small Molecule. Drug category: Adjuvants. Barbiturates. GABA Modulators. Hypnotics and Sedatives"}},{"Hexylcaine":{"RelatedTo":["Sodium channel protein type 10 subunit alpha"],"Synonym":[", Cyclaine","Hexilcaina (INN-Spanish)","Hexylcaine hydrochloride","Hexylcainum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00473","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00473","Definition":"Hexylcaine hydrochloride, also called cyclaine (Merck) or osmocaine, is a short-acting local anesthetic. It acts by inhibiting sodium channel conduction. Overdose can lead to headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function. Pharmacology: Hexylcaine is a local ester-class anesthetic. Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve. Mechanism of action: Hexyl caine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Drug type: Approved. Small Molecule. Drug category: Anesthetics. Local Anesthetics"}},{"High angular resolution diffusion imaging":{"CurationStatus":"uncurated","SuperCategory":"Diffusion-weighted magnetic resonance imaging","Id":"nlx_inv_090917","DefiningCitation":["Tuch DS","Reese TG","Wiegell MR"],"Abbrev":"HARDI"}},{"High Angular Resolution Diffusion Imaging Protocol":{"CurationStatus":"uncurated","SuperCategory":"Diffusion-weighted magnetic resonance imaging protocol","Id":"nlx_156828"}},{"High Bit":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0102","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150102","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Most significant bit for pixel sample data. Each sample shall have the same high bit. "}},{"High brightness":{"Synonym":"light","SuperCategory":"Color brightness","Id":"PATO_0000665","Definition":"Color brightness which is of high value."}},{"High frequency recombinant":{"Synonym":"Hfr","SuperCategory":"F minus mating type","Id":"PATO_0001349","Definition":"A bacterial mating type that indicates the F plasmid has integrated into the chromosome."}},{"High pass filter":{"CurationStatus":"uncurated","SuperCategory":"Filter","Id":"oen_0001244","Definition":"A filter that allows high frequencies to pass, stopping low frequencies."}},{"High saturation":{"Synonym":["shiny","bright"],"SuperCategory":"Color saturation","Id":"PATO_0001229","Definition":"Color saturation which is of high purity."}},{"High voltage electron microscope":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Transmission electron microscope","Id":"birnlex_2187","Definition":"transmission electron microscope cabable of operating an accelerating voltage in the range of 500- 1000 KeV"}},{"High-Dose Technique Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00C7","SuperCategory":"DICOM term","Id":"nlx_150103","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Type of high-dose treatment technique. Required if treatment technique requires a dose that would normally require overriding of treatment machine safety controls."}},{"High-pressure liquid chromotography instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Liquid chromotography instrument","Id":"birnlex_2400"}},{"High-pressure liquid chromotography protocol":{"Synonym":"HPLC protocol","CurationStatus":"uncurated","SuperCategory":"Protocol","Id":"nlx_inv_20090606"}},{"Higher order thalamic relay nucleus":{"CurationStatus":"uncurated","SuperCategory":"Thalamic relay nucleus","Id":"nlx_151963","DefinitionPMID":"12626004","Definition":"A thalamic relay nucleus that relays information from layer 5 of one cortical area to another, as distinguished from a first order relay nucleus that transmits subcortical information to the cortex, as proposed by Sherman and Guillery. All thalamic relays receive a layer-6 modulatory input from cortex, but higher-order relays in addition receive a layer-5 driver input, e.g., pulvinar nucleus."}},{"Hildebrandts horseshoe bat":{"Synonym":"Rhinolophus hildebrandtii","Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1669804","SuperCategory":"Rhinolophus","Id":"birnlex_200"}},{"Hilum of dentate nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-18","NeuronamesID":"684","CurationStatus":"uncurated","Umlscui":"C1289484","SuperCategory":"Regional part of brain","Id":"birnlex_1561","Is part of":"Dentate nucleus","Abbrev":"hdt"}},{"Hindbrain":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":"rhombencephalon","NeuronamesID":"531","CurationStatus":"uncurated","Umlscui":["C1522180"],"SuperCategory":"Regional part of brain","Id":"birnlex_942","Has role":"PONS reference structure","Is part of":"Brain","Definition":"Part of the brainconstituting the MEDULLA OBLONGATA (myelencephalon) and PONS (metencephalon). (adapted from MSH) * part of the brain developed from the posterior of the three primary brain vesicles of the embryonic neural tube; it comprises the metencephalon (cerebellum and pons) and myelencephalon (medulla oblongata). (CSP)"}},{"Hindbrain of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":["Medulla oblongata"],"SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153508","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Basic cell groups and regions of ABA 2009","Species":"Mouse","Definition":"Mouse brain region comprising the medulla and pons.  This parcellation scheme does not include the cerebellum in the hindbrain."}},{"Hindbrain of CIVM postnatal rat brain atlas":{"RelatedTo":"Axial Hindbrain of CIVM postnatal rat brain atlas","CurationStatus":"uncurated","PartiallyOverlapsWith":["medulla oblongata","pons"],"SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151514","ParcellationScheme":"CIVM postnatal rat brain atlas parcellation scheme","ParcellationSchemePMID":"23246176","Definition":"A superparcellation of the CIVM postnatal rat brain atlas consisting of the Axial Hindbrain and the Cerebellum"}},{"Hindbrain of WHS11":{"AtlasImage":["Hindbrain of WHS11.png"],"CurationStatus":"uncurated","PartiallyOverlapsWith":["pons","medulla oblongata","fourth ventricle"],"SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143765","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Brain of WHS11","Species":"Mouse","Definition":"Superparcellation of the Waxholm mouse brain atlas, comprising the pons, cerebellum, fourth ventricle and medulla"}},{"Hippocampal commissure":{"CurationStatus":"uncurated","SuperCategory":"Commissure","Id":"nlx_151980","Is part of":["Telencephalon"],"Definition":"Commissure connecting the hippocampal formations"}},{"Hippocampal formation":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"159","Umlscui":"C0175202","SuperCategory":"Regional part of brain","Id":"birnlex_715","Is part of":"Cerebral cortex,","Definition":"A part of the brain consisting of a three layered cortex located in the forebrain bordering the medial surface of the lateral ventricle.  The term hippocampal formation  is often used synonymously with hippocampus which consists of the hippocampus proper or Cornu Ammonis, the dentate gyrus and the subicular complex"}},{"Hippocampal formation of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":["Hippocampus","dentate gyrus","fasciola cinerea","induseum griseum","entorhinal cortex","subicular complex"],"SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_151330","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cortical plate of ABA 2009","Species":"Mouse","Definition":"Super-parcellation of cortical plate structures in the Allen Brain Atlas 2009 ontology, comprising the hippocampal area and retrohippocampal area"}},{"Hippocampal Formation of CIVM postnatal rat brain atlas":{"AtlasImage":["hippocampus p0.png"],"CurationStatus":"uncurated","PartiallyOverlapsWith":["Hippocampus"],"Comment":"The overlaps relationships were determined from the description","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151529","ParcellationScheme":"CIVM postnatal rat brain atlas parcellation scheme","Is part of":"Pallium of CIVM postnatal rat brain atlas","Definition":"The hippocampal formation is readily segmented on coronal T2-weighted MRI. The rostral extent of the hippocampus appears as a light ellipsoid structure emerging from the much darker surrounding ventral hippocampal commissure. Moving caudally the hippocampus is bounded on all sides by much darker structures: the corpus callosum dorsally, the fimbria laterally, and the diencephalon ventrally. Further caudal, the hippocampus becomes completely bounded laterally by the corpus callosum/external capsule/deep cerebral white matter complex, and medially by the diencephalon and internal capsule/cerebral peduncle, all of which appear much darker on T2 MRI. At its caudal extent the hippocampal formation still shares a lateral boundary with the corpus callosum. The medial border is somewhat more subtle and is defined by the thin, dark, speckled edge of the molecular layer of the subiculum."}},{"Hippocampal formation of GP94":{"CurationStatus":"graph position temporary","Pages":"445-52","JournalVolume":"33","Authors":["Gasbarri A","Packard MG","Campana E"],"Title":"Anterograde and retrograde tracing of projections from the ventral tegmental area to the hippocampal formation in the rat","EditorialNote":"This type of definition does not fit either with our definition of parcel or regional part of brain;  need to determine how this relates to hippocampal formation.","PartiallyOverlapsWith":["hippocampus","dentate gyrus"],"PublicationDate":"2994","SuperCategory":"GP94 parcel","PublicationName":"Brain Res Bull.","Id":"nlx_144306","JournalNumber":"4","OrganismPMID":"8124582","Species":"Rat","PartiallyOverlapsWithPMID":"8124582","Definition":"The combined region of Ammon's horn, subicular complex anddentate gyrus; only fields CA1-CA3 of the hippocampus were considered to be part of the HF, field CA4 being included in the hilus of the dentate gyrus","DefinitionPMID":"8124582"}},{"Hippocampal formation of RHA11":{"AtlasImage":"HippoFormationRHA11.jpg,","CurationStatus":"uncurated","PartiallyOverlapsWith":["Hippocampus","dentate gyrus","subiculum"],"Comment":"Hierarchy taken from http://cmbn-approd01.uio.no/zoomgen/hippocampus/structureindexB.do","SuperCategory":"RHA11 hippocampal parcellation scheme region","PublicationLink":"http://cmbn-approd01.uio.no/zoomgen/hippocampus/structureindexB.do","Id":"nlx_151938","ParcellationScheme":"RHA11 hippocampal parcellation scheme","Is part of":"Hippocampal region of RHA11","ParcellationSchemePMID":"21519393","Species":"Long Evans Rat,","Definition":"Superparcellation comprising the CA fields, the dentate gyrus, the subiculum and the fasciolarum cinereum."}},{"Hippocampal formation of WHS11":{"AtlasImage":"Hippocampal formation of WHS11.png,","PartiallyOverlapsWith":["fornix","Fimbria of hippocampus","dentate gyrus","Hippocampus"],"CurationStatus":"uncurated","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143700","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Telencephalon of WHS11","Species":"Mouse","Definition":"Delineation of hippocampal formation in Waxholm MRI atlas as seen in T1,T2*,T2W volumes.  Includes fornix, fimbria, dentate gyrus, Ammon's horn (hippocampus proper, alveus, and what Franklin and Paxinos (2000) identify as dorsal subiculum.  The fimbria and fornix are segmented separately, but grouped under this superstructure.  In T1 image, dorso-laterally bounded by corpus callosum (lower intensity) and cerebral cortex."}},{"Hippocampal molecular layer":{"Created":"2006-07-15","Synonym":"Molecular layer of hippocampus","CurationStatus":"uncurated","Comment":["We need to disambiguate this use of the term from the stratum moleculare"],"SuperCategory":"Cell layer","Id":"birnlex_1211","Definition":"A cytoarchitectural region of the hippocampus consisting of a composite of the two outermost layers of the hippocampus, the Stratum lacunosum-moleculare and the Stratum radiatum (Carpenter-83).  In CA3, there is an additional layer lying above the pyramidal cell layer, the stratum lucidum, which is also included here."}},{"Hippocampal mossy fiber":{"PMID":"PMC2492885","Synonym":"Dentate gyrus mossy fiber","CurationStatus":"pending final vetting","SuperCategory":"Axon","Id":"nlx_subcell_100312","Authors":["David G. Amaral","Helen E. Scharfman"],"Is part of":"Dentate gyrus granule cell","Title":"The dentate gyrus: fundamental neuroanatomical organization (dentate gyrus for dummies)","Definition":"Axon of dentate gyrus granule cell projecting to hippocampal area CA3, characterized by expansions (mossy fiber expansions) giving the fibers a mossy appearance.  These unmyelinated axons were first described by Ramon y Cajal."}},{"Hippocampal mossy fiber expansion":{"Synonym":["mossy fiber expansion","dentate gyrus mossy fiber expansion"],"CurationStatus":"uncurated","SuperCategory":"Synaptic Bouton","Id":"nlx_subcell_1005002","Is part of":"Hippocampal mossy fiber","Definition":"Synaptic expansion of hippocampal mossy fiber axon that makes contact with the thorny excrescences of hippocampal CA3 pyramidal cell dendrites"}},{"Hippocampal region of ABA 2009":{"Synonym":"Hippocampal region","CurationStatus":"uncurated","PartiallyOverlapsWith":["Hippocampus"],"SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_144467","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Hippocampal formation of ABA 2009","Species":"Mouse"}},{"Hippocampal region of RHA11":{"Synonym":"Hippocampal region","CurationStatus":"uncurated","SuperCategory":"RHA11 hippocampal parcellation scheme region","Id":"nlx_151912","ParcellationScheme":"RHA11 hippocampal parcellation scheme","ParcellationSchemePMID":"21519393","Species":"Long Evans Rat,","Definition":"Superparcellation from the Rat Hippocampal Atlas, comprising the hippocampal formation"}},{"Hippocampal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["Sulcus hippocampi","Hippocampal fissure"],"NeuronamesID":"23","CurationStatus":"uncurated","Umlscui":"C0228251","SuperCategory":"Sulcus","Id":"birnlex_4004","Abbrev":["his"]}},{"Hippocampus":{"Synonym":["Cornu ammonis","Ammon's horn","hippocampus proper","ammon horn"],"CurationStatus":"uncurated","Comment":["We have \"hippocampal formation\"","\"hippocampus\" and \"Hippocampus proper\".  I think tha hippocampus is probably a synonym of \"hippocampus proper\".  I would remove hippocampus proper","as I think it likely that many have annotated to hippocampus"],"Is_part_of":"Hippocampal formation","Curator":"Maryann Martone","Abbrev":"Hip","Created":"2006-07-15","Umlscui":"C0019564","SuperCategory":"Regional part of brain","Id":"birnlex_721","Is part of":"Hippocampal formation","Species":"Mammal","Definition":"A part of the hippocampal formation consisting of a three layered cortex located in the forebrain bordered by the medial surface of the lateral ventricle, the dentate gyrus and the subiculum.  It has 3 subfields termed CA1, CA2 and CA3. The term hippocampus is often used synonymously with  hippocampal formation which consists of the hippocampus proper or Cornu Ammonis, the dentate gyrus and the subiculum."}},{"Hippocampus CA1 basket cell":{"Located in":["Hippocampus","CA1 alveus"],"EditorialNote":"Not sure that this is what was meant by EC stellate II. May have to delete this class","Synonym":"Hippocampal CA1 basket cell","CurationStatus":"uncurated","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091205","Species":"Mammal,"}},{"Hippocampus CA1 IS-I neuron":{"Located in":["CA1 stratum radiatum"],"Synonym":"CA1 IS-I cell","CurationStatus":"uncurated","MolecularConstituents":"Calretinin","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","PublicationLink":"15539390","LocationOfAxonArborization":["CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale"],"Created":"11/6/2006","EditorialNote":"http://www.biosci.utexas.edu/directory/userDetails.aspx?id","ExampleImage":"Hippocampus CA1 IS-I neuron.jpg,","SuperCategory":"Neuron","Id":"nlx_cell_100209","Species":"Vertebrata","DefiningCitation":["Somogyi P & Klausberger T"],"Definition":"The IS (Interneuron-Specific) subpopulation of interneurons have axons that preferentially innervate other interneurons. The CA1 Interneuron Specific (IS) Type I cells is one of the many IS cell types from the CA1 region. The soma is located in stratum radiatum and pyramidale with dendrites spanning most layers and the axon innervating mainly calbindin positive and other calretinin positive cells (Acsady et al. 1996b; Gulyas et al. 1996). The possible expression of VIP by these cells is not known."}},{"Hippocampus CA1 IS-II neuron":{"Located in":"CA1 stratum radiatum","DendriteLocation":["CA1 stratum radiatum"],"Synonym":"CA1 IS-II cell","CurationStatus":"uncurated","MolecularConstituents":"Vasoactive intestinal peptide,","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","PublicationLink":"15539390","LocationOfAxonArborization":"CA1 stratum radiatum","Created":"11/6/2006","SuperCategory":"Neuron","Id":"nlx_cell_1006029","Species":"Vertebrata","DefiningCitation":["Somogyi P & Klausberger T"],"Definition":"The IS (Interneuron-Specific) subpopulation of interneurons have axons that preferentially innervate other interneurons. The CA1 Interneuron Specific (IS) type II cell is VIP+. The soma was reported mainly in stratum radiatum and the border with lacunosum-moleculare, and the dendrites are mostly in stratum lacunosum-moleculare (Acsady et al. 1996b; Gulyas et al. 1996). The axon innervates mainly CCK/VIP positive basket cells (Acsady et al. 1996b; Gulyas et al. 1996). The possible expression of calretinin by these cells is not known."}},{"Hippocampus CA1 IS-III neuron":{"Located in":["CA1 stratum radiatum"],"DendriteLocation":["CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale","CA1 stratum radiatum"],"Synonym":"CA1 IS-III cell","CurationStatus":"uncurated","MolecularConstituents":["Vasoactive intestinal peptide","Calretinin"],"Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","PublicationLink":"15539390","LocationOfAxonArborization":["CA1 alveus","CA1 stratum oriens"],"Created":"11/6/2006","SuperCategory":"Neuron","Id":"nlx_36222","Species":"Vertebrata","DefiningCitation":["Somogyi P & Klausberger T"],"Definition":"The IS (Interneuron-Specific) subpopulation of interneurons have axons that preferentially innervate other interneurons. CA1 Interneuron Specific (IS) type III cells are VIP+, calretinin+ and terminals mGluR7a+. The soma is located mainly in stratum pyramidale and radiatum with radial dendrites crossing most layers (Acsady et al. 1996a,b). The axon innervates mainly O-LM cells (Acsady et al. 1996a; Ferraguti et al. 2004) and terminals express high level of mGluR7a in the presynaptic active zone (Somogyi et al. 2003)."}},{"Hippocampus CA1 ivy neuron":{"Located in":"CA1 stratum pyramidale,","DendriteLocation":["CA1 alveus","CA1 stratum oriens","CA1 stratum radiatum"],"Synonym":["CA1 ivy cell"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"PublicationLink":"18367092","Curator":"Sridevi Polavaram","Has role":"Intrinsic neuron role,","LocationOfAxonArborization":["CA1 alveus","CA1 stratum oriens","CA1 stratum radiatum"],"Created":"11/5/2005","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_35220","DefiningCitation":["Fuentealba P et al."],"Definition":"Ivy cells are highly abundant GABAergic interneurons when compared to basket, bistratified, or axo-axonic cells. \"Ivy\" cells are named after their dense and fine axons innervating mostly basal and oblique pyramidal cell dendrites. They express nitric oxide synthase, neuropeptide Y, and high levels of GABAa receptor aplha1 subunit and they are also identified as slow-spiking interneurons that regulate the excitability of pyramidal cell dendrites through slowly rising and decaying GABAergic inputs."}},{"Hippocampus CA1 lacunosum moleculare neuron":{"LocationOfAxonArborization":["CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale","CA1 stratum radiatum"],"Located in":"CA1 stratum lacunosum-moleculare","DendriteLocation":["CA1 alveus","CA1 stratum oriens","CA1 stratum radiatum"],"Created":"11/5/2005","Synonym":"CA1 LM neuron","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"SuperCategory":"Neuron","Curator":"Sridevi Polavaram","PublicationLink":"7889123","Id":"nlx_92500","DefiningCitation":"Bernard C & Wheal HV (1994)","Definition":"CA1 Lacunosum-Moleculare (LM) interneurons are one of the inhibitory interneuron in the CA1 area. The L-M interneurons have been described as non-fast spiking cells (Kawaguchi and Hama, 1987) with membrane properties very different from those of pyramidal cells (Williams and Lacaille, 1993). Dendrites extend in the stratum lacunosum-moleculare, radiatum, and oriens and have a very wide extension in the transverse slice (Lacaille and Schwartzkroin, 1988a). The axonal arborization seems to cover a wide area in both transverse and longitudianal directions, projecting in stratum pyramidale and sometimes in the stratum oriens (Lacaille and Schwartzkroin, 1988a)."}},{"Hippocampus CA1 LM(R) PP neuron":{"Located in":"CA1 stratum radiatum","DendriteLocation":["CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale","CA1 stratum radiatum"],"Synonym":["CA1 lacunosum-moleculare radiatum perforant path associated cell","CA1 LM/R PP cell"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","PublicationLink":"15539390","Abbrev":"CA1 LM(R) PP neuron","LocationOfAxonArborization":["Dentate gyrus molecular layer","CA1 stratum radiatum"],"Created":"11/5/2005","SuperCategory":"Neuron","Id":"nlx_81310","Species":"Vertebrata","DefiningCitation":"Somogyi & Klausberger (2005)","Definition":"CA1 lacunosum-moleculare radiatum PP neuron is a type of CA1 interneuron which is associated with perforant pathway. The cell bodies of these cells are in stratum radiatum or at the border of stratum radiatum and lacunosum-moleculare. The dendritic field reaches the alveus and covers all layers (Hajos & Mody, 1997; Vida et al. 1998)."}},{"Hippocampus CA1 neurogliaform neuron":{"Located in":"CA1 stratum lacunosum moleculare","LacksMolecularConstituents":["VIP"],"DendriteLocation":["Dentate gyrus molecular layer"],"DendriteShape":"stellate","Synonym":["CA1 NG cells"],"CurationStatus":"uncurated","MolecularConstituents":["Neuropeptide Y"],"Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","PublicationLink":"16033887","Abbrev":"NG","LocationOfAxonArborization":["Dentate gyrus molecular layer"],"SpineDensityOnDendrites":"Smooth","Created":"11/6/2006","SuperCategory":"Neuron","Id":"nlx_cell_1006031","Species":"Vertebrata","DefiningCitation":["Price CJ et al."],"Definition":"CA1 neurogliaform neuron is a GABAergic interneuron, these cells are positive for NPY and co-express the actin-binding protein alpha-actinin-2. They are not positive for PV and VIP. Characteristically these neurons has a round cell body and short, non-spiny dendrites that were arranged in a stellate patterns around the cell body, spatially localized to the SLM, and often enter the molecular layer of the dentate gyrus. The axons are branched profusely close to soma occupying greater area than dendrites, like dendrites axons also tend to occupy mainly the SLM, often traveling fairly long distances along the SLM axis and mostly even entering the neighboring molecular layer of the dentate gyrus."}},{"Hippocampus CA1 oriens lacunosum moleculare neuron":{"Located in":["CA1 alveus"],"Synonym":"CA1 O-LM interneuron","MolecularConstituents":["Parvalbumin","Somatostatin"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","Abbrev":"CA1 O-LM","LocationOfAxonArborization":"CA1 stratum lacunosum moleculare,","PMID":"15539390","EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","Neurotransmitter":"GABA","ExampleImage":"Hippocampus CA1 oriens lacunosum moleculare neuron.gif,","SuperCategory":"Neuron","Id":"nlx_cell_091206","Species":"Vertebrata","DefiningCitation":"p70. Andersen et al. \"The Hippocampus Book\" 2007","Definition":"CA1 Oriens Lacunosum Moleculare (O-LM) cell is a neuron, which is characterized as a non-pyramidal cell type and interneuron that is mostly immunoreactive to GABAergic markers with the soma and dendrites mainly located in the CA1 stratum oriens and alveus, and axons extend directly to the stratum lacunosum-moleculare, ramifying there to form a dense plexus, forming symmetrical inhibitory synapses with the distal apical dendrites of pyramidal neurons while receiving excitatory input from CA1 recurrent collaterals in a disynaptic, feedback manner."}},{"Hippocampus CA1 pyramidal cell":{"Located in":"CA1 stratum pyramidale,","BranchingMetrics":"apical/basal","Synonym":["Hippocampal CA1 Pyramidal Neuron","CA1 pyramidal neuron"],"CurationStatus":"uncurated","FiringPatterns":"Regular firing and bursting","CellSomaSize":"Large soma","LocationOfAxonArborization":["Subiculum"],"SpineDensityOnDendrites":"spiny high density","LocationOfLocalAxonArborization":"Few","Neurotransmitter":"Glutamate,","SuperCategory":"Neuron","HasRole":"Principal neuron role","CellSomaShape":"Pyramidal","Species":"Vertebrata","AxonProjectionLaterality":"ipsilateral","DendriteLocation":["CA1 stratum oriens","CA1 stratum radiatum"],"Comment":["Prepended \"CA1\" to location of dendrites"],"Has role":"Principal neuron role","NeurotransmitterReceptors":["Glutamate"],"OriginOfAxon":"soma and sometimes dendrite","EditorialNote":"http://neuro.bcm.edu/saglab/","ExampleImage":"Hippocampus CA1 pyramidal cell.jpg,","Id":"sao830368389","AxonMyelination":"myelinated","Definition":"Pyramidal neuron with a soma located in hippocampal area CA1.  It receives input from Schaffer collaterals of CA3 pyramidal neurons, and sends its axon to the subiculum and entorhinal cortex."}},{"Hippocampus CA1 stratum oriens neuron":{"Located in":["CA1 stratum oriens"],"DendriteLocation":["CA1 stratum oriens","CA1 alveus","CA1 stratum pyramidale","CA1 stratum radiatum"],"Synonym":["vertical cells (Lacaille and williams"],"MolecularConstituents":"GABA A-gated anionic channel","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram,","Has role":"Intrinsic neuron role","LocationOfAxonArborization":["CA1 stratum oriens","CA1 alveus","CA1 stratum pyramidale","CA1 stratum radiatum"],"PMID":"7889123","SuperCategory":"Neuron","Id":"nlx_cell_090807","DefiningCitation":["Benard & Wheal","Hippocampus"],"Definition":"CA1 stratum oriens neuron is a neuron, which is characterized as an interneuron by inhibiting pyramidal cells through the activation of GABAa (Traub et al., 1987a) with soma located in CA1 stratum orines and alveus, dendrites extending into all strata (Lacaille and williams, 1990) and axons covering a wide area in the transverse direction, projecting onto basal dendrites and soma of pyramidal cells and other interneurons (Lacaille et al., 1987) in the hippocampus."}},{"Hippocampus CA1 trilaminar neuron":{"Located in":["CA1 alveus"],"DendriteLocation":["CA1 alveus","CA1 stratum oriens"],"Synonym":"CA1 trilaminar cell","DendriteShape":"horizontal","MolecularConstituents":["M2 receptor"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","LocationOfAxonArborization":["CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale","CA1 stratum radiatum"],"PMID":["15539390","18599766"],"Created":"11/6/2006","SuperCategory":"Neuron","Id":"nlx_27085","DefiningCitation":["Somogyi & Klausberger","2005 (15539390); Klausberger T & Somogyi P","2008 (18599766);Spruston"],"Definition":"The CA1 trilaminar neuron is a neuron that is characterized by its axon densely innervating three layers stratum oriens, pyramidale and radiatum (Sik et al. 1995) projecting to subiculum and possibly to other regions, while the soma and long horizontal dendrites are in stratum oriens with strong immunoreactivity for the m2 receptor in the somato-dendritic domain and intense presynaptic mGluR8a decoration. It must also be noted that the same name has been used for various other cells with axon in at least three laminae (Hajos & Mody, 1997; Pawelzik et al. 2002). However, for this particular cell class the axons project to subiculum and possibly to other brain areas as well."}},{"Hippocampus CA2 basket cell broad":{"Located in":["Hippocampus","CA2"],"LacksMolecularConstituents":"Calbindin 28K,","Located_in":"CA2 stratum pyramidale,","Synonym":"CA2 basket cell","CurationStatus":"uncurated","MolecularConstituents":"Parvalbumin","Comment":"This cell lacks calbindin.  We need to add a \"lacks molecular constituent\" property","LocationOfAxonArborization":["CA1 stratum pyramidale","CA2 alveus","CA2 stratum oriens","CA2 stratum pyramidale","CA2 stratum radiatum"],"PMID":"17611285","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091207","Species":"Vertebrata","DefiningCitation":"Mercer et. al. J. Neurosci 2007 PMID: 17611285","Definition":"The CA2 basket cells are the largest group of interneurons whose vertically oriented dendrites extend across all layers from stratum oriens into stratum lacunosum-moleculare and whose axons ramify extensively in stratum pyramidale. The broad basket cells have significantly broader dendritic width, and axonal arbors than that of other types of CA2 basket cells or of CA1 basket cells."}},{"Hippocampus CA2 basket cell narrow":{"Located in":"CA2 stratum pyramidale,","DendriteLocation":["CA2 alveus","CA2 stratum oriens","CA2 stratum radiatum"],"Synonym":"CA2 basket cell","MolecularConstituents":["Parvalbumin"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"LocationOfAxonArborization":["CA2 alveus","CA2 stratum oriens","CA2 stratum pyramidale"],"PMID":"17611285","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091208","DefiningCitation":"Mercer et al. J. Neurosci 2007 PMID: 17611285","Definition":"The CA2 basket cells are the largest group of interneurons in the CA2 region whose vertically oriented dendrites extend across all layers from stratum oriens into stratum lacunosum-moleculare and whose axons ramify extensively in stratum pyramidale. The narrow basket cells are narrow and both dendrites and axons are confined to the region of origin."}},{"Hippocampus CA2 bistratified cell broad":{"Located in":"CA2 stratum pyramidale,","DendriteLocation":["CA2 alveus","CA2 stratum oriens","CA2 stratum pyramidale","CA2 stratum radiatum","CA1 stratum radiatum"],"Synonym":"CA2 bistratified cell","MolecularConstituents":"Cholecystokinin,","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"LocationOfAxonArborization":["CA2 alveus","CA2 stratum oriens","CA2 stratum pyramidale","CA2 stratum radiatum","CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale"],"PMID":"17611285","Neurotransmitter":"GABA","SuperCategory":"Neuron","Id":"nlx_cell_091209","DefiningCitation":"Mercer et al. J. Neurosci 2007 PMID: 17611285","Definition":"The CA2 bistratified cells have radially oriented dendrites that resemble CA1 bistratified cells, but they extend through stratum oriens and stratum radiatum without entering stratum lacunosum-moleculare. The broad CA2 bistratified cells have dendrites that extend horizontally into all three CA subfields."}},{"Hippocampus CA2 bistratified cell narrow":{"Located in":"CA2 stratum pyramidale,","DendriteLocation":["CA2 alveus","CA2 stratum oriens","CA2 stratum pyramidale"],"Synonym":"CA2 bistratified cell","MolecularConstituents":"Cholecystokinin,","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"LocationOfAxonArborization":["CA2 alveus","CA2 stratum oriens","CA2 stratum pyramidale","CA2 stratum radiatum","CA1 alveus","CA1 stratum oriens","CA1 stratum pyramidale"],"PMID":"17611285","Neurotransmitter":"GABA","SuperCategory":"Neuron","Id":"nlx_cell_091004","DefiningCitation":"Mercer et al. J. Neurosci 2007 PMID: 17611285","Definition":"A type of neuron found in hippocampal area CA2 characterized by radially oriented dendrites that resemble CA1 bistratified cells, but they extend through stratum oriens and stratum radiatum without entering stratum lacunosum-moleculare.  The narrow CA2 bistratified cell dendrites and axons are more confined within the CA2 region."}},{"Hippocampus CA2 pyramidal neuron":{"Located in":["CA2"],"Located_in":"CA2 stratum pyramidale","Synonym":"CA2 pyramidal cell","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"LocationOfAxonArborization":["CA1 alveus","CA1 stratum oriens","CA1 stratum radiatum","CA2 alveus","CA2 stratum oriens","CA2 stratum radiatum","CA3 alveus","CA3 stratum oriens"],"PMID":"17611285","EditorialNote":"http://blog.targethealth.com/?p","Neurotransmitter":"Glutamate,","ExampleImage":"Hippocampus CA2 pyramidal neuron.jpg,","SuperCategory":"Neuron","Id":"nlx_cell_20090311","Species":"Vertebrata","DefiningCitation":"Mercer et al. J. Neurosci 2007 PMID 17611285","Definition":"CA2 pyramidal cells are the primary excitatory cells of CA2 region of the hippocampus. These cells have shorter dendrites when compared to CA1 pyramidal cells. The axons arbors into stratum radiatum, as well as into stratum oriens of CA1, CA2 and CA3 regions. The CA2 pyramids are innervated by schaffer collaterals in stratum oriens and stratum radiatum and by input from entorhinal cortex in stratum lacunosum moleculare."}},{"Hippocampus CA3 axo-axonic cell":{"Located in":"CA3 stratum pyramidale","DendriteLocation":["CA3 alveus","CA3 stratum oriens","CA3 stratum lacunosum moleculare","CA3 stratum radiatum"],"Synonym":"CA3 chandelier cell","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram","OriginOfAxon":"soma","LocationOfAxonArborization":["CA3 alveus","CA3 stratum oriens","proximal"],"PMID":"p353 PMID 8915675","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091212","HasRole":"Intrinsic neuron role","DefiningCitation":["Freund & Buzsaki","1996","p355"],"Definition":"CA3 Chandelier cells of the hippocampus are very similar to those in the dentate gyrus. The cell bodies are located within or immediately adjacent to the pyramidal cell layer and possess radially oriented dendrites spanning all layers. According to the distribution of the dendritic tree, chandelier cells are in a position to receive excitatory input from all major sources of afferents in both the CA1 and CA3 subfields."}},{"Hippocampus CA3 basket cell":{"Located in":"CA3 stratum pyramidale,","DendriteLocation":["CA3 alveus","CA3 stratum oriens","CA3 stratum lucidum","CA3 stratum radiatum"],"Synonym":"CA3 pyramidal basket cell","DendriteShape":["pyramidal"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram,","OriginOfAxon":"soma","LocationOfAxonArborization":["CA3 alveus","CA3 oriens proximal"],"PMID":["p357"],"Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091213","HasRole":"Intrinsic neuron role","DefiningCitation":["Freund & Buzsaki","1996","p357"],"Definition":"The CA3 basket cell is an interneuron located in hippocampus area CA3 characterized by a triangular or fusiform soma, with one to three dendrites extending from the cell soma.  One of the three dendrites originate from the apical pole of soma, which then branch profusely, ascend through stratum radiatum, and often penetrate stratum lacunosum-moelculare. Primary basal dendrites are more numerous. They also branch close to soma and fan out toward the alveus, spanning the entire depth of stratum oriens."}},{"Hippocampus CA3 IS-I cell":{"Located in":["CA3 alveus","CA3 stratum oriens","CA3 stratum radiatum"],"DendriteLocation":"CA3 stratum radiatum,","Synonym":"CA3 Interneuron-specific I cell","CurationStatus":"uncurated","MolecularConstituents":"Calretinin","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram,","OriginOfAxon":"soma","Abbrev":"CA3 IS I","LocationOfAxonArborization":"CA3 stratum radiatum,","PMID":"8915675","Neurotransmitter":"GABA,","SuperCategory":"Neuron","HasRole":"Intrinsic neuron role","Id":"nlx_cell_091210","Species":"Vertebrata","DefiningCitation":["Freund & Buzsaki","1996","p373"],"Definition":"The IS (Interneuron-Specific) subpopulation of interneurons have axons that preferentially innervate other interneurons. CA3 IS-I neurons are visualized for CR and occur in all subfields of hippocampus and dentate gyrus. The CA3 IS-I cells has soma located in strata radiatum, oriens and pyramidale. The dendritic tree arborizes extensively in stratum radiatum but may also invade other layers. The characteristic feature of these dendrites is that they from long dendrodendritic junctions with each other. The main axons ramify in stratum radiatum, where they emit several collaterals that course in all directions."}},{"Hippocampus CA3 IS-II cell":{"Located in":"CA3 stratum radiatum","DendriteLocation":"CA3 stratum lacunosum moleculare","Synonym":"CA3 interneuron-specific II cell","CurationStatus":"uncurated","MolecularConstituents":"Vasoactive Intestinal Polypeptide","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram,","OriginOfAxon":"soma","Abbrev":"CA3 IS II","LocationOfAxonArborization":"CA3 stratum radiatum,","PMID":"8915675","Neurotransmitter":"GABA","SuperCategory":"Neuron","HasRole":"Intrinsic neuron role","Id":"nlx_cell_091211","Species":"Vertebrata","DefiningCitation":["Freund & Buzsaki","1996","p374"],"Definition":"The IS (Interneuron-Specific) subpopulation of interneurons have axons that preferentially innervate other interneurons. CA3 IS-II cell type is visualized by immunostaining for VIP. IS-II neurons are characterized in hippocampus alone, where their somata are found in stratum radiatum. The dendritic tree consists of a tuft of smooth or sparsely spiny dendrites restricted to stratum lacunosum-moleculare, where they profusely arborize. The axon descends toward stratum pyramidale, thus forming weeping willowlike arbor."}},{"Hippocampus CA3 lacunosum moleculare neuron":{"Located in":"CA3 stratum lacunosum moleculare","DendriteLocation":"CA3 stratum lacunosum moleculare","Synonym":"CA3 LM interneurons","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Abbrev":"CA3 LM","LocationOfAxonArborization":["CA3 stratum radiatum"],"PMID":"19496174","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091214","CellSomaShape":"bipolar","DefiningCitation":"p70. Andersen et al. \"The Hippocampus Book\" 2007","Definition":"The CA3 Lacunosum Moleculare (LM) neurons are interneurons with somata in stratum lacunosum-moleculare that receive converging stimulation from the DG and entorhinal cortex as well as from within CA3. These LM neurons have dendrites that are oriented horizontally within the layer but occasionally have branches that extend into the pyramidal cell layer. The axon also takes a predominantly horizontal orientation and ramifies mainly in the stratum lacunosum-moleculare or superficial layer portion of the stratum radiatum."}},{"Hippocampus CA3 oriens interneuron":{"Located in":"CA3 alveus/oriens","Synonym":["CA3 SO interneuron","CA3 SO neuron","Hippocampus CA3 stratum oriens interneuron","CA3 stratum oriens interneuron"],"CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram,","LocationOfAxonArborization":["CA3 alveus/oriens","CA3 stratum radiatum","CA3 stratum lacunosum-moleculare"],"PMID":["7889123"],"Neurotransmitter":"GABA,","SuperCategory":"Neuron","HasRole":"Intrinsic neuron role","Id":"nlx_cell_091215","Species":"Vertebrata","DefiningCitation":["PMID 7889123"],"Definition":"The CA3 stratum oriens interneuron is a fast spiking interneuron in hippocampal area CA3 with a main dendrite arborization extending in the stratum oriens and a widespread axonal arborization in all strata (Kawaguchi et al., 1987). The vast majority of dendritic processes were confined to the same layers as the cell bodies (Kantona et al., 1999)."}},{"Hippocampus CA3 oriens lacunosum moleculare neuron":{"Located in":["CA3 stratum oriens"],"DendriteLocation":["CA3 alveus","CA3 stratum oriens","CA3 stratum lucidum","CA3 stratum pyramidale"],"Synonym":"OLM cell","MolecularConstituents":"Somatostatin","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"SynapticPhysiology":"output synapses: GABAa receptor","Abbrev":"OLM","LocationOfAxonArborization":"CA3 stratum lacunosum moleculare","PMID":"p367-p369 PMID 8915675","DefiningCriteria":"dense axonal arbors are restricted to stratum lacunosum-moelculare","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091216","CellSomaShape":"Pyramidal Soma Quality","DefiningCitation":"p70. Andersen et al. \"The Hippocampus Book\" 2007","Definition":"OLM cells (oriens/lacunosum-moleculare associated cell) has as its defining feature a dense axonal arbor that is confined to the stratum lacunosum-moleculare (also known as cells terminating in conjunction with entorhinal afferents). In principle the cell body and dendritic trees are located in the zones occupied by recurrent pyramidal cell collaterals. In CA3 this includes all strata except the stratum oriens."}},{"Hippocampus CA3 pyramidal cell":{"DendriteLength":"Total Length: 12,481.9 2,998.9 m","Located in":"CA3 stratum pyramidale,","AxonProjectionLaterality":"bilateral","BranchingMetrics":"apical/basal","DendriteLocation":["CA3 stratum oriens","CA3 stratum radiatum"],"Synonym":["Hippocampal CA3 Pyramidal Neuron","CA3 pyramidal neuron"],"CurationStatus":"uncurated","Authors":["Buckmaster PS","Strowbridge BW"],"NeurotransmitterReceptors":["Glutamate receptor"],"Has role":"Principal neuron role","Title":"A comparison of rat hippocampal mossy cells and CA3c pyramidal cells.","OriginOfAxon":"soma and sometimes dendrite","LocationOfAxonArborization":["CA3 stratum oriens","CA3 stratum radiatum","CA1 stratum oriens"],"CellSomaSize":"Large soma","PMID":"8283200","CellularSynapticTarget":"Hippocampus CA1 pyramidal cell,","SpineDensityOnDendrites":"spiny high density","EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","Neurotransmitter":"Glutamate,","LocationOfLocalAxonArborization":"CA3","ExampleImage":"Hippocampus CA3 pyramidal cell.gif,","SuperCategory":"Neuron","AxonMyelination":"myelinated","Id":"sao383526650","CellSomaShape":"Pyramidal","Species":"Vertebrata","Definition":"This is the major output neuron in area CA3 of the hippocampus.  It receives input from mossy fibers of the dentate gyrus.  Its axon projects to the contralateral hippocampus and subcortically to the septal nucleus, and sends axon collaterals called Shaffer collaterals to the nearby CA1 region."}},{"Hippocampus CA3 pyramidal cell axon":{"CurationStatus":"uncurated","SuperCategory":"Axon","Id":"nlx_36816","Is part of":"Hippocampus CA3 pyramidal cell","Definition":"The axon of a CA3 pyramidal cell"}},{"Hippocampus CA3 pyramidal cell synaptic bouton":{"CurationStatus":"uncurated","SuperCategory":"Synaptic Bouton","Id":"nlx_35833","Is part of":"Hippocampus CA3 pyramidal cell axon"}},{"Hippocampus CA3 radiatum neuron":{"Located in":"CA3 stratum radiatum","DendriteLocation":"CA3 stratum radiatum","Synonym":"CA3 R interneuron","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"LocationOfAxonArborization":["CA3 stratum pyramidale","CA3 stratum lucidum","CA3 stratum radiatum"],"PMID":"19496174","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091217","CellSomaShape":"bipolar","DefiningCitation":"Ascoli et al. 2009 J. Comp. Neurol. PMID: 19496174","Definition":"The CA3 Radiatum (R) neurons are interneurons with somata in stratum radiatum which receives converging stimulation from the DG and entorhinal cortex as well as from within CA3. The dendritic tree of R interneurons typically extend between the dorsal blade of the dentate gyrus and the stratum pyramidale of CA3. The axonal branches often extend beyond their layer of somatic residence into stratum lacunosum-moleculare or stratum pyramidale."}},{"Hippocampus CA3 spiny CR cell":{"Located in":["CA3 stratum lucidum"],"DendriteLocation":["CA3 stratum lucidum"],"Synonym":["CA3 Spiny CR immunoreactive cell"],"MolecularConstituents":"Calretinin,","CurationStatus":"uncurated","Comment":["This class is still under review and requires changes before making it final. In the mean time"],"Curator":"Sridevi Polavaram,","Abbrev":"CA3 spiny CR","LocationOfAxonArborization":"CA3 stratum lacunosum moleculare,","PMID":"8915675","Neurotransmitter":"GABA,","SuperCategory":"Neuron","Id":"nlx_cell_091218","HasRole":"Intrinsic neuron role","DefiningCitation":["Freund & Buzsaki","1996","p387"],"Definition":"The CA3 spiny CR cell is an interneuron in Hippocampus that is present mostly in regions where mossy fibers have a high density, i.e., in the hilus of the dentate gyrus and in stratum lucidum of CA3 subfield. The dendrites and somata frequently possess numerous long hair-like spines that penetrate into bundles of mossy fibers."}},{"Hippocampus of PHT00":{"Synonym":"hippocampus","CurationStatus":"pending final vetting","ISBN":"123582555","Curator":"CoCoMac","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"Hip","EditorialNote":"Looking at the hierarchy in the scalable brain atlas, the hippocampus includes the subicular complex and the dentate gyrus.  Neurolex considers this set of structures to compose the hippocampal formation","PartiallyOverlapsWith":["Hippocampus","subiculum","dentate gyrus"],"PublicationDate":"2000","SuperCategory":"Parcellation scheme parcel","Id":"nlx_br_2","Is part of":"Allocortex of PHT00","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Hippocampus proper of RHA11":{"EditorialNote":"The Rat Hippocampal Atlas does not show the hippocampus proper in its hierarchy;  however, in the text, they do state that \"The Cornu Ammonis or Ammon's Horn (CA) also referred to as hippocampus proper, is characterized by a thin layer of densely packed pyramidal cells, enclosed by an outer plexiform layer and an inner polymorph layer, also called stratum oriens.\"  Therefore, I am using it to group the 3 CA fields together.","CurationStatus":"graph position temporary","PartiallyOverlapsWith":"Hippocampus","SuperCategory":"RHA11 hippocampal parcellation scheme region","Curator":["Maryann Martone"],"Id":"nlx_151939","ParcellationScheme":"RHA11 hippocampal parcellation scheme","Is part of":"Hippocampal formation of RHA11","Species":["Long Evans Rat"],"Definition":"Superparcellation comprising the CA fields of the hippocampus."}},{"Hippocampus regio inferior of Cajal":{"Synonym":"regio inferior","CurationStatus":"uncurated","SuperCategory":"Cytoarchitectural fields of hippocampal formation","Id":"nlx_anat_1008014","Definition":"One of two cytoarchitectural division of hippocampus proposed by Ramon y Cajal consisting of a large-celled proximal region of the hippocampus proper.  This region corresponds to CA2 and CA3 in the nomenclature proposed by Lorente de No (Adapted from Paxinos, G. The rat nervous system, Ed 2, Academic Press, San Diego, 1995)"}},{"Hippocampus regio superior of Cajal":{"Synonym":"regio superior","CurationStatus":"uncurated","SuperCategory":"Cytoarchitectural fields of hippocampal formation","Id":"nlx_anat_1008015","Definition":"One of two cytoarchitectural divisions of the hippocampus proper proposed by Ramon y Cajal consisting of a smaller celled distal region, equivalent to CA1 in the nomenclature proposed by Lorente de No. (adapted from Paxinos G. The rat central nervous system, 2nd ed, Academic Press, San Diego 1995)"}},{"Hipposiderinae":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":["C1271366"],"SuperCategory":"Rhinolophidae","Id":"birnlex_489"}},{"Hipposideros":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1020575","SuperCategory":"Hipposiderinae","Id":"birnlex_500"}},{"Hipposideros terasensis":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1210684","SuperCategory":"Hipposideros","Id":"birnlex_511"}},{"Hirudinea":{"EditorialNote":"Listed as a an Order in GBIF.","Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0023209","SuperCategory":"Hirudinida","Id":"birnlex_383"}},{"Hirudinida":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1095854","SuperCategory":"Clitellata","Id":"birnlex_374"}},{"Hirudinidae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998040","SuperCategory":"Hirudiniformes","Id":"birnlex_181"}},{"Hirudiniformes":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998039","SuperCategory":"Arhynchobdellida","Id":"birnlex_176"}},{"Hirudo":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0579183","SuperCategory":"Hirudinidae","Id":"birnlex_186"}},{"Hirudo P Cell":{"Located in":"Segmental ganglia","Synonym":["Pressure Cell"],"CurationStatus":"uncurated","SuperCategory":"Neuron","Is_part_of":"Leech Segmental Ganglion","Id":"nlx_79073","Species":"Medicinal leech,","Definition":"A sensory neuron responsive to pressure stimuli of the skin. There are 4 of them in each segmental ganglia of the leech, and they are located in the lateral and posterior packets."}},{"Hirudo Retzius cell":{"Located in":"Segmental ganglion","Synonym":["Retzius"],"CurationStatus":"uncurated","FiringPatterns":"Spontaneous spiking","Has role":"Modulatory","Authors":["Muller","Nicholls"],"OriginOfAxon":"soma","Title":"Neurobiology of the Leech","CellSomaSize":"70-100 um","Neurotransmitter":"Serotonin,","PublicationDate":"1981","SuperCategory":"Neuron","Polarity":"Unipolar","Id":"nlx_31744","CellSomaShape":"Spherical Soma Quality","Is part of":"Leech Segmental Ganglion","Species":"Medicinal leech,","Definition":"A large, serotonergic neuron located in the central packet of the segmental ganglion in the medicinal leech. Two of these cell are located in each segmental ganglia and are electrically coupled to each other."}},{"Histamine":{"RelatedTo":"Histamine receptor","Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"Monoamines","Id":"nifext_5016","Has role":"Neurotransmitter,","Definition":"is produced by basophils and mast cells (in connective tissues) and is involved in local immune responses and regulating physiological function in the gut and acting as a neurotransmitter. - adapted from Wikipedia"}},{"Histamine Phosphate":{"RelatedTo":["Histamine H2 receptor","Histamine H1 receptor"],"Synonym":[", Histamine","Histamine biphosphate","Histamine dihydrogen phosphate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:51193","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00667","Definition":"Histamine stimulates gastric gland secretion, causing an increased secretion of gastric juice of high acidity. This action is probably due mainly to a direct action on parietal and chief gland cells. Pharmacology: Histamine stimulates gastric gland secretion, causing an increased secretion of gastric juice of high acidity. This action is probably due mainly to a direct action on parietal and chief gland cells. Mechanism of action: Histamine acts directly on the blood vessels to dilate arteries and capillaries; this action is mediated by both H 1- and H 2-receptors. Capillary dilatation may produce flushing of the face, a decrease in systemic blood pressure, and gastric gland secretion, causing an increased secretion of gastric juice of high acidity. Increased capillary permeability accompanies capillary dilatation, producing an outward passage of plasma protein and fluid into the extracellular spaces, an increase in lymph flow and protein content, and the formation of edema. In addition, histamine has a direct stimulant action on smooth muscle, producing contraction if H 1-receptors are activated, or mostly relaxation if H 2-receptors are activated. Also in humans, the stimulant effect of histamine may cause contraction of the intestinal muscle. However, little effect is noticed on the uterus, bladder, or gallbladder. Histamine has some stimulant effect on duodenal, salivary, pancreatic, bronchial, and lacrimal glands. Drug type: Approved. Small Molecule. Drug category: Diagnostic aid. Histamine Agents"}},{"Histamine receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6332"}},{"Histamine-gated chloride channel":{"Created":"2007-09-19","SuperCategory":"Anionic cys-loop ligand-gated ion channel","Id":"nifext_5246"}},{"Histaminergic neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-07-13T03:28:45Z","Contributor":"djs93","SuperCategory":"Aminergic neuron","Id":"nlx_148083","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007367","Definition":"Any neuron (FBbt_00005106) that releases as a neurotransmitter, some histamine (CHEBI:18295)."}},{"Histaminergic system":{"CurationStatus":"uncurated","SuperCategory":"Molecular system","Id":"nlx_anat_1005021","Definition":"any molecule, protein, cell, tissue or organ that is related to histamine."}},{"Histochemical protocol":{"Synonym":"Histochemistry","CurationStatus":"uncurated","SuperCategory":"Microscopy_contrast_enhancement_protocol","Id":"nlx_inv_20090605"}},{"Histogram Bin Width":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3008","SuperCategory":"DICOM term","Id":"nlx_150104","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"The number of consecutive stored pixel values included in a bin. All bins shall be of equal width. Required if a Sequence Item is present."}},{"Histogram Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3020","SuperCategory":"DICOM term","Id":"nlx_150105","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UL","Definition":"Histogram Data encoded as 32 bit unsigned counts of the number of pixel values in each bin. Required if a Sequence Item is present."}},{"Histogram Explanation":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3010","SuperCategory":"DICOM term","Id":"nlx_150106","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Free form text explanation of the meaning of the LUT."}},{"Histogram First Bin Value":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3004","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150107","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US or SS","Definition":"The stored pixel value corresponding to the lowest pixel value counted in the first bin. All image pixel values less than this value are not included in the histogram. Required if a Sequence Item is present. "}},{"Histogram Last Bin Value":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3006","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150108","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US or SS","Definition":"The stored pixel value corresponding to the highest pixel value counted in the last bin. All image pixel values greater than this value are not included in the histogram. Required if a Sequence Item is present."}},{"Histogram Number of Bins":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3002","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150109","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"The number of bins (entries) in the histogram. Required if a Sequence Item is present."}},{"Histogram Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0060_3000","SuperCategory":"DICOM term","Id":"nlx_150110","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Defines a sequence of Histograms. One or more Items may be included in this Sequence."}},{"HLH DNA-binding protein inhibitor":{"Synonym":"DNA-binding protein inhibitor ID ,\"ID protein\"","CurationStatus":"uncurated","Database_Reference":"PIRSF005808","Comment":"Category","SuperCategory":"Protein","Id":"PRO:000000003","Definition":"A protein with a core domain composition consisting of a Helix-loop-helix DNA-binding domain (PF00010) (HLH), common to the basic HLH family of transcription factors, but lacking the DNA binding domain to the consensus E box response element (CANNTG). By binding to basic HLH transcription factors, proteins in this class regulate gene expression. (PRO:CNA)"}},{"Hoehn and Yahr scale":{"PMID":"6067254","RelatedTo":"Parkinsons disease","Synonym":["Hoehn & Yahr scale","Hoehn & Yahr staging"],"Related disease":"Parkinson's disease","CurationStatus":"uncurated","SuperCategory":"Rating scale","Id":"C0451215","Has role":"Movement control assessment","Species":"Human","DefinitionPMID":"15372591","Definition":"a commonly used system for describing how the symptoms of Parkinson's disease progress.Current Scale Specification:Stage 0: No signs of disease.Stage 1: Unilateral symptoms only.Stage 1.5: Unilateral and axial involvement.Stage 2: Bilateral symptoms. No impairment of balance.Stage 2.5: Mild bilateral disease with recovery on pull test.Stage 3: Balance impairment. Mild to moderate disease. Physically independent.Stage 4: Severe disability, but still able to walk or stand unassisted.Stage 5: Needing a wheelchair or bedridden unless assisted."}},{"Holacanthopterygii":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1059405","SuperCategory":"Euacanthomorpha","Id":"birnlex_595"}},{"Holmes-Adie Syndrome":{"Created":"2007-10-05","Synonym":["Adie Syndrome","HAS","Adie's Syndrome"],"CurationStatus":"uncurated","SuperCategory":"Autonomic Nervous System Disease","Id":"birnlex_12581","Definition":"A neurological disorder affecting the pupil of the eye and the autonomic nervous system.  It is characterized by one eye with a pupil that is larger than normal and constricts slowly in bright light  (tonic pupil), along with the absence of deep tendon reflexes, usually in the Achilles tendon.   HAS is thought to be the result of a viral or bacterial infection that causes inflammation and damage to neurons in the ciliary ganglion, an area of the brain that controls eye movements, and the spinal ganglion, an area of the brain involved in the response of the autonomic nervous system.  HAS begins gradually in one eye, and often progresses to involve the other eye.  At first, it may only cause the loss of deep tendon reflexes on one side of the body, but then progress to the other side.  The eye and reflex symptoms may not appear at the same time.  People with HAS may also sweat excessively, sometimes only on one side of the body.  The combination of these 3 symptoms \u2013 abnormal pupil size, loss of deep tendon reflexes, and excessive sweating \u2013 is usually called Ross's syndrome, although some doctors will still diagnosis the condition as a variant of HAS.  Some individuals will also have cardiovascular abnormalities.  The HAS symptoms can appear on their own, or in association with other diseases of the nervous system, such as Sjogren's syndrome or migraine.  It is most often seen in young women.  It is rarely an inherited condition. (NINDS Disorder Index, http://www.ninds.nih.gov/disorders/holmes_adie/holmes_adie.htm)"}},{"Holtzman Sprague-Dawley rat":{"Created":"2007-08-13","CurationStatus":"pending_final_vetting","Umlscui":"C0324535","SuperCategory":"Sprague Dawley","Id":"birnlex_421"}},{"Homarus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998231","SuperCategory":"Nephropidae","Id":"birnlex_619"}},{"Homatropine Methylbromide":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1","Muscarinic acetylcholine receptor M5","Muscarinic acetylcholine receptor M4"],"Synonym":[", Arkitropin","Camatropine","DL-Homatropine methyl bromide","DL-Methylbromide","Esopin","Homapin","Homatromide","Homatropine methyl bromide","Humulon lead salt","Hycodan","probilagol","Malcotran","Mesopin","Methyl Bromide Homatropine","Methylhomatropine","Methylhomatropine bromide","Novatrin","Novatrine","Novatropine","Npvatropine","Sed-tems","Sethyl"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:50373","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00725","Definition":"Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness. Pharmacology: Homatropine methylbromide belongs to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness. Mechanism of action: Homatropine is a quaternary ammonium muscarinic acetylcholine receptor antagonist. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Homatropine methylbromide inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Depending on the dose, anticholinergics may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. Drug type: Approved. Small Molecule. Drug category: Anti-Ulcer Agents. Antimuscarinics. Antispasmodics"}},{"Hominidae":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":"Pongidae","Created":"2006-10-07","CurationStatus":"raw_import","SuperCategory":"Hominoidea","Id":"birnlex_110"}},{"Hominoidea":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":"Pongidae","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C1675848","SuperCategory":"Catarrhini","Id":"birnlex_529"}},{"Homo":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C1300203","SuperCategory":"Homo Pan Gorilla group","Id":"birnlex_232"}},{"Homo Pan Gorilla group":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C1224354","SuperCategory":"Hominidae","Id":"birnlex_238"}},{"Homophilic":{"SuperCategory":"Cellular adhesivity","Id":"PATO_0001440","Definition":"A cellular adhesivity quality inhering in a molecule in one cell by virtue of its attachment to an identical molecule in an adjacent cell."}},{"Honey bee":{"Synonym":["Apis mellifica","Apis mellifera Linnaeus"],"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0323351","SuperCategory":"Apis","Id":"birnlex_447"}},{"Hook":{"SuperCategory":"Surgical Instrument","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","Id":"nlx_20670","Has role":"Instrument role","Definition":"Small sharp and blunt hooks and spatulas are useful in lifting or moving tissue during surgical or dissecting procedures."}},{"Hooper visual organization test":{"Created":"7/10/2009 14:06","CurationStatus":"uncurated","Contributor":"Naomi Kenner","CAO_Id":"CAO_00829","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Hooper_visual_organization_test","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146051","Definition":"a neuropsychological test of visual spatial ability that presents participants with a line drawing of a common object that has been broken into fragments, and asks participants to name what the object would be if reassembled."}},{"Horizontal":{"Synonym":"Horizontal Soma Quality","SuperCategory":"Soma Shape","Id":"nlx_121","Definition":"The soma has a wider center region than the fusiform cell type but is clearly not pyramid-shaped."}},{"Horizontal (PATO 0001855)":{"SuperCategory":"Position","Id":"PATO_0001855","Definition":"A placement quality inhering in a bearer by virtue of being in the plane of the horizon."}},{"Horizontal Cell Morphology":{"Created":"2007-09-05","SuperCategory":"Cell Morphological Quality","Id":"nifext_1"}},{"Horizontal fiber system neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"HFS","SuperCategory":"Small field neuron of the central complex","Has_synaptic_terminal_in":["fan-shaped body layer 4"],"Id":"nlx_147369","Is part of":"Adult central complex","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003635","Fasciculates_with":"pb-fb tract","hasDBXref":"FlyBrain_NDB:10254","Definition":"Neuron whose cell body lies in the cortex just dorsal to the protocerebral bridge and that innervates a single glomerulus of the protocerebral bridge, a segment pair of the fan-shaped body and one of the two ventral bodies (lateral accessory lobes). Bundles of 3 or 4 horizontal fiber system neurons connect each glomerulus to a fan-shaped body segment and then run horizontally in layer 4 where they arborize in all 4 shells. Arborizations in the protocerebral bridge are spiny, terminals in the ventral bodies are blebs, both types of terminals are formed in the fan-shaped body."}},{"Horizontal fiber system neuron pb1":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["fan-shaped body segment pair X"],"Id":"nlx_148249","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007574","hasDBXref":"VFB:FBbt_00007574","Definition":"Horizontal fiber system neuron that innervates protocerebral bridge glomerulus 1, fasciculates with pb-fb tract Z, innervates the contralateral fan-shaped body segment pair X and the contralateral lateral accessory lobe."}},{"Horizontal fiber system neuron pb2":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["lateral accessory lobe","protocerebral bridge glomerulus 2"],"Id":"nlx_148248","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007573","hasDBXref":"VFB:FBbt_00007573","Definition":"Horizontal fiber system neuron that innervates the protocerebral bridge glomerulus 2, and fasciculates with pb-fb tract Z. Crossing contralaterally, it innervates both the fan-shaped body segment pair Y and the lateral accessory lobe."}},{"Horizontal fiber system neuron pb3":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["fan-shaped body segment pair Z"],"Id":"nlx_148247","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007572","hasDBXref":"VFB:FBbt_00007572","Definition":"Horizontal fiber system neuron that innervates protocerebral bridge glomerulus 3, fasciculates with pb-fb tract Y, innervates contralateral fan-shaped body segment pair Z and the contralateral lateral accessory lobe."}},{"Horizontal fiber system neuron pb4":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["fan-shaped body segment pair Z"],"Id":"nlx_148246","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007571","hasDBXref":"VFB:FBbt_00007571","Definition":"Horizontal fiber system neuron that innervates the protocerebral bridge glomerulus 4 and fasciculates with pb-fb tract Y. It also innervates the ipsilateral fan-shaped body segment pair Z and the contralateral lateral accessory lobe."}},{"Horizontal fiber system neuron pb5":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["protocerebral bridge glomerulus 5"],"Id":"nlx_148245","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007570","hasDBXref":"VFB:FBbt_00007570","Definition":"Horizontal fiber system neuron that innervates protocerebral bridge glomerulus 5, fasciculates with pb-fb tract X, innervates the ipsilateral fan-shaped body segment pair Y and the ipsilateral lateral accessory lobe."}},{"Horizontal fiber system neuron pb6":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["protocerebral bridge glomerulus 6"],"Id":"nlx_148244","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007569","hasDBXref":"VFB:FBbt_00007569","Definition":"Horizontal fiber system neuron that innervates protocerebral bridge glomerulus 6 and fasciculates with pb-fb tract X. It also innervates the ipsilateral fan-shaped body segment pair X and the ipsilateral lateral accessory lobe."}},{"Horizontal fiber system neuron pb7":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["protocerebral bridge glomerulus 7"],"Id":"nlx_148243","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007568","hasDBXref":"VFB:FBbt_00007568","Definition":"Horizontal fiber system neuron that innervates protocerebral bridge glomerulus 7, fasciculates with pb-fb tract W, innervates the ipsilateral fan-shaped body segment pair W and the ipsilateral lateral accessory lobe."}},{"Horizontal fiber system neuron pb8":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-01-12T03:00:37Z","Contributor":"djs93","SuperCategory":"Horizontal fiber system neuron","Comment":["See figure 6 of Hanesch et al."],"Has_synaptic_terminal_in":["protocerebral bridge glomerulus 8"],"Id":"nlx_148242","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007567","hasDBXref":"VFB:FBbt_00007567","Definition":"Horizontal fiber system neuron that innervates protocerebral bridge glomerulus 8, fasciculates with pb-fb tract W, innervates the ipsilateral fan-shaped body segment pair W and the ipsilateral lateral accessory lobe."}},{"Horizontal Field of View":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_000C","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150111","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FL","Definition":"The horizontal field of view in degrees."}},{"Horizontal fissure":{"Synonym":["Fissura Horizontalis"],"CurationStatus":"uncurated","SuperCategory":"Superficial feature part of the cerebellum","Id":"nlx_anat_20081255","Definition":"Fissure between cerebellar hemispheric lobules VIIA and VIIBi."}},{"Horizontal limb of the diagonal band":{"Synonym":["Horizontal limb of the diagonal band of Broca"],"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_118","Is part of":"Diagonal band","Abbrev":"hDBB"}},{"Horizontal neuronal orientation":{"SuperCategory":"Orientation","Id":"nlx_48"}},{"Hormone":{"CurationStatus":"uncurated","SuperCategory":"Molecule role","Id":"nlx_15289"}},{"Horner Syndrome":{"Synonym":["Claude Bernard-Horner Syndrome","Miosis","Innervational Defect","Bernard Syndrome","Sympathetic Ocular-Ophthalmoplegia","Ptosis Sympathetic"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Autonomic Nervous System Disease","Id":"birnlex_12586","DefiningCitation":["Miller et al.","Clinical Neuro-Ophthalmology","4th ed"],"Definition":"A syndrome associated with defective sympathetic innervation to one side of the face, including the eye. Clinical features include MIOSIS; mild BLEPHAROPTOSIS; and hemifacial ANHIDROSIS (decreased sweating)(see HYPOHIDROSIS). Lesions of the BRAIN STEM; cervical SPINAL CORD; first thoracic nerve root; apex of the LUNG; CAROTID ARTERY; CAVERNOUS SINUS; and apex of the ORBIT may cause this condition (MeSH)."}},{"Horse radish peroxidase":{"Synonym":"Horseradish peroxidase","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_75066","Has role":["Enzyme","Detector role"],"Abbrev":"HRP","Definition":"An enzyme found in horseradish that is used extensively in molecular biology applications primarily for its ability to amplify a weak signal and increase detectability of a target molecule"}},{"Hot":{"SuperCategory":"Temperature","Id":"PATO_0000678","Definition":"A temperature which is relatively high."}},{"Human":{"Created":"2006-10-05","EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":["homo sapien","homo sapiens","man"],"CurationStatus":"uncurated","Umlscui":"C0086418","SuperCategory":"Homo","Id":"birnlex_516","Definition":"person"}},{"Human immunodeficiency virus":{"CurationStatus":"uncurated","SuperCategory":"Lentivirus","Id":"nlx_62536","Abbrev":"HIV"}},{"Human Performer Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4009","SuperCategory":"DICOM term","Id":"nlx_150112","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Human performer that is involved or responsible for performing the Workitem. Only a single Item shall be permitted in this sequence."}},{"Human Performers Name":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4037","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150113","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Name of the human performer."}},{"Human Performers Organization":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4036","SuperCategory":"DICOM term","Id":"nlx_150114","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Organization to which the human performer is accountable for the activities in the Workitem."}},{"Human Serum Albumin":{"RelatedTo":["AMBP protein","Apolipoprotein E"],"Synonym":["Serum albumin precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00062","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00062","Definition":"Human serum albumin isolated from expired blood plasma Pharmacology: Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. Mechanism of action: Acts as a high molecular weight, very soluble osmolyte Drug type: Approved. Biotech. Drug category: Serum substitutes"}},{"Human subject report":{"Synonym":"patient report","Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Subject report","Id":"birnlex_2328"}},{"Huntingtin":{"SuperCategory":"Protein","Id":"nlx_mol_20090302","Abbrev":"Htt","Definition":"is the protein coded by the gene, huntingtin, identified in 1993. It is variable in its structure as there are many polymorphisms of the gene which can lead to variable numbers of glutamine residues present in the protein. In its wild-type form, it contains 6-35 glutamine residues; however, in individuals affected by Huntington's Disease, it contains more than 36 glutamine residues. Huntingtin has a predicted mass of ~350kDa, although  this varies and is largely dependent on the number of glutamine residues in the protein. Normal huntingtin is generally accepted to be 3144 amino acids in size.  Adapted from Wikipedia"}},{"Huntingtons disease":{"Synonym":["Huntington's","Huntington's Chorea","Huntington's disease","Chronic Progressive Hereditary Chorea (Huntington)"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Neurodegenerative disease","Curator":"Bill Bug","Id":"birnlex_12500","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Abbrev":"HD","Definition":"A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea."}},{"Hyaline Inclusion":{"Synonym":"Pale body","CurationStatus":"uncurated","SuperCategory":"Cellular Inclusion","Id":"nlx_369","Abbrev":"HI","Definition":"Pale eosinophilic inclusions with halos in H&E (hematoxylin and eosin) preparations."}},{"Hyaluronidase":{"RelatedTo":["Serum albumin","N-acetylgalactosamine-6-sulfatase","Hyaluronidase PH-20","Transforming growth factor beta-1","Hyaluronidase-2","Hyaluronidase-1"],"Synonym":["Hyal-1","Hyaluronidase 1 precursor","Hyaluronidase PH-20","Sperm adhesion molecule 1","Sperm surface protein PH-20","hyaluronidase","Vitragan","Vitrase"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00070","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00070","Definition":"Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye. Pharmacology: Hyaluronidase hydrolyzes hyaluronic acid and increase diffusion of injected drugs, thus facilitating their absorption. Hyaluronidase is used for enhancing absorption and distribution of other injected drugs. Mechanism of action: Hyaluronidase is a spreading or diffusing substance. It increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and increases diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption. Drug type: Approved. Biotech. Investigational. Drug category: Anesthetic Adjuvants. Permeabilizing Agents"}},{"Hybrid of mus spretus x mus musculus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2008-04-23","CurationStatus":"raw_import","Umlscui":"C1210594","SuperCategory":"Mus","Id":"birnlex_7411"}},{"Hybrid strains of mus musculus musculus x domesticus":{"Created":"2006-10-07","EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of  the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":"Mus musculus musculus x domesticus","CurationStatus":"uncurated","SuperCategory":"Mouse","Id":"birnlex_224","Definition":"Genomic polymorphism analysis (RFLP)          indicates \"these strains cannot be regarded as archetypes of M.m. domesticus as suggested          by protein polymorphisms and mitochondrial DNA sequence analysis, but rather as genetic          hybrids between the two subspecies\" (C.E. Bishop, et al., Most classical Mus musculus          domesticus laboratory mouse strains carry a Mus musculus musculus Y chromosome, Nature,          1985, v315, p70)."}},{"Hydralazine":{"RelatedTo":["Prolyl 4-hydroxylase subunit alpha-1"],"Synonym":["Hydralazine hydrochloride"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01275","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01275","Definition":"A direct-acting vasodilator that is used as an antihypertensive agent. (PubChem) Pharmacology: A vasodilator, hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. It is commonly used in the condition of pregnancy called preeclampsia. Mechanism of action: Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. Hydralazine, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Vasodilator Agents"}},{"Hydration sphere":{"Synonym":"Waters of hydration","CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001216","Definition":"A cloud of water molecules that surrounds an ion in solution."}},{"Hydrocephalic":{"SuperCategory":"Edematous","Id":"PATO_0001853"}},{"Hydrochlorothiazide":{"RelatedTo":["Carbonic anhydrase 1","Carbonic anhydrase 2","Solute carrier family 12 member 3","Carbonic anhydrase 4"],"Synonym":["Dihydrochlorothiazid","Dihydrochlorothiazide","Dihydrochlorothiazidum","Dihydrochlorurit","Dihydrochlorurite","Dihydroxychlorothiazidum","HCTZ","HCZ","Hydrochlorothiazid","Hydrochlorthiazide","Acuretic","Aldoril","Apresazide","Aquarills","Aquarius","Bremil","Caplaril","Capozide","Chlorosulthiadil","Chlorzide","Cidrex","Dichlorosal","Dichlorotride","Dichlotiazid","Dichlotride","Diclotride","Dicyclotride","Direma","Disalunil","Diu-Melusin","Drenol","Esidrex","Esimil","Fluvin","Hidril","Hidrochlortiazid","Hidroronol","Hidrotiazida","Hydril","Hydro-Aquil","Hydro-Diuril","Hydrodiuretic","Hydropres","Hydrosaluric","Hydrothide","Hydrozide","Hypothiazid","Hypothiazide","Idrotiazide","Ivaugan","Jen-Diril","Lotensin Hct","Maschitt","Megadiuril","Moduretic","Nefrix","Neo-Codema","Neoflumen","Newtolide","Panurin","Ro-Hydrazide","Servithiazid","Thiaretic","Thiuretic","Thlaretic","Timolide","Urodiazin","Vetidrex"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00999","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00999","Definition":"A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. (PubChem) Pharmacology: Thiazides such as hydrochlorothiazide promote water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Mechanism of action: As a diuretic, hydrochlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like hydrochlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of hydrochlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Diuretics. Sodium Chloride Symporter Inhibitors"}},{"Hydrocodone":{"RelatedTo":["Delta-type opioid receptor","Kappa-type opioid receptor"],"Synonym":["Dihydrocodeinone","Hidrocodona (INN-Spanish)","Hydrocodon","Hydrocodonum (INN-Latin)","Hydrocone","Hydroconum","Idrocodone (Dcit)","Bekadid","Codinovo","Dico","Dicodid"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5779","Has role":"Drug","Is part of":"Vicodin","DefiningCitation":"http://www.drugbank.ca/drugs/DB00956","Definition":"Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. (PubChem) Pharmacology: Hydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Mechanism of action: Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug type: Approved. Illicit. Small Molecule. Drug category: Analgesics. Analgesics, Opioid. Antitussive Agents. Antitussives. Narcotics"}},{"Hydrocortamate":{"RelatedTo":["Annexin A1"],"Synonym":[", Hydrocortamate Hydrochloride","Magnacort"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:50851","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00769","Definition":"Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Pharmacology: Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated. Mechanism of action: Hydrocortamate binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory, steroidal. Corticosteroid. Glucocorticoids. Immunosuppressive Agents"}},{"Hydrocortisone":{"RelatedTo":["Nitric oxide synthase","inducible","Arachidonate 5-lipoxygenase","Annexin A1","Sex hormone-binding globulin","Glucocorticoid receptor"],"Synonym":["11beta-Hydroxycortisone","17alpha-Hydroxycorticosterone","Anti-inflammatory hormone","Dihydrocostisone","Hidrocortisona (INN-Spanish)","Hydrocorticosterone","Hydrocortisone Acetate","Hydrocortisone Base","Hydrocortisone Butyrate","Hydrocortisone Sodium Phosphate","Hydrocortisone Valerate","Hydrocortisone alcohol","Hydrocortisone free alcohol","Hydrocortisonum (INN-Latin)","Hydroxycortisone","Idrocortisone (DCIT)","Acticort","Aeroseb HC","Aeroseb-HC","Ala-Scalp","Ala-cort","Alacort","Algicirtis","Alphaderm","Amberin","Anflam","Anusol HC","Aquacort","Aquanil HC","Balneol-hc","Barseb HC","Basan-Corti","Beta-hc","CaldeCORT Spray","Cetacort","Clear aid","Cleiton","Cobadex","Colocort","Compound F","Cort-Dome","Cort-Quin","Cortaid","Cortanal","Cortef","Cortef Acetate","Cortenema","Cortesal","Corticreme","Cortifan","Cortifoam","Cortiment","Cortisol","Cortisol alcohol","Cortisolonum","Cortisporin","Cortisporin Otico","Cortispray","Cortolotion","Cortonema","Cortoxide","Cortril","Cremesone","Cremicort-H","Cutisol","Delacort","Derm-Aid","Dermacort","Dermaspray","Dermil","Dermocortal","Dermolate","Dioderm","Dome-cort","Domolene-HC","Dricort","Drotic","EF corlin","Efcorbin","Efcortelan","Efcortelin","Eldecort","Eldercort","Epicort","Epiderm H","Esiderm H","Evacort","Ficortril","Fiocortril","Flexicort","Foille Insetti","Genacort","Glycort","Gyno-Cortisone","H-Cort","Heb Cort","Heb-Cort","Hemsol-HC","Hi-cor","Hidalone","Hidro-Colisona","Hycort","Hycortol","Hycortole","Hydracort","Hydrasson","Hydro-adreson","Hydro-colisona","Hydrocort","Hydrocortal","Hydrocortistab","Hydrocortisyl","Hydrocortone","Hydroskin","Hysone","Hytisone","Hytone","Hytone lotion","Incortin-H","Incortin-hydrogen","Kendall's compound F","Komed HC","Kyypakkaus","Lacticare HC","Lacticare-HC","Lactisona","Locoid","Locoid Lipocream","Lubricort","Maintasone","Medicort","Meusicort","Micort-hc","Mildison","Milliderm","Neosporin-H Ear","Nogenic HC","Nutracort","Nystaform-HC","Optef","Orabase HCA","Otalgine","Otobiotic","Otocort","Otosone-F","Pandel","Pediotic Suspension","Penecort","Permicort","Polcort H","Preparation H Hydrocortisone Cream","Prepcort","Prevex HC","Proctocort","Proctofoam","Protocort","Racet","Rectoid","Reichstein's Substance M","Remederm HC","Sanatison","Scalpicin Capilar","Schericur","Scheroson F","Sigmacort","Signef","Stie-cort","Stiefcorcil","Synacort","Systral Hydrocort","THE","Tarcortin","Tetrahydro E","Tetrahydrocompound E","Texacort","Texacort lotion 25","Thyrotropic-releasing factor","Timocort","Transderma H","Traumaide","Uniderm","Urocortisone","Vioform-Hydrocortisone","VoSol HC","Vytone","Westcort"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00741","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00741","Definition":"The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. (PubChem) Pharmacology: Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated. Mechanism of action: Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents"}},{"Hydroflumethiazide":{"RelatedTo":["Carbonic anhydrase 1","Carbonic anhydrase 2","Solute carrier family 12 member 1","Carbonic anhydrase 4","Calcium-activated potassium channel subunit alpha 1"],"Synonym":["Dihydroflumethazide","Hidroflumetiazid","Hydroflumethazide","Hydroflumethizide","Trifluoromethylhydrazide","Trifluoromethylhydrothiazide","Diuredemina","Diurometon","Enjit","Flutizide","Glomerulin","Hidroalogen","Robezon"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00774","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00774","Definition":"A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) Pharmacology: Hydroflumethiazide is an oral thiazide used to treat hypertension and edema. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. Like other thiazides, Hydroflumethiazide promotes water loss from the body (diuretics). Thiazides inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Mechanism of action: As a diuretic, Hydroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Hydroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Hydroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Diuretics. Diuretics, Thiazide. Sodium Chloride Symporter Inhibitors"}},{"Hydrogen Peroxide Sensor":{"CurationStatus":"uncurated","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","SuperCategory":"Chemical quantification instrument","Id":"nlx_54302","Has role":"Instrument role","Definition":"Amperometric biosensors are used for hydrogen peroxide measurement."}},{"Hydrogen Sulfide Sensor":{"CurationStatus":"uncurated","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","SuperCategory":"Chemical quantification instrument","Id":"nlx_76046","Has role":"Instrument role","Definition":"Amperometric hydrogen sulfide electrodes measure hydrogen sulfide."}},{"Hydromorphone":{"RelatedTo":["Delta-type opioid receptor","Kappa-type opioid receptor"],"Synonym":["Dihydromorfinon (Czech)","Dihydromorphinone","Hidromorfona (INN-Spanish)","Hydromorfona (Spanish)","Hydromorphon","Hydromorphone HCL","Hydromorphonum (INN-Latin)","DiMo","Dilaudid","Dilaudid Oros","Dilaudid-hp","Dimorphone","Hymorphan","Idromorfone","Laudacon","Laudicon","Novolaudon","Palladone"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5790","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00327","Definition":"An opioid analgesic made from morphine and used mainly as an analgesic. It has a shorter duration of action than morphine. (PubChem) Pharmacology: Hydromorphone is a hydrogenated ketone derivative of morphine that acts as a narcotic analgesic. It has a shorter duration of action than morphine. Hydromorphone is approximately 8 times more potent on a milligram basis than morphine. In addition, hydromorphone is better absorbed orally than is morphine. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Hydromorphone appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers. Mechanism of action: Hydromorphone is a narcotic analgesic; its principal therapeutic effect is relief of pain. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Hydromorphone also binds with kappa-receptors which are thought to mediate spinal analgesia, miosis and sedation. Drug type: Approved. Illicit. Small Molecule. Drug category: Analgesics, Opioid. Narcotics"}},{"Hydrophilic":{"SuperCategory":"Hydrophilicity","Id":"PATO_0001887","Definition":"A quality inhering in a bearer by virtue of having a strong affinity for water; tending to dissolve in, mix, or be wetted by water."}},{"Hydrophilicity":{"SuperCategory":"Physical quality","Id":"PATO_0001886","Definition":"A physical quality inhering in a bearer by virtue of whether it has an affinity for water, it is readily absorbing or dissolving in water."}},{"Hydrophobic":{"SuperCategory":"Hydrophobicity","Id":"PATO_0001885","Definition":"A quality inhering in a bearer by virtue of lacking affinity for water; tending to repel and not absorb water, tending not to dissolve in or mix with or be wetted by water."}},{"Hydrophobicity":{"SuperCategory":"Physical quality","Id":"PATO_0001884","Definition":"A physical quality inhering in a bearer by virtue of whether it is water-repellent; tending to repel and not absorb water."}},{"Hydrophobicity model":{"Synonym":["hydrophobicity analysis"],"Created":"2007-10-10","CurationStatus":"uncurated","SuperCategory":"Sequence-based model","Id":"birnlex_2317","Definition":"A mathematical description of the solvent interaction properties of an amino acid sequence based on the biophysical properties of the amino acid side chain moeties.  Such models are used to indicate putative internal hydrophobic domains and transmembrane spanning regions in polypeptides."}},{"Hydroxocobalamin":{"RelatedTo":["Transcobalamin-1","Methylmalonic aciduria type A protein","mitochondrial","Amnionless protein","Transcobalamin-2","Cob(I)yrinic acid a,c-diamide adenosyltransferase","mitochondrial","Methionine synthase","Methionine synthase reductase","mitochondrial","Methylmalonyl-CoA mutase","mitochondrial","Cubilin"],"Synonym":["Hydroxocobalamin Vitamin B12","Hydroxocobalamin acetate","Hydroxocobalamin monohydrochloride","Hydroxocobalaminacetat","Hydroxomin","Vitamin B12a","Acti-B12","Alpharedisol","Cyanokit","Hydro Cobex"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27786","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00200","Definition":"Injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. (PubChem) Pharmacology: Hydroxocobalamin is a synthetic, injectable form of Vitamin B12. Hydroxocobalamin is actually a precursor of two cofactors or vitamins (Vitamin B12 and Methylcobalamin) which are involved in various biological systems in man. Vitamin B12 is required for the conversion of methylmalonate to succinate. Deficiency of this enzyme could therefore interfere with the production of lipoprotein in myelin sheath tissue and so give rise to neurological lesions. The second cofactor, Methylcobalamin, is necessary for the conversion of homocysteine to methionine which is essential for the metabolism of folic acid. Deficiency of tetrahydrafolate leads to reduced synthesis of thymidylate resulting in reduced synthesis of DNA which is essential for cell maturation. Vitamin B12 is also concerned in the maintenance of sulphydryl groups in reduced form, deficiency leading to decreased amounts of reduced SH content of erythrocytes and liver cells. Overall, vitamin B12 acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis. It is necessary for growth, cell replication, hematopoiesis, and nucleoprotein as well as myelin synthesis. This is largely due to its effects on metabolism of methionine folic acid, and malonic acid. Mechanism of action: Vitamin B12 exists in four major forms referred to collectively as cobalamins; deoxyadenosylcobalamin, methylcobalamin, hydroxocobalamin, and cyanocobalamin. Two of these, methylcobalamin and 5-deoxyadenosyl cobalamin, are primarily used by the body. Methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells. Drug type: Approved. Small Molecule. Drug category: Anti-anemic Agents. Hematinics. Nutritional Supplement. Vitamin B Complex"}},{"Hydroxychloroquine":{"RelatedTo":"DNA","Synonym":["2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol","Gen-Hydroxychloroquine 200mg Tablets","HCQ","Hidroxicloroquina (inn-spanish)","Hydroxychloroguine","Hydroxychloroquine sulfate","Hydroxychloroquinum (inn-latin)","Idrossiclorochina (dcit)","Oxichlorochinum","Oxichloroquine","Oxychlorochin","Oxychloroquine","Ercoquin","Plaquenil"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01611","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01611","Definition":"A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Pharmacology: Hydroxychloroquine possesses antimalarial actions and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. The precise mechanism of action is not known. Mechanism of action: Although the exact mechanism of action is unknown, it may be based on ability of hydroxychloroquine to bind to and alter the properties of DNA. Hydroxychloroquine has also has been found to be taken up into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid metabolism. In suppressive treatment, hydroxychloroquine inhibits the erythrocytic stage of development of plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity against the erythrocytic stages of plasmodial infection. As an antirheumatic, hydroxychloroquine is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown. Drug type: Approved. Small Molecule. Drug category: Antimalarials. Antirheumatic Agents. Dermatologic Agents. Enzyme Inhibitors"}},{"Hydroxypropyl cellulose":{"Synonym":["Hydroxypropylmethylcellulose phthalate","Hypromellose phthtalate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00840","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00840","Definition":"Hydroxypropyl cellulose is an ether of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated forming -OCH2CH(OH)CH3 groups. Lacrisertis a formulation of hydroxypropyl cellulose that is used for artificial tears. It is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes. As a food additive, hydroxypropyl cellulose is used as a thickener and as an emulsion stabilizer. Pharmacology: Hydroxypropyl cellulose (cellulose, 2-hydroxypropyl ether) is a derivative of cellulose with both water solubility and organic solubility. Hydroxypropyl cellulose acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Hydroxypropyl cellulose also acts to lubricate and protect the eye. Hydroxypropyl cellulose usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision. Progressive visual deterioration which occurs in some patients may be retarded, halted, or sometimes reversed. Mechanism of action: Hydroxypropyl cellulose is a derivative of cellulose that is soluble in both water and organic solvents. It is particularly good at trapping water and producing a film that serves as a barrier to water loss. Hydroxypropyl cellulose possesses good surface activity but does not gel as it forms open helical coils. In general Hydroxypropyl cellulose is a water-soluble thickener, emulsifier and film-former often used in tablet coating. Drug type: Approved. Small Molecule. Drug category: Artificial Tears. Ophthalmic Protectant"}},{"Hydroxystilbamidine Isethionate":{"RelatedTo":"DNA","Synonym":["HSB"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01040","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01040","Definition":"Hydroxystilbamidine Isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than amphotericin B. Hydroxystilbamidine Isethionate is also used in pathology for diagnostic purposes. Pharmacology: Hydroxystilbamidine isethionate is a member of the diamidines, a large family of biochemially and pharmacologically interesting compounds. It has a rather unusual combination of properties, exhibiting antitrypanosomal, antimaliarial, antifungal and carcinostatic activities. It also appears to act as an immunosuppressant. This drug may be used in the treatment of blastomycosis, a disease cased by the dimorphic fungus or mold called Blastomyces dermatitids. Blastomycosis is a pulmonary infection that can lead to fever, cough and (rarely) symptoms similar to tuberculosis. Hydroxystilbamidine has largely been replaced with amphotericin B. Mechanism of action: Hydroxystilbamidine isethionate (HSB) acts on extracellular DNA and lysosomes. In Trypanosomes there is extensive and selective binding of HSB to the kinetoplastic DNA. This inhibits cell division and reproduction. In yeast there is evidence of binding to extranuclear DNA causing numerous mutations. HSB is also taken up in the lysosomes and leads to a significant increase in the number of lysosome-like bodies and secretion granules in trypanosomal organisms. HSB may also stabilize lysosomal membranes. HSB has also been found to bind RNA and is a powerful inhibitor of cellular ribonucleases. Drug type: Approved. Small Molecule. Drug category: Anti-trypanosomal Agents. Antifungal Agents. Antimalarial Agents. Antimycotic Agents"}},{"Hydroxyurea":{"RelatedTo":"Ribonucleoside-diphosphate reductase large subunit","Synonym":["Carbamohydroxamic Acid","Carbamohydroximic Acid","Carbamohydroxyamic Acid","Carbamoyl Oxime","Carbamyl Hydroxamate","HU","Hydroxicarbamidum","Hydroxycarbamide","Hydroxycarbamine","Hydroxylurea","Idrossicarbamide (Dcit)","N-Carbamoylhydroxylamine","N-Hydroxyurea","Sterile Urea","Biosupressin","Droxia","Hidrix","Hydrea","Hydreia","Hydura","Hydurea","Litaler","Litalir","Onco-Carbide","Oxyurea"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:44423","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01005","Definition":"An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. (PubChem) Pharmacology: Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro. In vivo Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction. Mechanism of action: Hydroxyurea is converted to a free radical nitroxide (NO) in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme. The entire replicase complex, including ribonucleotide reductase, is inactivated and DNA synthesis is selectively inhibited, producing cell death in S phase and synchronization of the fraction of cells that survive. Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents. Hydroxyurea also increases the level of fetal hemoglobin, leading to a reduction in the incidence of vasoocclusive crises in sickle cell anemia. Levels of fetal hemoglobin increase in response to activation of soluble guanylyl cyclase (sGC) by hydroxyurea-derived NO. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Antisickling Agents. Enzyme Inhibitors. Nucleic Acid Synthesis Inhibitors"}},{"Hydroxyzine":{"RelatedTo":"Histamine H1 receptor","Synonym":["Hidroxizina (INN-Spanish)","Hydroksyzyny (Polish)","Hydroxine","Hydroxizine","Hydroxizinum","Hydroxycine","Hydroxyzin","Hydroxyzine Base","Hydroxyzine Hcl","Hydroxyzine Pamoate","Hydroxyzinum (INN-Latin)","Hydroxyzyne","Idrossizina (Dcit)","Alamon","Atara","Atarax","Ataraxoid","Atarazoid","Atarox","Atazina","Aterax","Deinait","Durrax","Equipoise","Equipose","Fenarol","Hy-Pam 25","Hychotine","Masmoran","Neo-Calma","Neurozina","Nevrolaks","Orgatrax","Pamazone","Paxistil","Placidol","Plaxidol","Quiess","Tran-Q","Tranquizine","Traquizine","Vesparaz-Wirkstoff","Vistaril","Vistaril Pamoate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5818","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00557","Definition":"A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite cetirizine, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative. (PubChem) Pharmacology: Hydroxyzine, a piperazine antihistamine structurally related to buclizine, cyclizine, and meclizine, is used to treat histamine-mediated pruritus or pruritus due to allergy, nausea and vomiting, and, in combination with an opiate agonist, anxiolytic pain. Hydroxyzine is also used as a perioperative sedative and anxiolytic and to manage acute alcohol withdrawal. Hydroxyzine's active metabolite, cetirizine, is also used as an H1-antagonist. Mechanism of action: Hydroxyzine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The sedative properties of hydroxyzine occur at the subcortical level of the CNS. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic. Drug type: Approved. Small Molecule. Drug category: Antipruritics. Anxiolytics sedatives and hypnotics. Histamine H1 Antagonists"}},{"Hygrosensitive neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Sensory neuron (FBbt Term)","Id":"nlx_147908","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00005923"}},{"Hylobates":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-06","CurationStatus":"raw_import","Umlscui":"C0020410","SuperCategory":"Hylobatidae","Id":"birnlex_533"}},{"Hylobatidae":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-06","CurationStatus":"raw_import","Umlscui":"C0085234","SuperCategory":"Hominoidea","Id":"birnlex_643"}},{"Hymenoptera":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0020415","SuperCategory":"Endopterygota","Id":"birnlex_491"}},{"Hyoscyamine":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M1"],"Synonym":["Hyocyamine","L-Atropine","L-Hyopscyamine","L-Hyoscamine","L-Hyoscyamine","L-Tropine Tropate","Anaspaz","Buwecon","Cystospaz","Daturine","Donnamar","Duboisine","Duretter","Egacene","Egazil","Gastrosed","Levbid","Levsin","Levsinex","Neoquess","NuLev","OIN","Peptard","Scopolia Extract"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00424","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00424","Definition":"Hyoscyamine is a chemical compound, a tropane alkaloid it is the levo-isomer to atropine. It is a secondary metabolite of some plants, particularly henbane (Hyoscamus niger.)Hyoscyamine is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, pancreatitis, colic and cystitis. It has also been used to relieve some heart problems, control some of the symptoms of Parkinson's disease, as well as for control of respiratory secretions in end of life care. Pharmacology: L-Hyoscyamine, the active optical isomer of atropine (dl-hyoscyamine), is a tertiary amine anticholinergic gastrointestinal agent. Mechanism of action: Hyoscyamine competes favorably with acetylcholine for binding at muscarinic receptors in the salivary, bronchial, and sweat glands as well as in the eye, heart, and gastrointestinal tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor muscle and of the gastrointestinal smooth muscle, and decreased gastrointestinal motility. Drug type: Approved. Small Molecule. Drug category: Adjuvants, Anesthesia. Anti-Arrhythmia Agents. Antiarrhythmic Agents. Antimuscarinics. Antispasmodics. Bronchodilator Agents. Muscarinic Antagonists. Mydriatics. Parasympatholytics"}},{"Hyperactive":{"SuperCategory":"Active","Id":"PATO_0000760","Definition":"A quality of occurrent inhering in a bearer by virtue of its exhibiting increased activity."}},{"Hyperkinesis":{"Synonym":["Hyperkinetic Movements","Hyperkinesia","Motor Hyperactivity"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Dyskinesia","Id":"birnlex_12657","Definition":"Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders (MeSH)."}},{"Hypermorphic growth":{"SuperCategory":"Peramorphic growth","Id":"PATO_0001755","Definition":"A peramorphic growth quality which is due to a delayed offset."}},{"Hyperphosphorylated Molecular Quality":{"CurationStatus":"uncurated","SuperCategory":"Phosphorylated Molecular Quality","Id":"nlx_67915"}},{"Hyperplastic":{"Synonym":"overdeveloped","SuperCategory":"Increased size","Id":"PATO_0000644","Definition":"Proliferation of cells within an organ or tissue beyond that which is ordinarily seen."}},{"Hyperpolarization":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001136","Definition":"An increasae in the negative membrane potential of a cell.  Hyperpolarization decreases the likelihood that a cell will fire an action potential."}},{"Hyperpolarization and cyclic-nucleotide gated channel":{"Synonym":"HCN channel","Created":"2007-09-06","SuperCategory":"Tetrameric Voltage-gated ion channel","Id":"nifext_2516"}},{"Hyperresponsive to":{"Synonym":["hyperresponsive"],"SuperCategory":"Responsive to","Id":"PATO_0001192","Definition":"A response quality inhering in a bearer by virtue of its excessive reaction to a stimulus or an agent."}},{"Hypertonia":{"Synonym":["Hypertonicity"],"CurationStatus":"uncurated","SuperCategory":"Abnormality of the central nervous system","Id":"HP:0001276"}},{"Hypertrophic":{"Synonym":"Hypertrophy","SuperCategory":"Increased size","Id":"PATO_0000584","Definition":"An increased size quality inhering in a bearer by virtue of its exhibiting enlargement of a cell of constituent group of cells (for example, organ)."}},{"Hypertrophic growth":{"SuperCategory":"Growth rate","Id":"PATO_0001493"}},{"Hypoactive":{"SuperCategory":"Active","Id":"PATO_0000761","Definition":"A quality of occurrent inhering in a bearer by virtue of its exhibiting reduced activity."}},{"Hypoglossal nerve fiber bundle":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","EditorialNote":"NeuroNames uses the preferred term \"hypoglossal nerve fibers\", but I'm trying to avoid plurals.  NN preferred term included as a synonym.","Synonym":["root of hypoglossal nerve","central part of hypoglossal nerve"],"NeuronamesID":"795","CurationStatus":"uncurated","Umlscui":"C0175555","SuperCategory":"Regional part of brain","Id":"birnlex_1288","Is part of":["White matter"]}},{"Hypoglossal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":"hypoglossal nerve nucleus","CurationStatus":"uncurated","NeuronamesID":"754","Umlscui":"C0228802","EfferentProjections":"Tongue","SuperCategory":"Nucleus of CNS","Id":"birnlex_2644","Has role":"Cranial nerve nucleus","Is part of":"Medulla oblongata","Species":"Mammal","Definition":"Nucleus forming a longitudinal cell column in the medulla, close beneath the floor of the 4th ventricle, containing motor neurons that innervate the muscles of the tongue (Brodal, Neurological Anatomy, 3rd ed., 1981, pg 453)"}},{"Hypoglossal nucleus GABA neuron":{"Located in":"Hypoglossal nucleus,","Synonym":"hypoglossal GABA neuron","CurationStatus":"uncurated","Pages":"42-53","JournalVolume":"263","Has role":"Intrinsic neuron role","Authors":["Takasu N","Nakatani T","Arikuni T"],"RetrievedOn":"Pub Med","Title":["Immunocytochemical localization of gamma-aminobutyric acid in the hypoglossal nucleus of the macaque monkey"],"CellSomaSize":"Macaque: 14.6 +/- 2.5 um and minor diameter 8.9 +/- 1.4 um (n","PMID":"3667970","Neurotransmitter":"GABA,","PublicationDate":"1987","SuperCategory":"Neuron","PublicationName":"Journal of Comparative Neurology","Id":"nlx_90278","CellSomaShape":"Fusiform Soma Quality","JournalNumber":"1","Species":"Macaca fuscata fuscata,","DefiningCitation":"Takasu et al. J Comp Neurol. 1987 Sep 1;263(1):42-53.","Definition":"Neuron in hypoglossal nucleus characterized by a small spindle shaped or fusiform soma"}},{"Hypoglossal nucleus motor neuron":{"Located in":"Hypoglossal nucleus,","Synonym":["hypoglossal motor neuron","hypoglossal nucleus motoneuron","hypoglossal motoneuron","12th nerve motor neuron"],"CurationStatus":"uncurated","Pages":"42-53","JournalVolume":"263","Authors":["Takasu N","Nakatani T","Arikuni T"],"Has role":["Principal neuron role"],"RetrievedOn":"Pub Med","Title":["Immunocytochemical localization of gamma-aminobutyric acid in the hypoglossal nucleus of the macaque monkey"],"PMID":"3667970","CellularSynapticTarget":"muscule of tongue","Neurotransmitter":"Acetylcholine,","PublicationDate":"1987","SuperCategory":"Neuron","PublicationName":"Journal of Comparative Neurology","Id":"nlx_cell_100311","Polarity":"Multipolar","JournalNumber":"1","Species":"Vertebrata","Definition":"Motor neuron whose soma lies in the hypoglossal nucleus"}},{"Hypoglossal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Hypoglossal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153329","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Hypokinesia":{"Synonym":["Hypodynamia"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Dyskinesia","Id":"birnlex_12658","Definition":"Slow or diminished movement of body musculature. It may be associated with BASAL GANGLIA DISEASES; MENTAL DISORDERS; prolonged inactivity due to illness; and other conditions (MeSH)."}},{"Hypophysis":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["Pituitary gland"],"CurationStatus":"uncurated","Is_part_of":"Intermediate hypothalamic region","Abbrev":"Hp","EditorialNote":"Need to check on this.  Brainmaps has the hypohysis as part of the hypothalamus, as does Brain Info (http://braininfo.rprc.washington.edu/whereisit.aspx?language","Created":"2007-08-19","NeuronamesID":"382","Umlscui":"C0032005","SuperCategory":"Regional part of brain","Id":"birnlex_1353","Is part of":"Intermediate hypothalamic region","Species":"Mammal"}},{"Hypoplastic":{"Synonym":["Hypoplasia"],"SuperCategory":"Decreased size","Id":"PATO_0000645","Definition":"Underdevelopment or incomplete development of a tissue or organ."}},{"Hyporesponsive to":{"Synonym":["hyporesponsive"],"SuperCategory":"Responsive to","Id":"PATO_0001194","Definition":"A quality inhering in a bearer by virtue of its limited reaction to a stimulus or an agent."}},{"Hypothalamic lateral zone of ABA 2009":{"PartiallyOverlapsWith":"Hypothalamic lateral zone","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153091","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Hypothalamic medial zone of ABA 2009":{"PartiallyOverlapsWith":"Hypothalamic medial zone","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153306","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Hypothalamus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":"Hypencephalon","NeuronamesID":"275","CurationStatus":"uncurated","Umlscui":"C0020663","SuperCategory":"Regional part of brain","Id":"birnlex_734","Is part of":["Diencephalon"],"Species":"Vertebrate","Abbrev":"Hy","Definition":"Ventral part of the diencephalon extending from the region of the optic chiasm to the caudal border of the mammillary bodies and forming the inferior and lateral walls of the third ventricle.The ventral topographic division of the interbrain. The first adequate description of the hypothalamus as a layer of gray matter surrounding the lower half of the third ventricle (Galen, c173) was provided by Wharton (1656, see 1966 translation, p. 170). His (1893, pp. 159-162) introduced the term but assigned the preoptic region (Swanson, 1976, pp. 229-235) of the hypothalamus to the telencephalon (His, 1893b). The definition here was introduced for vertebrates by Kuhlenbeck (1927, p. 67, Ch. 9)."}},{"Hypothalamus of ABA 2009":{"PartiallyOverlapsWith":"Hypothalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153794","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Hypothalamus of CIVM postnatal rat brain atlas":{"AtlasImage":["hypothalamus p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151524","Is part of":"Forebrain of CIVM postnatal rat brain atlas","Definition":"The hypothalamus can be segmented in coronal T2-weighted or diffusion-weighted images (DWI). The rostral border between the hippocampus and preoptic area is not well defined in these images. Our solution is to create an arbitrary plane dividing the two just caudal to the optic chiasm, or at roughly the level of the vertical descent of the fornix in to the hypothalamus. On T2 MRI the lateral border with the brighter amygdala and darker horizontal limbs of the diagonal band is relatively well defined. Caudally, the much darker optic tracts define the lateral border as they course between the amygdala and hypothalamus. The dorsal border with the diencephalon can be identified based on the dark speckled appearance of the ventral zona incerta. The caudal amygdala becomes triangular in shape just dorsal to the pituitary comprised of the mammillary bodies and supramammillary nuclei. At its caudal extent the egg-shaped medial mamillary nucleus becomes a free-floating structure just ventral to the dark fasciculus retroflexus and dorsal to the anterior pituitary."}},{"Hypothalamus of WHS11":{"AtlasImage":["hypothalamus of WHS11.png"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"hypothalamus","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143752","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Diencephalon of WHS11","Species":"Mouse","Definition":"Delineation of hypothalamus in Waxholm mouse brain atlas, as seen in T1 and T2*\tweighted volumes.  As seen in sagittal: bounded dorsally by thalamus. Various features such as contrast between tissues, contours followed from adjacent structures and fiat boundaries as contour extensions visualized in  3D.  Excludes part of fornix lying in the hypothalamus."}},{"Hypothalamus oxytocin neuroendocrine magnocellular cell":{"Located in":"Hypothalamus","CurationStatus":"uncurated","Neurotransmitter":"Oxytocin,","SuperCategory":"Magnocellular neurosecretory cell","Id":"nlx_416","Species":["Mammal"]}},{"Hypothalamus oxytocin releasing neuroendocrine magnocellular neuron":{"Located in":"Hypothalamus","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_84773"}},{"Hypothalamus vasopressin neuroendocrine magnocellular neuron":{"Located in":"Hypothalamus","Neurotransmitter":"Vasopressin,","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_268","Species":"Vertebrata"}},{"Hypotrophic":{"Synonym":"Shrunken","SuperCategory":"Decreased size","Id":"PATO_0000585","Definition":"A decreased size quality inhering in a bearer by virtue of its exhibiting reduced size of a cell or constituent group of cells (for example, organ)."}},{"Hypotrophic growth":{"SuperCategory":"Growth rate","Id":"PATO_0001494"}},{"Hystricognathi":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":"Hystricomorpha","Created":"2007-08-06","CurationStatus":"raw_import","Umlscui":"C1271396","SuperCategory":"Rodent","Id":"birnlex_270"}},{"I A, slow":{"RelatedTo":"Single channel current","Synonym":["IA slow"],"CurationStatus":"uncurated","Comment":"Need to determine whether this is a subtype of A current;  definition is ambiguous","SuperCategory":"A current","Id":"nlx_159","DefiningCitation":"ModelDB:3277","Definition":"Slowly inactivating \"delay\" potassium current I K(D), similar to the A-type current but inactivates slowly (seconds). Participates in spike repolarization."}},{"I CAN":{"RelatedTo":"Single Channel Current","CurationStatus":"uncurated","SuperCategory":"Non-selective current","Id":"oen_0001302","Has role":"Current","DefiningCitation":"ModelDB:255","Definition":"Calcium Activated Nonspecific cation channel"}},{"I Cl,Ca":{"RelatedTo":"Single Channel Current","Synonym":"I Chloride","CurationStatus":"uncurated","Comment":"Can enhance or decrease response depending on the Cl- equilibrium potential","SuperCategory":"Chloride current","Id":"oen_0001306","Has role":"Current","DefiningCitation":"ModelDB:252","Definition":"Calcium activated chloride current"}},{"I CNG":{"RelatedTo":["Single Channel Current"],"CurationStatus":"uncurated","Comment":["Dark current in photoreceptors","activated by cGMP; light response in ON retinal bipolar cells; receptor current in olfactory sensory neurons","activated by cAMP"],"SuperCategory":"Non-selective current","Id":"oen_0001303","Has role":"Current","DefiningCitation":"ModelDB:254","Definition":"Cyclic-Nucleotide Gated nonspecific cation channel"}},{"I h":{"RelatedTo":"Single Channel Current","Synonym":["I IR,I Q","I h"],"CurationStatus":"uncurated","SuperCategory":"Non-selective current","Id":"oen_0001301","Has role":"Current","DefiningCitation":"ModelDB:251","Definition":"A current called I_h today had several names historically: Inward rectifier; \"Queer\"; activated by hyperpolarization/mixed cation current"}},{"I K,Ca":{"RelatedTo":"Single Channel Current","CurationStatus":"uncurated","Comment":"Action potential repolarization and interspike interval","SuperCategory":"Non-selective current","Id":"oen_0001304","Has role":"Spike repolarization","DefiningCitation":"ModelDB:253","Definition":"Includes BK, IK, SK, and I AHP currents; K current activated by increases in [Ca2+]i; voltage dependence varies"}},{"I L high threshold":{"RelatedTo":"Synaptic transmission","Synonym":"I Calcium","CurationStatus":"uncurated","Comment":"Underlies Ca2+ spikes that are prominent in dendrites; involved in synaptic transmission","SuperCategory":"Calcium current","Id":"oen_0001310","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:243","Definition":"\"Long-lasting\"; slowly inactivating; threshold around -20 mV"}},{"I M":{"RelatedTo":["Single Channel Current"],"Synonym":"I Potassium","CurationStatus":"uncurated","Comment":"Contributes to slow spike frequency adaptation","SuperCategory":"Potassium current","Id":"oen_0001311","Has role":"Current","DefiningCitation":"ModelDB:250","Definition":"Activated by depolarization above -65 mV; slow, weak and non-inactivating; blocked by ligands like acetylcholine acting through muscarinic (M) receptors"}},{"I Mixed":{"RelatedTo":"Single Channel Current","CurationStatus":"uncurated","SuperCategory":"Non-selective current","Id":"oen_0001305","Has role":"Current","DefiningCitation":"ModelDB:2397"}},{"I N":{"RelatedTo":"Synaptic transmission","Synonym":"I Calcium","CurationStatus":"uncurated","Comment":"Underlies Ca2+ spikes that are prominent in dendrites; involved in synaptic transmission","SuperCategory":"Calcium current","Id":"oen_0001309","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:244","Definition":"\"Neither\"; rapidly inactivating; threshold around -20 mV"}},{"I p,q":{"RelatedTo":"Single Channel Current","Synonym":"I Calcium","CurationStatus":"uncurated","SuperCategory":"Calcium current","Id":"oen_0001307","Has role":"Current","DefiningCitation":"ModelDB:246","Definition":"Includes both p-type and q-type currents"}},{"I T low threshold":{"RelatedTo":["Single Channel Current"],"Synonym":"I Calcium","CurationStatus":"uncurated","Comment":"Underlies rhythmic burst firing; some dendritic action potentials","SuperCategory":"Calcium current","Id":"oen_0001308","Has role":"Current","DefiningCitation":"ModelDB:245","Definition":"\"Transient\"; rapidly inactivating, threshold negative to -65mV"}},{"I1 motor neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Direct flight muscle motor neuron","Id":"nlx_147780","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004070"}},{"Ibandronate":{"RelatedTo":"Farnesyl pyrophosphate synthetase","Synonym":["Ibandronate sodium","Ibandronate sodium monohydrate","Ibandronic Acid","R484","ibandronate","Bondronat","Boniva"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00710","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00710","Definition":"Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures. Pharmacology: Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures. Mechanism of action: The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Drug type: Approved. Investigational. Small Molecule. Drug category: Antihypocalcemic Agents. Antiresorptives. Bisphosphonates. Bone Density Conservation Agents"}},{"Ibotenic acid":{"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nlx_chem_20090604","Has role":"Excitotoxin","Definition":"A chemical compound that is naturally occurring in the mushrooms Amanita muscaria and Amanita pantherina, among others. Ibotenic acid is a powerful neurotoxin that is used as an excitoxin and has shown to be highly neurotoxic when injected directly into the brains of mice and rats. (adapted from Wikipedia)"}},{"Ibritumomab":{"RelatedTo":["B-lymphocyte antigen CD20","High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1s subcomponent","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["Ig gamma-2A chain C region","membrane-bound form","radiolabeled murine anti-CD20"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00078","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00078","Definition":"Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. Pharmacology: Zevalin binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells. Mechanism of action: Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. The chelate tiuxetan, which tightly binds radioactive In-111 or Y-90, is covalently linked to the amino groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells. Drug type: Approved. Biotech. Drug category: Antineoplastic Agents"}},{"Ibuprofen":{"RelatedTo":["Prostaglandin G/H synthase 1","Prostaglandin G/H synthase 2"],"Synonym":["Ibuprophen","P-Isobutylhydratropic Acid","Para-Isobutylhydratropic Acid","Actiprofen","Adran","Advil","Advil Liqui-Gels","Amersol","Amibufen","Anco","Andran","Anflagen","Apo-Ibuprofen","Apsifen","Apsifen-F","Artril 300","Bluton","Brufanic","Brufen","Brufort","Buburone","Butylenin","Cap-Profen","Children's Advil","Children's Elixsure","Children's Ibuprofen","Children's Motrin","Codral","Dolgin","Dolgirid","Dolgit","Dolo-Dolgit","Dolocyl","Ebufac","Emodin","Epobron","Femadon","Fenbid Spansule","Haltran","Ibu","Ibu-Attritin","Ibu-Slo","Ibu-Tab","Ibu-Tab 200","Ibufen","Ibumetin","Ibuprin","Ibuprocin","Ibuprohm","Ibutid","Ifen","Inabrin","Inoven","Junior Strength Advil","Junior Strength Ibuprofen","Junior Strength Motrin","Lamidon","Lebrufen","Lidifen","Liptan","Medipren","Midol","Midol 200","Motrin","Mynosedin","Napacetin","Nobfelon","Nobfen","Nobgen","Novogent N","Novoprofen","Nuprin","Nurofen","Pantrop","Paxofen","Pedia-Profen","Pediaprofen","Pediatric Advil","Profen","Rafen","Rebugen","Roidenin","Rufen","Seclodin","Suspren","Tab-Profen","Tabalon","Trendar"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5855","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01050","Definition":"A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis. (PubChem) Pharmacology: Ibuprofen is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, that is thought to be associated with the inhibition of prostaglandin synthesis. Ibuprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain. Mechanism of action: The exact mechanisms of action of Ibuprofen is unknown. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis, and results in the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Drug type: Approved. Small Molecule. Drug category: Analgesics. Analgesics, Non-Narcotic. Anti-Inflammatory Agents, Non-Steroidal. Anti-inflammatory Agents. Cyclooxygenase Inhibitors. Nonsteroidal Antiinflammatory Agents (NSAIDs)"}},{"Ibutilide":{"RelatedTo":["Potassium voltage-gated channel subfamily H member 2","Potassium channel subfamily K member 1","Voltage-dependent L-type calcium channel subunit beta-1","Voltage-dependent L-type calcium channel subunit alpha-1C","Potassium voltage-gated channel subfamily H member 6","Voltage-dependent calcium channel gamma-1 subunit","Potassium channel subfamily K member 6","Voltage-dependent calcium channel subunit alpha-2/delta-1","Potassium voltage-gated channel subfamily H member 7"],"Synonym":["Ibutilida (INN-Spanish)","Ibutilide","Ibutilide Fumarate","Ibutilidum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00308","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00308","Definition":"Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. (Wikipedia) Pharmacology: Ibutilide prolongs the action potential duration and increases both atrial and ventricular refractoriness in vivo, i.e., class III electrophysiologic effects. Voltage clamp studies indicate that ibutilide, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act. Mechanism of action: Ibutilide is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca2+ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K+ current, by binding within potassium channel pores. In other words, Ibutilide binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels Drug type: Approved. Small Molecule. Drug category: Anti-Arrhythmia Agents"}},{"Icodextrin":{"Synonym":["Dextrine","icodextrin","Adept","Dextrin","Caloreen","Extraneal"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00702","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00702","Definition":"Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways. Pharmacology: Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways. Mechanism of action: Icodextrin is a starch-derived, water-soluble glucose polymer linked by alpha (1-4) and alpha (1-6) glycosidic bonds with an average molecular weight between 13,000 and 19,000 daltons. It functions as a colloid osmotic agent to achieve ultrafiltration during long (12-16 hour) peritoneal dialysis dwells. In other words it helps clean waste out of the body when the kidneys are not functioning properly. Icodectrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration through the dwell. This is due to the fact that the polymer is minimially absorbed across the peritoneal membrane. Icodextrin achieves superior fluid removal compared with glucose-based dialysates. Drug type: Approved. Investigational. Small Molecule. Drug category: Osmotic Agents"}},{"Icon Image Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0088_0200","SuperCategory":"DICOM term","Id":"nlx_150115","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"This icon image is representative of the Image."}},{"Iconic memory":{"Created":"5/4/2011 11:01","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00333","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Iconic_memory","SuperCategory":"Visual memory","Id":"birnlex_1811","Definition":"very brief sensory memory of some visual stimuli, that occur in the form of mental pictures."}},{"Icosapent":{"RelatedTo":["Prostaglandin G/H synthase 1","Peroxisome proliferator-activated receptor gamma","Prostaglandin G/H synthase 2","Free fatty acid receptor 1","BC2697302","Sodium/calcium exchanger 1","Long-chain-fatty-acid--CoA ligase 4","Peroxisome proliferator-activated receptor delta","Transient receptor potential cation channel subfamily V member 1","Long-chain-fatty-acid--CoA ligase 3"],"Synonym":["EPA","Eicosapentaenoic acid","Icosapentaenoic acid","Timnodonic acid"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00159","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00159","Definition":"Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. (PubChem) Pharmacology: Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid. Mechanism of action: The anti-inflammatory, antithrombotic and immunomodulatory actions of EPA is probably due to its role in eicosanoid physiology and biochemistry. Most eicosanoids are produced by the metabolism of omega-3 fatty acids, specifically, arachidonic acid. These eicosanoids, leukotriene B4 (LTB4) and thromboxane A2 (TXA2) stimulate leukocyte chemotaxis, platelet aggregation and vasoconstriction. They are thrombogenic and artherogenic. On the other hand, EPA is metabolized to leukotriene B5 (LTB5) and thromboxane A3 (TXA3), which are eicosanoids that promote vasodilation, inhibit platelet aggregation and leukocyte chemotaxis and are anti-artherogenic and anti-thrombotic. The triglyceride-lowering effect of EPA results from inhibition of lipogenesis and stimulation of fatty acid oxidation. Fatty acid oxidation of EPA occurs mainly in the mitochondria. EPA is a substrate for Prostaglandin-endoperoxide synthase 1 and 2. It also appears to affect the function and bind to the Carbohydrate responsive element binding protein (ChREBP) and to a fatty acid receptor (G-coupled receptor) known as GP40. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient"}},{"Ictal":{"SuperCategory":"Physiological state","Id":"PATO_0001913","Definition":"A physiological state which is characterized by periods of high-frequency high amplitude electrical activity in neuronal tissue."}},{"Idarubicin":{"RelatedTo":"DNA topoisomerase 2-alpha","Synonym":["Idarubicin Hcl","Idarubicin Hydrochloride","Idarubicina (INN-Spanish)","Idarubicine (INN-French)","Idarubicinum (INN-Latin)","Idamycin","Idamycin PFS","Idarubicin Aglycone"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:42068","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01177","Definition":"An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. (PubChem) Pharmacology: Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. Mechanism of action: Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Drug type: Approved. Small Molecule. Drug category: Antibiotics. Antibiotics, Antineoplastic. Antineoplastic Agents"}},{"Identical Documents Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A525","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150116","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Duplicates of this document stored with different SOP Instance UIDs. One or more Items may be included in this sequence. Required if this Key Object Selection document references instances in more than one Study."}},{"Identical twin brother":{"Created":"2008-03-14","CurationStatus":"definition_incomplete","Umlscui":"C0337535","SuperCategory":"Twin brother","Id":"birnlex_7395"}},{"Identical twin sister":{"Created":"2008-03-14","CurationStatus":"definition_incomplete","Umlscui":"C0337522","SuperCategory":"Twin sister","Id":"birnlex_7402"}},{"Identifier mapping resource":{"CurationStatus":"uncurated","SuperCategory":"Data or information resource","Id":"nlx_157898","Keywords":"Resource:CINERGI","Definition":"A resource that defines the relationship between concepts in different vocabularies."}},{"Identifier resolution":{"Synonym":["Identifier resolution service"],"CurationStatus":"uncurated","SuperCategory":"Production service resource","Id":"nlx_157906","Keywords":"Resource:CINERGI","Definition":"A resource that provides identifier resolution. This includes the scope of resources for which a collection of identifiers may proxy, the syntax for generating new identifiers, the kinds of representations that are recognized for the identified resources, and how an identifier is dereferenced to obtain the desired representation. (CINERGI)"}},{"Identifying value":{"CurationStatus":"uncurated","SuperCategory":"Value","Id":"birnlex_2296"}},{"Idoxuridine":{"RelatedTo":"DNA polymerase","Synonym":["5IDU","5IUDR","Allergan 201","Allergan 211","ID2","IDU","IDUR","IUDR","Idossuridina (DCIT)","Idoxuridin","Idoxuridina (INN-Spanish)","Idoxuridinum (INN-Latin)","Iododeoxyridine","Iodoxuridine","Antizona","Dendrid","Emanil","Heratil","Herpe-Gel","Herpes-Gel","Herpesil","Herpid","Herpidu","Herplex","Herplex Liquifilm","Idexur","Idoxene","Idu Oculos","Iducher","Idulea","Iduridin","Iduviran","Joddeoxiuridin","Kerecid","Ophthalmadine","Spectanefran","Stoxil","Synmiol"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00249","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00249","Definition":"An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent. (PubChem) Pharmacology: In chemical structure idoxuridine closely approximates the configuration of thymidine, one of the four building blocks of DNA (the genetic material of the Herpes virus). As a result, idoxuridine is able to replace thymidine in the enzymatic step of viral replication or \"growth\". The consequent production of faulty DNA results in a pseudostructure which cannot infect or destroy tissue. In short, by pre-empting a vital building block in the genetic material of the Herpes simplex virus, Herplex-D topical solution destroys the infective and destructive capacity of the viral material. The virus infected cell may only be attacked during the period of active synthesis of DNA. This occurs early in the development of the Herpes simplex lesion, but at different times in different cells. Therefore, ideally, the affected area should remain saturated with the antiviral agent. Mechanism of action: Idoxuridine acts as an antiviral agent against DNA viruses by inhibiting thymidilate phosphorylase and viral DNA polymerases. The effect of Idoxuridine results in the inability of the virus to reproduce or to infect/destroy tissue. Drug type: Approved. Small Molecule. Drug category: Antiviral Agents. Nucleic Acid Synthesis Inhibitors"}},{"Idursulfase":{"RelatedTo":"Mannose-6-phosphate receptor-binding protein 1","SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01271","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01271","Definition":"Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types. Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons. The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures. The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine. Pharmacology: Idursulfase is a purified form of the lysosomal enzyme human iduronate-2-sulfatase of recombinant DNA origin. It is designed to replace the natural enzyme, increasing catabolism of certain accumulated glycosaminoglycans (GAG), which abnormally accumulate in multiple tissue types in patients with mucopolysaccharidosis II (MPS-II, or Hunter syndrome). Mechanism of action: Hunter's Syndrome is an X-linked recessive disease caused by insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. This enzyme cleaves the terminal 2-O-sulfate moieties from the glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate. Due to the missing or defective iduronate-2-sulfatase enzyme in patients with Hunter's Syndrome, GAG progressively accumulate in the lysosomes of a variety of cells, leading to cellular engorgement, organomegaly, tissue destruction and organ system dysfunction. Treatment of Hunter's Syndrome patients with idursulfase provides exogenous enzyme for uptake into cellular lysosomes. Mannose-6-phosphate (M6P) residues on the oligosaccharide chains allow specific binding of the enzymes to the M6P receptors on the cell surface, leading to cellular internalization of the enzyme, targeting to intracellular lysosomes and subsequent catabolism of accumulated GAG. Drug type: Approved. Biotech. Drug category: Enzyme Replacement Agents"}},{"Ifosfamide":{"RelatedTo":"DNA (cytosine-5)-methyltransferase 1","Synonym":["Asta Z 4942","I-Phosphamide","Ifosfamid","Ifosfamide Sterile","Ifsofamide","Iphosphamid","Iphosphamide","Isofosfamide","Isophosphamide","Cyfos","Holoxan 1000","IFEX","Ifex/Mesnex Kit","Ifosfamide/Mesna Kit","Isoendoxan","Mitoxana"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01181","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01181","Definition":"Positional isomer of cyclophosphamide which is active as an alkylating agent and an immunosuppressive agent. (PubChem) Pharmacology: Ifosfamide selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of ifosfamide-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mechanism of action: After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily due to cross-linking of strands of DNA and RNA, as well as inhibition of protein synthesis. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Alkylating. Immunosuppressive Agents"}},{"III1 motor neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Direct flight muscle motor neuron","Id":"nlx_147779","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004069"}},{"III3 motor neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Direct flight muscle motor neuron","Id":"nlx_147777","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004067"}},{"Illumination":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2010_015E","SuperCategory":"DICOM term","Id":"nlx_150117","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Luminance of a hypothetical viewing device illuminating a piece of monochrome transmissive film, or for the case of reflective media, luminance obtainable from diffuse reflection of the illumination present. Expressed as L0, in candelas per square meter."}},{"Illumination Type Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0016","SuperCategory":"DICOM term","Id":"nlx_150118","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Coded value for illumination. Zero or one item shall be present in the sequence."}},{"Iloprost":{"RelatedTo":["Prostaglandin E2 receptor","EP2 subtype","Prostacyclin receptor","Tissue-type plasminogen activator"],"Synonym":["iloprost"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01088","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01088","Definition":"Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH). Pharmacology: Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer. Mechanism of action: Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension. Drug type: Approved. Investigational. Small Molecule. Drug category: Antihypertensive Agents"}},{"Image":{" limit":"1000","Created":"2007-10-05","EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","CurationStatus":"uncurated","SuperCategory":"Data or information resource"," format":"CSV","Id":"birnlex_11005","Keywords":"Resource:CINERGI","Definition":"A resource that provides a picture or likeness of somebody or something."}},{"Image acquisition protocol":{"Created":"2007-03-07","Synonym":["Imaging"],"CurationStatus":"graph position temporary","Comment":"Asserted hierarchy is constructed largely (but not exclusively) based on type of electromagnetic radiation used as the imaging probe","SuperCategory":"Protocol","Curator":"Maryann Martone,","Id":"birnlex_2126","Definition":"Protocol that specifies the acquisition of imaging data"}},{"Image acquisition software":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Data acquisition software","Id":"birnlex_2212"}},{"Image analysis software":{"Created":"2006-06-01","Synonym":["image analysis tool"],"CurationStatus":"uncurated","SuperCategory":"Data processing software","Id":"birnlex_2195"}},{"Image Area Dose Product":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_115E","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150119","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Total area-dose-product to which the patient was exposed, accumulated over the complete Performed Procedure Step and measured in dGy*cm*cm, including fluoroscopy. "}},{"Image Box Content Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2130_0040","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150120","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"TBD (retired)."}},{"Image Box Presentation LUT Flag":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2000_006A","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150121","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Image Center Point Coordinates Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_071A","SuperCategory":"DICOM term","Id":"nlx_150122","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"The coordinates of the center point of the Image in the Slide Coordinate System Frame of Reference. This sequence shall contain exactly one item."}},{"Image collection":{"RelatedTo":"Image","CurationStatus":"uncurated","SuperCategory":"Data or information resource","Id":"nlx_151956","Keywords":"Resource:CINERGI","Definition":"A collection of images, without a database query function."}},{"Image Comments":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_4000","SuperCategory":"DICOM term","Id":"nlx_150123","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"User-defined comments about the image."}},{"Image creation":{"Synonym":"image acquisition","CurationStatus":"uncurated","Contributor":"Jie Zheng","SuperCategory":"Planned process","Id":"OBI_0001007","Has role":"Protocol","Definition":"A planned process that captures an image of an object."}},{"Image Dimensions":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0005","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150124","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Image Format":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0040","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150125","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Image Frame Origin":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0051","SuperCategory":"DICOM term","Id":"nlx_150126","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Frame number of Multi-frame Image to which this overlay applies; frames are numbered from 1."}},{"Image Geometry Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0070","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150127","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"TBD (retired)."}},{"Image Horizontal Flip":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0041","SuperCategory":"DICOM term","Id":"nlx_150128","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Whether or not to flip the image horizontally after any Image Rotation has been applied such that the left side of the image becomes the right side."}},{"Image ID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0400","SuperCategory":"DICOM term","Id":"nlx_150129","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"User or equipment generated Image identifier."}},{"Image Index":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_1330","SuperCategory":"DICOM term","Id":"nlx_150130","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"An index identifying the position of this image within a PET Series."}},{"Image interpretation attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_151704","Definition":"Attributes about the radiological interpretation of the image"}},{"Image Laterality":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0062","SuperCategory":"DICOM term","Id":"nlx_150131","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Laterality of (possibly paired) body part (as described in Anatomic Region Sequence (0008,2218)) examined. Shall be consistent with any laterality information contained in Primary Anatomic Structure Modifier Sequence (0008,2230), if present."}},{"Image Location":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0200","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150132","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Image Orientation":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0035","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150133","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"TBD (retired)."}},{"Image Orientation (Patient)":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0037","SuperCategory":"DICOM term","Id":"nlx_150134","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The direction cosines of the first row and the first column with respect to the patient."}},{"Image Origin":{"SuperCategory":"DICOM term","Id":"nlx_152149 ","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Image Overlay Box Content Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2130_0060","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150135","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"TBD (retired)."}},{"Image Overlay Flag":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2000_0067","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150136","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Image Path Filter Pass Band":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0004","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150137","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Pass band of image path filter in nm. This Attribute has two Values. The first is the shorter and the second the longer wavelength relative to the peak. The values are for the - 3dB nominal (1/2 of peak) pass through intensity. "}},{"Image Path Filter Pass-Through Wavelength":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0003","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150138","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Nominal pass-through wavelength of image path filter in nm."}},{"Image Path Filter Type Stack Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0018","SuperCategory":"DICOM term","Id":"nlx_150139","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Describes stack of filters used in image path. Zero or more items may be present in the sequence."}},{"Image Plane Pixel Spacing":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3002_0011","SuperCategory":"DICOM term","Id":"nlx_150140","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Physical distance (in mm) between the center of each image pixel, specified by a numeric pair - adjacent row spacing (delimiter) adjacent column spacing."}},{"Image Position":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0030","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150141","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"TBD (retired)."}},{"Image Position (Patient)":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0032","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150142","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The x, y, and z coordinates of the upper left hand corner (center of the first voxel transmitted) of the image, in mm. "}},{"Image processing software":{" limit":"1000","Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Data processing software"," format":"CSV","Id":"birnlex_2191","Definition":"An application or program that is used for any form of signal processing for which the input is an image, such as photographs, magnetic resonance images, or frames of video; the output of image processing can be either an image or a set of characteristics or parameters related to the image."}},{"Image reconstruction algorithm":{"Created":"2006-06-01","CurationStatus":"curation_complete","SuperCategory":"Algorithm","Id":"birnlex_2202","Definition":"Algorithm used to compute a reconstruction from a set of images, e.g., R-weighted back projection."}},{"Image reconstruction software":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Image analysis software","Id":"birnlex_2186","Definition":"Software application involved in 'image reconstruction', the generation of interpretable image results from a raw acquisition of spatially resolved data. (NITRC)"}},{"Image registration":{"SuperCategory":"Data transformation","Id":"nlx_inv_20090402","Definition":"Data transformation where different sets of images are aligned to a single coordinate system."}},{"Image repository":{"RelatedTo":"Image","CurationStatus":"uncurated","SuperCategory":"Data repository","Id":"nlx_152207","Definition":"A repository that provides access to images and allows deposition of images from contributors or the community at large, e.g., the Cell Image Library (http://cellimagelibrary.org)"}},{"Image Rotation":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0042","SuperCategory":"DICOM term","Id":"nlx_150143","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"How far to rotate the image clockwise in degrees, before any Image Horizontal Flip (0070,0041) is applied. Notes: Negative values are not permitted since the Value  Representation is unsigned."}},{"Image Transformation Matrix":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_5210","SuperCategory":"DICOM term","Id":"nlx_150144","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Comment ":" general term","Value_Representation":"DS","Definition":"The matrix used to transform one frame of reference to another."}},{"Image Translation Vector":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_5212","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150145","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Translation Vector as described in C.8.5.6.1.9 of the DICOM specification. Used for spatially related images where the relationship includes translations."}},{"Image Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0008","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150146","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Image identification characteristics. The Image Type (0008,0008) Attribute identifies important image identification characteristics. These characteristics are: a. Pixel Data Characteristics. b. Patient Examination Characteristics. c. Modality Specific Characteristics."}},{"Imaged Nucleus":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0085","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150147","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Nucleus that is resonant at the imaging frequency. Examples: 31P, 1H."}},{"Images in Acquisition":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1002","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150148","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of images that resulted from this acquisition of data."}},{"Imagined movement":{"Created":"4/27/2011 15:34","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00751","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Imagined_movement","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145973","Definition":"Subjects imagine performing some movement (e.g., finger tapping, reaching)."}},{"Imagined objects-scenes":{"Created":"4/27/2011 14:07","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00752","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Imagined_objects-scenes","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145974","Definition":"Subject generate vivid images of objects, places, concepts, hypothetical events (not in their past), or the completion of tasks."}},{"Imaging assay":{"Created":"2007-10-05","EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Synonym":"Imaging","CurationStatus":"uncurated","SuperCategory":"Assay","Id":"birnlex_11026"}},{"Imaging data attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_153869 ","Definition":"TBD"}},{"Imaging Device-Specific Acquisition Parameters":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00CC","SuperCategory":"DICOM term","Id":"nlx_150149","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User-specified device-specific parameters that describe how the imager will acquire the image."}},{"Imaging Frequency":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0084","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150150","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Precession frequency in MHz of the nucleus being imaged."}},{"Imaging hardware attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_151699","Definition":"parameters that describe the hardware used in the scan"}},{"Imaging instrument":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Measurement device","Id":"birnlex_2094"}},{"Imaging platform":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Platform","Id":"birnlex_2200"}},{"Imaging procedure attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_151702","Definition":"attributes about the imaging session such as date, when ordered"}},{"Imaging protocol attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_151697","Definition":"parameters that are used by the acquisition hardware to acquire the data"}},{"Imaging role":{"CurationStatus":"uncurated","SuperCategory":"Role","Id":"nlx_158013","Definition":"Role of an imaging protocol or assay, e.g., MRI is a neuroimaging technique if it images the nervous system."}},{"Imaging Service Request Comments":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_2400","SuperCategory":"DICOM term","Id":"nlx_150151","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"User-defined comments on the Imaging Service Request. Note: The Comments attribute is intended to transmit non-structured information, which can be displayed to the operator of the equipment (e.g. Modality)."}},{"Imatinib":{"RelatedTo":["Proto-oncogene tyrosine-protein kinase ABL1","Beta platelet-derived growth factor receptor","Mast/stem cell growth factor receptor","Alpha platelet-derived growth factor receptor","Macrophage colony-stimulating factor 1 receptor","Multidrug resistance protein 1","High affinity nerve growth factor receptor","ATP-binding cassette sub-family G member 2","RET proto-oncogene"],"Synonym":["Imatinib Mesylate","Imatinib Methansulfonate","Gleevec"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:45783","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00619","Definition":"Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. Pharmacology: Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity. Mechanism of action: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) and stem cell factor (SCF) - called c-kit. Imatinib was identified in the late 1990s by Dr Brian J. Druker. Its development is an excellent example of rational drug design. Soon after identification of the bcr-abl target, the search for an inhibitor began. Chemists used a high-throughput screen of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Protein Kinase Inhibitors"}},{"Imiglucerase":{"RelatedTo":"D-glucosyl-N-acylsphingosine","Synonym":["Acid beta-glucosidase","Beta-glucocerebrosidase","D-glucosyl-N-acylsphingosine glucohydrolase","Glucosylceramidase precursor","Ceredase (Genzyme)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00053","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00053","Definition":"Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW"}},{"Imipenem":{"RelatedTo":"Beta-lactamase","Synonym":["IMP","Imipemide","Imipenem","n-formimidoyl thienamycin","N-formimidoylthienamycin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:5879","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01598","Definition":"Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with cilastatin, a renal dipeptidase inhibitor. (PubChem) Pharmacology: Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation. Mechanism of action: Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various gram-positive and gram-negative bacteria. It remains very stable in the presence of beta-lactamase (both penicillinase and cephalosporinase) produced by some bacteria, and is a strong inhibitor of beta-lactamases from some gram-negative bacteria that are resistant to most beta-lactam antibiotics. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents"}},{"Imipramine":{"RelatedTo":["Adenosine A1 receptor","Sodium-dependent noradrenaline transporter"],"Synonym":[", Antideprin","Berkomine","Censtim","Censtin","DPID","Declomipramine","Dimipressin","Dyna-Zina","Dynaprin","Estraldine","Eupramin","IM","Imavate","Imidobenzyle","Imipramina","Imipramine Hcl","Imiprin","Imizin","Imizine","Imizinum","Impramine","Intalpram","Iramil","Irmin","Janimine","Melipramin","Melipramine","Nelipramin","Norfranil","Pramine","Prazepine","Presamine","Promiben","Psychoforin","Sk-Pramine","Surplix","Timolet","Tipramine","Tofranil","Base","Tofranil-Pm","Tofraniln A"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:47499","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00458","Definition":"The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. (PubChem) Pharmacology: Imipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack. Mechanism of action: Imipramine works by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. It binds the Sodium-dependent serotonin transporter and Sodium-dependent noradrenaline transporter, preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. As norepinephrine and serotonin are used to stimulate the synapse, and depression has been linked to a lack of stimulation of the recipient neuron at a synapse, slowing the reuptake of these neurotransmitters allows them to remain in the synaptic gap longer than it normal, increasing the stimulation of the recipient neuron and relieving the symptoms of depression. However, it does not act primarily by stimulation of the central nervous system. The clinical effect is also hypothesized as being due to potentiation of adrenergic synapses by blocking uptake of norepinephrine at nerve endings. Drug type: Approved. Small Molecule. Drug category: Adrenergic Uptake Inhibitors. Antidepressive Agents, Tricyclic. Norepinephrine-Reuptake Inhibitors"}},{"Imiquimod":{"RelatedTo":"Toll-like receptor 7","Synonym":["Imiquimod acetate","imiquimod"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:36704","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00724","Definition":"Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma. Pharmacology: Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs. Mechanism of action: Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion. Drug type: Approved. Investigational. Small Molecule. Drug category: Adjuvants, Immunologic. Antineoplastic Agents. Antiviral Agents. Interferon Inducers"}},{"Immature":{"Synonym":"underdeveloped","SuperCategory":"Maturity","Id":"PATO_0001501","Definition":"A quality inhering in a bearer by virtue of lacking complete growth, differentiation, or development."}},{"Immature chimpanzee":{"CurationStatus":"uncurated","SuperCategory":"Chimpanzee","Id":"nlx_organ_109086","Definition":"A chimpanzee 0 to 15 years old."}},{"Immature dog":{"CurationStatus":"uncurated","SuperCategory":"Dog","Id":"nlx_organ_109079","Definition":"A dog 3 to 7 weeks old, with the day of birth defined as day 0."}},{"Immature human":{"CurationStatus":"uncurated","SuperCategory":"Human","Id":"nlx_organ_109057","Definition":"A human less than 18 years old."}},{"Immature Insulin Granule":{"PMID":"8063699","Synonym":"Pale granule","CurationStatus":"uncurated","SuperCategory":"Insulin Granule","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/8063699","Id":"nlx_12553","DefiningCitation":["Huang","X.F."],"DefinitionPMID":"8063699","Definition":"A proinsulin-containing secretory vesicle which occurs within pancreatic beta cells. Immature insulin are also called \"pale granules\" due to their pale appearance under an transmission electron microscope. Immature insulin granules bud off the trans-most Golgi cisternae as part of the insulin synthesis process. When the proinsulin in converted to a mature form of insulin and clusters into an electron dense core, it is said to become an mature insulin granule."}},{"Immature mouse":{"CurationStatus":"uncurated","SuperCategory":"Mouse","Id":"nlx_organ_109066","Definition":"A mouse 0 to 3 months old, with the day of birth defined as day 0."}},{"Immature rat":{"CurationStatus":"uncurated","SuperCategory":"Rat","Id":"nlx_organ_109072","Definition":"A rat before leaving their nest, 0 to 17 days old, with the day of birth defined as day 0."}},{"Immediate recall test":{"Created":"3/4/2011 12:55","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00830","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Immediate_recall_test","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146052","Definition":"involves presenting a subject with material that is to be memorized.  Once the material is removed the subject is to immediately demonstrate everything that they remember from the material."}},{"Immersion":{"Created":"2006-06-02","CurationStatus":"uncurated","Umlscui":"C0020940","SuperCategory":"Agent delivery process","Id":"birnlex_2131","Definition":"A process for delivering an agent to an object of study in which the object is physically submersed in the agent."}},{"Immobile":{"Synonym":"fixed","SuperCategory":"Mobility","Id":"PATO_0000300","Definition":"A mobility quality of being incapable to move freely."}},{"Immortal":{"SuperCategory":"Viability","Id":"PATO_0001991","Definition":"capable of indefinite growth or division."}},{"Immune globulin":{"RelatedTo":["High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1s subcomponent","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["Ig alpha-2 chain C region","immune globulin","Civacir","Flebogamma (Instituto Grifols SA)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00028","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00028","Definition":"Mixture of IgG1 and other antibodies derived from human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. Flebogamma contains the IgG antibody specificities found in the general human population. IgG subclasses are fully represented in the following proportions: IgG1 is 70.3%, IgG2, 24.7%, IgG3, 3.1%, and IgG4,1.9% Pharmacology: Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immune globulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens. Mechanism of action: Antibodies prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage tagging or neutralization (via binding) of pathogen toxins. Drug type: Approved. Biotech. Investigational. Drug category: Anti-Infectives. Immunomodulatory Agents"}},{"Immuno detection protocol":{"CurationStatus":"uncurated","SuperCategory":"Experimental protocol","Id":"nlx_152212","Definition":"Type of protocol used to detect the immunoreagent in immuno-labeling protocols, e.g., immunofluorescence, immunogold"}},{"Immunoadsorption":{"EditorialNote":"Need more details on whether this is a cell purification method as per     22819776 ","CurationStatus":"uncurated","SuperCategory":"Assay","Id":"nlx_152506"}},{"Immunocytochemistry":{"CurationStatus":"uncurated","SuperCategory":"Immunolabeling","Id":"nlx_inv_20090608"}},{"Immunocytochemistry protocol":{"Synonym":"immunocytochemistry","Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Immunolabeling protocol","Id":"birnlex_2244"}},{"Immunofluorescence":{"Synonym":"immunofluorescent staining","CurationStatus":"uncurated","SuperCategory":"Immuno detection protocol","Id":"nlx_94976","Abbrev":"IF"}},{"Immunogold protocol":{"RelatedTo":"Colloidal gold","CurationStatus":"uncurated","SuperCategory":"Immunolabeling protocol","Id":"nlx_152195"}},{"Immunohistochemical protocol":{"Created":"2007-10-09","EditorialNote":"Note:  Some use the term \"immunohistochemistry\" to refer to protocols that employ an enzymatic chromagen as opposed to a particulate or fluorescent marker.  Going back to the original Greek (histo","CurationStatus":"uncurated","SuperCategory":"Immunolabeling protocol","Id":"birnlex_2241","Abbrev":"IHC","Definition":"A protocol that specifies the process of immunohistochemistry.  Immunohistochemistry is the process of localizing proteins in cells of a tissue section exploiting the principle of antibodies binding specifically to antigens in biological tissues. It takes its name from the roots \"immuno,\" in reference to antibodies used in the procedure, and \"histo,\" meaning tissue (compare to immunocytochemistry). (from wikipedia)"}},{"Immunohistochemistry":{"Synonym":"IHC","CurationStatus":"uncurated","SuperCategory":"Immunolabeling","Id":"nlx_inv_20090609","Definition":"Immunolabeling protocol application that involves localizing proteins in a tissue section through exploiting the principle of antibodies binding specifically to antigens in biological tissues. It takes its name from the roots \"immuno,\" in reference to antibodies used in the procedure, and \"histo,\" meaning tissue (compare to immunocytochemistry). (from wikipedia)"}},{"Immunolabeling":{"RelatedTo":["Gene expression"],"Synonym":"immunostaining","CurationStatus":"uncurated","SuperCategory":"Staining","Id":"nlx_inv_20090607","Definition":"A type of staining that is achieved through the binding of an antibody or part of an antibody to a target within a cell or tissue.  The site of binding is visualized through the binding of a chromagen either directly to the primary antibody or to a secondary reagent that interacts with the primary antibody."}},{"Immunolabeling protocol":{"Created":"2006-05-15","CurationStatus":"uncurated","Umlscui":"C0242349","SuperCategory":"Contrast enhancement protocol","Id":"birnlex_2046","Definition":"A means of localizing particular antigens within cells or tissue where the localization depends on the interaction of the binding region of an antibody with a specific epitope.  The antibody itself may carry a detectable tag, e.g., a fluorophore, or the tag may be applied through additional steps."}},{"Immunology":{"CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100630","Definition":"Branch of medicine that concerns itself with the study of the immune system."}},{"Immunoprecipitation assay":{"EditorialNote":"OBI has immunoprecipitation under \"process\";  we insert \"assay\" in between process and immunoprecipitation.  Not sure what to do here.","Synonym":"Immunoprecipitation","CurationStatus":"graph position temporary","Comment":"OBI definition:  a process which realizes a material separation objective by relying on antibodies to specifically bind to a material entity","SuperCategory":"Assay","Curator":["Maryann Martone"],"Id":"OBI_0000690","Is part of":"Immunoprecipitation protocol","Definition":"An assay by which an antigen is precipitated from solution using an antibody."}},{"Immunoprecipitation protocol":{"CurationStatus":"uncurated","SuperCategory":"Protocol","Id":"nlx_48937","Definition":"A protocol employing immunoprecipitation to separate an antigen from a solution based on antibody binding"}},{"Imperforate":{"SuperCategory":["Structure"],"Id":"PATO_0001821"}},{"Impermeable":{"SuperCategory":"Permeability","Id":"PATO_0000983"}},{"Implant Present":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1300","SuperCategory":"DICOM term","Id":"nlx_150152","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Whether or not an implant is present."}},{"Implicit memory":{"Created":"7/10/2009 14:06","EditorialNote":"Birnlex had implicit memory and non-declarative memory as synonyms, although Cognitive Atlas lists them separately, even though the definitions ar esimilar.  Needs review","CurationStatus":"graph position temporary","Contributor":"Agatha Lenartowicz","CAO_Id":"CAO_00337","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Implicit_memory","SuperCategory":"Memory","Curator":"Maryann Martone,","Id":"birnlex_1904","Has role":"Cognitive Atlas Concept","Definition":"Type of memory in which experiences increases performance of task without one's conscious awareness of these previous experiences. This type of memory applies to habit learning, skills, conditioning."}},{"Impressions":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0300","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150153","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"Short impressions summarizing the full results."}},{"Impulse":{"SuperCategory":"Physical quality","Id":"PATO_0001022","Definition":"A physical quality inhering in a bearer by virtue of the change in its momentum."}},{"In column energy filter":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Energy filter","Id":"birnlex_2164"}},{"In contact with":{"Synonym":"contiguous","SuperCategory":"Relational structural quality","Id":"PATO_0001961","Definition":"A relational structural quality inhering in a bearer that is touching another entity."}},{"In vivo calcium imaging assay":{"Synonym":["in vivo calcium imaging","in vivo Ca2+ imaging"],"CurationStatus":"uncurated","SuperCategory":"Assay","Id":"nlx_152498"}},{"In vivo Immunolabeling protocol":{"CurationStatus":"uncurated","SuperCategory":"Immunolabeling protocol","Id":"nlx_62786","Definition":"An immunolabeling protocol in which the primary antibody is applied to living cells or tissues."}},{"In-concatenation Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_9162","SuperCategory":"DICOM term","Id":"nlx_150154","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Identifier for one SOP Instance belonging to a concatenation. Required if Concatenation UID (0020,9161) is present."}},{"In-concatenation Total Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_9163","SuperCategory":"DICOM term","Id":"nlx_150155","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"The number of SOP Instances sharing the same Concatenation UID."}},{"In-plane Phase Encoding Direction":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1312","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150156","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The axis of phase encoding with respect to the image. "}},{"In-situ hybridization":{"RelatedTo":"Gene expression","Synonym":"in situ hybridization","CurationStatus":"uncurated","SuperCategory":"Staining","Id":"nlx_inv_20090610","Abbrev":"ISH","Definition":"A type of hybridization that uses a labeled complementary DNA or RNA strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g. plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells and in circulating tumor cells (CTCs) (from Wikipedia)"}},{"In-situ hybridization protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Specimen preparation protocol","Id":"birnlex_2295"}},{"In-stack Position Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_9057","SuperCategory":"DICOM term","Id":"nlx_150157","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UL","Definition":"The ordinal number of a frame in a group of frames, with the same Stack ID Required if Stack ID (0020,9056) is present."}},{"Inactive":{"SuperCategory":"Behavioral quality of a process","Id":"PATO_0001706","Definition":"Lacking activity."}},{"Inborn Metabolic Brain Disease":{"Synonym":["Inborn Metabolic Encephalopathy","Inborn Metabolic Central Nervous System Disease","Inherited Metabolic Brain Disease","Inborn Metabolic CNS Disease","Inborn Metabolic CNS Disorder","Inborn Metabolic Central Nervous System Disorder","Inborn Errors of Metabolism","Brain","Familial Metabolic Brain Disease","Familial Metabolic Brain Disorder","Inherited Metabolic Brain Disorder"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Metabolic Nervous System Disease","Id":"birnlex_12706","Definition":"Brain disorders resulting from inborn metabolic errors, primarily from enzymatic defects which lead to substrate accumulation, product reduction, or increase in toxic metabolites through alternate pathways. The majority of these conditions are familial, however spontaneous mutation may also occur in utero (MeSH)."}},{"Inbred mouse strain":{"Created":"2006-10-05","EditorialNote":"Currently (2006-10-07), the children of this class have been made mutually disjoint. In reality, there may be some mixing amongst strains - e.g., some strains and substrains were derived from crosses of other inbred strains. Ultimately, the disjoint sets will need to be worked out very carefully, but this approximately is kept for now as it will likely do no harm and serve as a reminder that this issue may require more thorough review in the future.","Synonym":["C57BL/6J","C57BL/6NJ"],"CurationStatus":"uncurated","Contributor":"Robert W. Williams","SuperCategory":"Mus musculus domesticus","Id":"birnlex_189","Is part of":"C57 family","Species":"10090","DefiningCitation":"http://jaxmice.jax.org/strain/000664.html","Abbrev":["B6, B6J","B","Black 6"]}},{"Inbred rat strain":{"PMID":"D011919","Synonym":["Inbred rat; Strain","inbred rat; Rat inbred strain"],"CurationStatus":"uncurated","SuperCategory":"Rat","Id":"nlx_77031","Definition":"Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. (MeSH)"}},{"Include Display Application":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2200_0009","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150158","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD."}},{"Include Non-DICOM Objects":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2200_0008","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150159","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD."}},{"Incompatible":{"SuperCategory":"Compatibility","Id":"PATO_0000345","Definition":"A quality of being incapable of harmonious coexistence."}},{"Inconspicuous":{"SuperCategory":"Conspicuousness","Id":"PATO_0000464","Definition":"A quality inhering in a bearer by virtue of not being clearly visible."}},{"Increased acidity":{"Synonym":"High acidity","SuperCategory":"Acidity","Id":"PATO_0001844","Definition":"An acidity which is relatively high."}},{"Increased age":{"Synonym":"high age","SuperCategory":"Age","Id":"PATO_0001764","Definition":"An age which is relatively high."}},{"Increased Area":{"SuperCategory":"Area","Id":"PATO 0002057","Definition":"An area which is relatively high."}},{"Increased circumference":{"SuperCategory":"Circumference","Id":"PATO_0001898","Definition":"A circumference which is relatively high."}},{"Increased co-expression":{"CurationStatus":"uncurated","SuperCategory":"Co-expression","Id":"nlx_qual_1010006","Has role":"NIF annotation standard for differential expression"}},{"Increased co-staining":{"CurationStatus":"uncurated","SuperCategory":"Co-staining","Id":"nlx_qual_1010002","Has role":"NIF annotation standard for differential expression"}},{"Increased coiling":{"Synonym":"high coiling.","SuperCategory":"Coiled","Id":"PATO_0001795","Definition":"A coiling which is relatively increased."}},{"Increased concentration":{"Synonym":"High concentration","SuperCategory":"Concentrated (PATO 0001159)","Id":"PATO_0001162","Definition":"A concentration which is relatively high."}},{"Increased consumption":{"Synonym":["high consumption"],"SuperCategory":"Consumption quality","Id":"PATO_0000767","Definition":"A consumption which is relatively high."}},{"Increased contractility":{"Synonym":"high contractility","SuperCategory":"Contractile","Id":"PATO_0001580","Definition":"A contractility which is relatively high."}},{"Increased curvature":{"SuperCategory":"Curved","Id":"PATO_0001592","Definition":"A curvature which is relatively high."}},{"Increased density":{"Synonym":"high density","SuperCategory":"Dense","Id":"PATO_0001788","Definition":"A density which is relatively high."}},{"Increased depth":{"Synonym":"high depth","SuperCategory":"Depth","Id":"PATO_0001596","Definition":"A depth which is relatively high."}},{"Increased diameter":{"SuperCategory":"Diameter","Id":"PATO_0001714","Definition":"A diameter which is relatively large."}},{"Increased distance":{"Synonym":"long distance","SuperCategory":"Distance","Id":"PATO_0000374","Definition":"A distance which is greater relative to the normal or average."}},{"Increased distribution":{"Synonym":"high distribution","SuperCategory":"Distributed","Id":"PATO_0001671","Definition":"A distribution which is relatively high."}},{"Increased duration of temperature":{"Synonym":"high duration of temperature","SuperCategory":"Duration of temperature","Id":"PATO_0001312","Definition":"A duration of temperature which is greater relative to the normal or average in respect to the quality of temperature of enduring or continuing in time."}},{"Increased elevation":{"Synonym":"high elevation.","SuperCategory":"Elevation","Id":"PATO_0001688","Definition":"An elevation which is relatively high."}},{"Increased expression":{"Synonym":["Up-regulated","Upregulated","Up-regulated expression"],"CurationStatus":"uncurated","SuperCategory":"Differential expression","Id":"nlx_qual_100811","Has role":"NIF annotation standard for differential expression","Definition":"Expression that is increased relative to a control group at a significance level generally of p<\/"}},{"Increased fatigability":{"Synonym":"High fatigability","SuperCategory":"Fatigability","Id":"PATO_0001816","Definition":"A fatigability which is relatively high."}},{"Increased fecundity":{"Synonym":"high fecundity","SuperCategory":"Fecundity","Id":"PATO_0001695","Definition":"A fecundity which is relatively high."}},{"Increased female fertility":{"Synonym":"high female fertility","SuperCategory":"Female fertile","Id":"PATO_0001831","Definition":"A female fertility which is relatively high."}},{"Increased female receptivity":{"Synonym":"high female receptivity","SuperCategory":"Female receptivity","Id":"PATO_0001723","Definition":"A female receptivity which is high."}},{"Increased fertility":{"Synonym":"high fertility","SuperCategory":"Fertile","Id":"PATO_0001835","Definition":"A fertility which is relatively high."}},{"Increased flexibility":{"Synonym":"high flexibility","SuperCategory":"Flexible","Id":"PATO_0001776","Definition":"A flexibility which is relatively high."}},{"Increased flow":{"Synonym":"high flow","SuperCategory":"Flow","Id":"PATO_0001839","Definition":"A flow that is relatively high."}},{"Increased fluorescence":{"Synonym":"high fluorescence","SuperCategory":"Fluorescent","Id":"PATO_0001926","Definition":"A fluorescence which is higher than normal."}},{"Increased frequency":{"Synonym":["high frequency"],"SuperCategory":"Frequency","Id":"PATO_0000380","Definition":"A frequency that is relatively high."}},{"Increased functionality":{"Synonym":"High Functionality","SuperCategory":"Functional","Id":"PATO_0001625","Definition":"Functionality which is an increased ability to perform a regular function(s)."}},{"Increased gene expression":{"CurationStatus":"uncurated","SuperCategory":"Differential gene expression","Id":"nlx_45980","Has role":"NIF annotation standard for differential expression","Definition":"Gene expression that is increased relative to a control group at a significance level of p<\/"}},{"Increased height":{"Synonym":"tall","SuperCategory":"Height","Id":"PATO_0000570","Definition":"A height which is relatively high."}},{"Increased intensity":{"Synonym":"high intensity","SuperCategory":"Intensity","Id":"PATO_0001782","Definition":"Having intensity which is relatively high."}},{"Increased length":{"Synonym":"long","SuperCategory":"Length (PATO 0000122)","Id":"PATO_0000573","Definition":"A length which is relatively large."}},{"Increased life span":{"Synonym":"high life span","SuperCategory":"Life span","Id":"PATO_0001603","Definition":"A life span which is relatively high."}},{"Increased magnetism":{"Synonym":"high magnetism","SuperCategory":"Magnetic","Id":"PATO_0001683","Definition":"A magnetism which is relatively high."}},{"Increased magnitude":{"Synonym":"high magnitude","SuperCategory":"Magnitude","Id":"PATO_0002017"}},{"Increased male fertility":{"Synonym":"high male fertility","SuperCategory":"Male fertile","Id":"PATO_0001832","Definition":"A male fertility which is relatively high."}},{"Increased male receptivity":{"Synonym":"high male receptivity","SuperCategory":"Male receptivity","Id":"PATO_0001725","Definition":"A male receptivity which is high."}},{"Increased mass":{"Synonym":["large mass"],"SuperCategory":"Mass","Id":"PATO_0001563","Definition":"A mass which is relatively high."}},{"Increased number":{"SuperCategory":"Count","Id":"PATO_0000470"}},{"Increased occurrence":{"Synonym":"increased incidence","SuperCategory":"Occurrence quality","Id":"PATO_0002051","Definition":"An occurence which is relatively high."}},{"Increased odor":{"SuperCategory":"Odorous","Id":"PATO_0001893","Definition":"An odor quality of having increased odor."}},{"Increased Osmolality":{"Synonym":"high osmolality","SuperCategory":"Osmolality","Id":"nlx_82","Definition":"Osmolality which is relatively high."}},{"Increased osmolarity":{"Synonym":"high osmolarity","SuperCategory":"Osmolarity","Id":"PATO_0001657","Definition":"An osmolarity which is relatively high."}},{"Increased perimeter":{"SuperCategory":"Perimeter","Id":"PATO_0001712","Definition":"A perimeter which is relatively high."}},{"Increased period":{"SuperCategory":"Period","Id":"PATO_0000498"}},{"Increased permeability":{"SuperCategory":"Permeable (PATO 0000982)","Id":"PATO_0001577"}},{"Increased photosensitivity":{"Synonym":"high photosensitivity","SuperCategory":"Photosensitive","Id":"PATO_0001698","Definition":"A photosensitivity which is relatively high."}},{"Increased position":{"Synonym":"high position","SuperCategory":"Physical quality","Id":"PATO_0001475","Definition":"A position which is relatively high."}},{"Increased pressure":{"Synonym":"high pressure","SuperCategory":"Pressure","Id":"PATO_0001576","Definition":"A pressure which is relatively high."}},{"Increased radioactivity":{"Synonym":"high radioactivity","SuperCategory":"Radioactive","Id":"PATO_0001742","Definition":"A radioactivity which is relatively high."}},{"Increased rate":{"Synonym":["high rate"],"SuperCategory":"Rate","Id":"PATO_0000912","Definition":"A rate which is relatively high."}},{"Increased relaxation":{"Synonym":"High relaxation","SuperCategory":"Relaxation","Id":"PATO_0001811","Definition":"A relaxation which is relatively high."}},{"Increased resistance to":{"Synonym":["increased resistance"],"SuperCategory":"Resistant to","Id":"PATO_0001650","Definition":"A resistance to a stimulus which is relatively high."}},{"Increased sensitivity of occurrent":{"Synonym":"high sensitivity of occurrent","SuperCategory":"Sensitivity of occurrent","Id":"PATO_0001551","Definition":"A sensitivity of occurrent which is higher than normal/average."}},{"Increased sensitivity of occurrent to oxygen":{"Synonym":"high sensitivity of occurrent to oxygen","SuperCategory":"Aerobic (for occurrence)","Id":"PATO_0001553","Definition":"A sensitivity of occurent to oxygen which is higher than normal/average."}},{"Increased sensitivity to irradiation":{"Synonym":"high sensitivity to irradiation","SuperCategory":"Sensitivity to irradiation","Id":"PATO_0001808","Definition":"A sensitivity to irradiation which is relatively high."}},{"Increased sensitivity toward":{"Synonym":["high sensitivity toward"],"SuperCategory":"Sensitive toward","Id":"PATO_0001549","Definition":"A sensitivity toward an external stimulus which is higher than normal/average."}},{"Increased size":{"Synonym":["large","great","big"],"SuperCategory":"Size","Id":"PATO_0000586","Definition":"A size which is greater relative to the normal or average."}},{"Increased solubility":{"Synonym":"high solubility","SuperCategory":"Soluble in","Id":"PATO_0001663","Definition":"A solubility which is relatively high."}},{"Increased speed":{"Synonym":["fast speed"],"SuperCategory":"Speed/velocity","Id":"PATO_0000303","Definition":"A speed which is relatively high."}},{"Increased staining":{"CurationStatus":"uncurated","SuperCategory":"Differential staining","Id":"nlx_qual_100814","Has role":"NIF annotation standard for differential expression","Definition":"Staining that is increased relative to a control group at a significance level of p<\/"}},{"Increased strength":{"Synonym":"high strength","SuperCategory":"Strength","Id":"PATO_0001778","Definition":"A strength which is relatively high."}},{"Increased susceptibility toward":{"Synonym":["low susceptibility toward"],"SuperCategory":"Susceptible toward","Id":"PATO_0001669","Definition":"A susceptibility toward an external stimulus which is higher than normal/average."}},{"Increased temperature":{"Synonym":"high temperature","SuperCategory":"Temperature","Id":"PATO_0001305","Definition":"A temperature which is greater relative to the normal or average temperature."}},{"Increased thickness":{"Synonym":["Thick","Thickened"],"SuperCategory":"Thickness","Id":"PATO_0000591","Definition":"A thickness which is relatively high."}},{"Increased threshold":{"Synonym":"High threshold","CurationStatus":"uncurated","SuperCategory":"Threshold","Id":"PATO_0000706","Has role":"\tElectrophysiology concept","Definition":"A threshold which is relatively high."}},{"Increased time":{"Synonym":["high time"],"SuperCategory":"Time","Id":"PATO_0000715","Definition":"A time which is relatively high."}},{"Increased tonicity":{"Synonym":"high tonicity","SuperCategory":"Tonicity","Id":"PATO_0001618","Definition":"A tonicity which is relatively high."}},{"Increased turgor":{"SuperCategory":"Turgor","Id":"PATO_0001622"}},{"Increased variability":{"Synonym":"high variability","SuperCategory":"Variant","Id":"PATO_0001584","Definition":"A variability quality which is relatively high."}},{"Increased variability of color":{"Synonym":"High variability of color","SuperCategory":"Variant color","Id":"PATO_0001612","Definition":"A variability of color which is relatively high."}},{"Increased variability of rate":{"Synonym":"high variability of rate","SuperCategory":"Variability of rate","Id":"PATO_0001587","Definition":"A variability of rate which is relatively high."}},{"Increased variability of size":{"Synonym":"high variability of size","SuperCategory":"Variability of size","Id":"PATO_0001958","Definition":"A variability of size which is relatively high."}},{"Increased variability of temperature":{"Synonym":"high variability of temperature","SuperCategory":"Variant temperature","Id":"PATO_0001308","Definition":"Variability of temperature which is relatively high."}},{"Increased viscosity":{"Synonym":"high viscosity","SuperCategory":"Viscous","Id":"PATO_0001693","Definition":"A viscosity which is relatively high."}},{"Increased volume":{"Synonym":["low volume"],"SuperCategory":"Volume (PATO 0000918)","Id":"PATO_0000595","Definition":"A volume which is relatively high."}},{"Increased weight":{"Synonym":["heavy weight"],"SuperCategory":"Weight","Id":"PATO_0000582","Definition":"A weight that is relatively high."}},{"Increased wetness":{"Synonym":"High wetness","SuperCategory":"Wet","Id":"PATO_0001825","Definition":"A wetness that is relatively high."}},{"Increased width":{"Synonym":["Broad"],"SuperCategory":"Width (PATO 0000921)","Id":"PATO_0000600","Definition":"A width which is relatively high."}},{"Indapamide":{"RelatedTo":["Potassium voltage-gated channel subfamily E member 1"],"Synonym":["Indapamida (INN-Spanish)","Indapamidum (INN-Latin)","Apo-Indapamide","Arifon","Bajaten","Cormil","Damide","Fludex","Gen-Indapamide","Idapamide","Indaflex","Indamol","Ipamix","Lozide","Lozol","Natrilix","Natrix","Noranat","Novo-Indapamide","Nu-Indapamide","Pressurai","Tandix","Tertensif"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00808","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00808","Definition":"A benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. (PubChem) Pharmacology: Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide bears a structural similarity to the triazide diuretics which are known to decrease vascular smooth muscle reactivity. However, it differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. Indapamide appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. This same effect may cause hypokalcemia in susceptible individuals. Indapamide has also been shown to cause uterine myometrial relaxation in experimental animals. Overall, indapamide has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance. Mechanism of action: Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Diuretics"}},{"Indecainide":{"RelatedTo":"Sodium channel protein type 5 subunit alpha","Synonym":["9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide","9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid","Indecainida (Spanish)","Indecainidum (Latin)","Ricainid","Ricainide"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00192","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00192","Definition":"Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Pharmacology: Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Mechanism of action: Indecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Drug type: Approved. Small Molecule. Drug category: Antidysrhythmic Agents. Sodium channel blockers"}},{"Indented Nucleus Quality":{"SuperCategory":"Nucleus Quality","Id":"sao1277586470","Definition":"Nucleus with one or more indentations in the nuclear membrane."}},{"Independent Components Analysis":{"Created":"2008-03-14","CurationStatus":"uncurated","SuperCategory":"Algorithm","Id":"birnlex_3055","Abbrev":"ICA","Definition":"A computational method for separating a multivariate signal into additive subcomponents supposing the mutual statistical independence of the non-Gaussian source signals. It is a special case of blind source separation. (from Wikipedia)."}},{"Independent continuant":{"Example":["an organism","a heart","a leg","a person","a symphony orchestra","a chair","the bottom right portion of a human torso"],"Synonym":["substantial entity"],"SuperCategory":"Continuant","Id":"IndependentContinuant","Definition":" A continuant (snap:Continuant) that is a bearer of quality (snap:Quality) and realizable entity (snap:RealizableEntity) entities, in which other entities inhere and which itself cannot inhere in anything., "}},{"Independent self-construal":{"PMID":"21359209","CurationStatus":"uncurated","SuperCategory":"Cognitive process","PublicationLink":"http://www.plosone.org/article/info:doi/10.1371/journal.pone.0016901","Id":"nlx_66396","DefinitionPMID":"21359209","Definition":"A self-concept in which the self is thought of as an isolated unit that strives to be unique, autonomous and assertive, functioning in parallel with, but not dependent upon, others. "}},{"Indifference":{"SuperCategory":"Preference","Id":"PATO_0000772","Definition":"A preference quality of having no preference to a perceived stimulus."}},{"Indinavir":{"RelatedTo":["Gag-Pol polyprotein"],"Synonym":["Compound J","Indinavir sulfate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:44032","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00224","Definition":"A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. (PubChem) Pharmacology: Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Mechanism of action: Indinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Drug type: Approved. Small Molecule. Drug category: Anti-HIV Agents. HIV Protease Inhibitors"}},{"Indirect flight muscle motor neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Motor neuron (FBbt Term)","Id":"nlx_147784","Is part of":"Mesothoracic neuromere","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004074","Definition":"."}},{"Indirect flight muscle motor neuron MN1":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Indirect flight muscle motor neuron","Id":"nlx_147785","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004075"}},{"Indirect flight muscle motor neuron MN2":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Indirect flight muscle motor neuron","Id":"nlx_147786","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004076"}},{"Indirect flight muscle motor neuron MN3":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Indirect flight muscle motor neuron","Id":"nlx_147787","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004077"}},{"Indirect flight muscle motor neuron MN4":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Indirect flight muscle motor neuron","Id":"nlx_147788","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004078"}},{"Indirect flight muscle motor neuron MN5":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Indirect flight muscle motor neuron","Id":"nlx_147789","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004079"}},{"Indiscriminate":{"SuperCategory":"Discrimination","Id":"PATO_0001318","Definition":"A discrimination quality of being incapable of perceiving differences between two or more stimuli."}},{"Individual body part movement":{"CurationStatus":"uncurated","SuperCategory":"Motor activity","Id":"birnlex_1901"}},{"Indomethacin":{"RelatedTo":["Prostaglandin G/H synthase 1"],"Synonym":["IMN","Indometacine","Indometacyna","Indomethacine","Indomethacinum","Indomethancin","Indomethazine","Indomethine","Indometicina","indomethacin","Amuno","Apo-Indomethacin","Argun","Arthrexin","Artracin","Artrinovo","Artrivia","Bonidin","Bonidon","Bonidon Gel","Catlep","Chibro-Amuno","Chrono-Indicid","Chrono-Indocid","Confortid","Dolcidium","Dolcidium Pl","Dolovin","Durametacin","Elmetacin","Flexin Continus","Hicin","Idomethine","Imbrilon","Inacid","Indacin","Indaflex","Indameth","Indmethacine","Indo-Lemmon","Indo-Phlogont","Indo-Rectolmin","Indo-Spray","Indo-Tablinen","Indocid","Indocid Pda","Indocid Sr","Indocin","Indocin I,V","Indocin I,V,","Indocin Sr","Indolar Sr","Indomecol","Indomed","Indomee","Indomethegan","Indomo","Indomod","Indoptic","Indoptol","Indorektal","Indoxen","Inflazon","Infrocin","Inteban Sp","Lausit","Liometacen","Metacen","Metartril","Methazine","Metindol","Miametan","Mikametan","Mobilan","Novo-Methacin","Novomethacin","Nu-Indo","Reumacide","Rhemacin La","Rheumacin La","Sadoreum","Tannex"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:49662","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00328","Definition":"A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes. (PubChem) Pharmacology: Indomethacin, a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. Mechanism of action: Antiinflammatory effects of Indomethacin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Inflammatory Agents, Non-Steroidal. Anti-inflammatory Agents. Cardiovascular Agents. Cyclooxygenase Inhibitors. Gout Suppressants. Nonsteroidal Antiinflammatory Agents (NSAIDs). Tocolytic Agents"}},{"Inductive reasoning activity":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Reasoning activity","Id":"birnlex_1851"}},{"Inductive reasoning aptitude":{"Created":"4/1/2011 12:54","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00899","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Inductive_reasoning_aptitude","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146123","Definition":"is a measurable aptitude for how well a person can identify a pattern within a large amount of data."}},{"Inductive reasoning function":{"Created":"2007-03-06","Synonym":"Induction (http://www.springerreference.com/docs/html/chapterdbid/306077.html).","CurationStatus":"uncurated","SuperCategory":"Reasoning function","Id":"birnlex_1878","Definition":"Inductive reasoning is the process of inferring general principles from specific observations (http://www.springerreference.com/docs/html/chapterdbid/306077.html)."}},{"Induseum griseum":{"Synonym":"dorsal hippocampal continuation","CurationStatus":"uncurated","NeuronamesID":"173","SuperCategory":"Regional part of brain","Id":"nlx_49940","Is part of":"Telencephalon,","AfferentProjections":"Olfactory bulb,","Abbrev":"IG","Definition":"Thin layer of cortex lying on the dorsal surface of the corpus callosum.  It has been debated whether it is more related to the hippocampus or the olfactory bulb (Shipley et al., Olfactory System In Paxinos The Rat Nervous System, 2nd ed)"}},{"Induseum griseum of ABA 2009":{"AtlasImage":["Induseum griseum.jpg"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"Induseum griseum","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_151340","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Hippocampal region of ABA 2009","Organism":"mouse","Species":"Mouse"}},{"Inelastic":{"SuperCategory":"Elasticity","Id":"PATO_0001172","Definition":"An elasticity quality inhering in a bearer by virtue of its inability to recover its size and shape after deformation in any way."}},{"Infant":{"CurationStatus":"uncurated","SuperCategory":"Maturity","Id":"nlx_61600","Definition":"A maturity quality inhering in an organism that has passed the newborn stage extending to a period after birth where the organism is in an immature state and still in the earliest period of life."}},{"Infant chimpanzee":{"Synonym":"Chimpanzee infant","CurationStatus":"uncurated","SuperCategory":"Chimpanzee","Id":"nlx_organ_109082","Definition":"A chimpanzee 1 to 2 years old, with the day of birth defined as day 0."}},{"Infant human":{"Synonym":"Human infant","CurationStatus":"uncurated","SuperCategory":"Human","Id":"nlx_organ_109053","Definition":"A child between 1 and 23 months of age. (MeSH)"}},{"Infant rat":{"Synonym":"Rat infant","CurationStatus":"uncurated","SuperCategory":"Rat","Id":"nlx_organ_109069","Definition":"A rat 10 to 18 days old, with the day of birth defined as day 0."}},{"Infantile Globoid Cell Leukodystrophy":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Globoid Cell Leukodystrophy","Id":"birnlex_12535"}},{"Infantile Myoclonic Epilepsy":{"Synonym":"Early Childhood Myoclonic Epilepsy","Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Myoclonic Epilepsy","Id":"birnlex_12720"}},{"Infantile Spasms":{"Synonym":["Jackknife Seizures","Nodding Spasm","Hypsarrhythmia","Salaam Attacks","Lightning Attacks","Salaam Seizures","Spasmus Nutans"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Generalized Epilepsy","Id":"birnlex_12744","DefiningCitation":["Menkes","Textbook of Child Neurology","5th ed"],"Definition":"An epileptic syndrome characterized by the triad of infantile spasms, hypsarrhythmia, and arrest of psychomotor development at seizure onset. The majority present between 3-12 months of age, with spasms consisting of combinations of brief flexor or extensor movements of the head, trunk, and limbs. The condition is divided into two forms: cryptogenic (idiopathic) and symptomatic (secondary to a known disease process such as intrauterine infections; nervous system abnormalities; BRAIN DISEASES, METABOLIC, INBORN; prematurity; perinatal asphyxia; TUBEROUS SCLEROSIS; etc.) (MeSH)."}},{"Infectious disease":{"CurationStatus":"uncurated","SuperCategory":"Disease","Id":"nlx_18995"}},{"Inferior antennal lobe commissure":{"Has_role":"Fly_Anatomy_Ontology","Innervates":"antennal lobe","Created":"2010-11-30T03:22:40Z","Synonym":"iALC","Contributor":"sr544","SuperCategory":"Antennal commissure","Id":"nlx_148662","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100352","hasDBXref":"VFB:FBbt_00100352","Definition":"Ventral-most of two commissures connecting the antennal lobes and running in front of the ellipsoid body."}},{"Inferior calcarine sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["lower calcarine sulcus","inferior ramus of calcarine fissure"],"NeuronamesID":"130","CurationStatus":"uncurated","Umlscui":"C0262249","SuperCategory":"Superficial feature part of occipital lobe","Id":"birnlex_4021","Abbrev":["iccs"]}},{"Inferior central nucleus":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_861","Is part of":"Pontine reticular formation"}},{"Inferior cerebellar peduncle":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"restiform body","CurationStatus":"uncurated","NeuronamesID":"778","Umlscui":"C0152393","SuperCategory":"Regional part of brain","Curator":["Maryann Martone"],"Id":"birnlex_1691","Is part of":["Cerebellar penducular complex"],"Abbrev":"icp","Definition":"Regional part of medullary white matter (according to Neuronames) primarily found at the level of the open medulla, consisting of a large bundle of fibers projecting to and projecting from the cerebellum.  The icp is continuous with the dorsal spinocerebellar tract and also contains a large number of fibers originating in the inferior olivary complex (MM)."}},{"Inferior colliculus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"pending final vetting","NeuronamesID":"467","Umlscui":"C0228411","EfferentProjections":"Medial geniculate body,","SuperCategory":"Regional part of brain","Id":"birnlex_806","Is part of":"Midbrain tectum","Species":"Mammal","Abbrev":"IC","Definition":"Part of the midbrain tectum, consisting of paired predominantly gray matter elevations on the dorsal aspect of the midbrain, located caudal to the superior colliculus, dorsal to the periaqueductal gray of the cerebral aqueduct and rostral to the cerebellum.  According to Neuronames, the inferior colliculus comprises the central, pericentral and external nucleus and two predominantly white matter structures, the brachium of the inferior colliculus and the commissure of the inferior colliculus (MM)."}},{"Inferior colliculus central nucleus of ABA 2009":{"PartiallyOverlapsWith":"Inferior colliculus  central nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153019","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Inferior colliculus dorsal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Inferior colliculus  dorsal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153124","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Inferior colliculus external nucleus of ABA 2009":{"PartiallyOverlapsWith":"Inferior colliculus  external nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153041","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Inferior colliculus of ABA 2009":{"PartiallyOverlapsWith":"Inferior colliculus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153738","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Inferior colliculus of WHS11":{"AtlasImage":["Inferior colliculus of WHS11.png"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"Inferior colliculus","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143778","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Midbrain of WHS11","Species":"Mouse","Definition":"Delineation of inferior colliculus on Waxholm mouse brain atlas, as seen in T2* weighted volume.  As seen in sagittal: Lower intensity than superior colliculus.As seen in coronal: Appears as bilateral lobes situated between the cerebellum and superior colliculus"}},{"Inferior frontal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","DefiningCriteria":"topography","CurationStatus":"uncurated","NeuronamesID":"67","Umlscui":"C0152298","TomoDefiningCriteria":["Component of the frontal lobe"],"SuperCategory":"Regional part of brain","Id":"birnlex_873","Has role":["Right IFG and preSMA altogether play a role in stopping action (i.e."],"Species":"Human","HasRolePMID":"21979383","Abbrev":"IFG","Definition":"Component of the frontal lobe, lateral aspect.  The rostral boundary is the first appearance of the inferior frontal sulcus whereas the caudal boundary is the precentral gyrus. The medial and lateral boundaries are the lateral bank of the inferior frontal sulcus and the medial bank of the lateral orbital sulcus and/or the circular insular sulcus respectively (Christein Fennema-Notestine)."}},{"Inferior frontal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"63","SuperCategory":"Sulcus","Id":"birnlex_1619","Is part of":"Frontal lobe","Species":"Human","DefiningCitation":"http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID","Abbrev":"ifrs"}},{"Inferior horn of the lateral ventricle":{"Created":"2006-07-15","Synonym":"temporal horn of lateral ventricle","CurationStatus":"uncurated","Umlscui":"C0152283","SuperCategory":"Regional part of brain","Id":"birnlex_1292","Is part of":["Lateral ventricle"],"Definition":"The part of the lateral ventricle extending downward and anteriorly in the temporal lobe."}},{"Inferior oblique extraocular muscle":{"Synonym":["inferior oblique"],"CurationStatus":"uncurated","SuperCategory":"Extraocular muscle","Id":"UBERON:0006320","Definition":"Extraocular muscle that moves the eye obliquely, in an upward and lateral direction.  It is innervated by the 3rd cranial nerve (adapted from Wikipedia)"}},{"Inferior occipital gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"138","Umlscui":"C1110643","SuperCategory":"Regional part of brain","Id":"birnlex_1399","Is part of":"Occipital lobe"}},{"Inferior occipital sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"Sulcus occipitalis inferior","NeuronamesID":"126","CurationStatus":"uncurated","Umlscui":"C0262253","SuperCategory":"Superficial feature part of occipital lobe","Id":"birnlex_4020","Abbrev":["iocs"]}},{"Inferior olivary complex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-07","Synonym":"Inferior olive","CurationStatus":"pending final vetting","NeuronamesID":"745","Umlscui":"C0228540","EfferentProjections":["Cerebellar cortex"],"SuperCategory":"Regional part of brain","Id":"birnlex_1164","Has role":"Precerebellar nucleus","Is part of":"Medulla oblongata,","Species":"Mammal,"}},{"Inferior olivary complex of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Inferior olivary complex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153521","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Species":"Mouse"}},{"Inferior olivary nucleus interneuron":{"Located in":"Inferior olivary complex","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_151562","Species":"Vertebrata"}},{"Inferior olivary nucleus principal neuron":{"Located in":"inferior olivary complex","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_151561","Species":"Vertebrata"}},{"Inferior parietal cortex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","EditorialNote":"Both NeuroNames and UMLS use \"inferior parietal lobule\" as the preferred term.","Synonym":"inferior parietal lobule","CurationStatus":"uncurated","NeuronamesID":"89","Umlscui":"C0152304","SuperCategory":"Regional part of brain","Id":"birnlex_1194","Is part of":"Parietal lobe","Species":"Human","Definition":"Component of the parietal lobe.  The inferior parietal cortex label includes the inferior parietal gyrus and the angular gyrus and lies inferior to the superior parietal gyrus. The rostral and caudal boundaries were the supramarginal gyrus and the parieto-occipital incisure respectively. The medial and lateral boundaries were the superior parietal gyrus and the middle temporal gyrus respectively (Christine Fennema-Notestine)."}},{"Inferior Parietal Sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","NeuronamesID":"811","CurationStatus":"uncurated","SuperCategory":"Superficial feature part of parietal cortex","Id":"birnlex_4010","Abbrev":"IPS","Definition":"The term superior parietal sulcus (H) refers to a superficial feature of the parietal lobe that extends from the dorsal surface of the superior parietal lobule across the margin of the parietal lobe into the precuneus (Ono-90). (NN)"}},{"Inferior part of vestibular ganglion":{"Created":"2007-08-28","CurationStatus":"uncurated","Umlscui":"C1186167","SuperCategory":"Regional part of vestibular ganglion","Id":"birnlex_2552"}},{"Inferior postcentral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"Sulcus postcentralis inferior","NeuronamesID":"83","CurationStatus":"uncurated","Umlscui":"C0262256","SuperCategory":"Superficial feature part of parietal cortex","Id":"birnlex_4032","Abbrev":"ipcs"}},{"Inferior precentral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":["Sulcus precentralis inferior","inferior part of precentral fissure"],"CurationStatus":"uncurated","NeuronamesID":"53","Umlscui":"C0262257","SuperCategory":"Sulcus","Id":"birnlex_1627","Is part of":"Precentral sulcus"}},{"Inferior pulvinar nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["nucleus pulvinaris thalami","nucleus pulvinaris inferior","nucleus pulvinar pars inferior"],"CurationStatus":"graph position temporary","TomoDefiningCriteria":"located ventrally between the medial and lateral geniculate bodies","EfferentProjections":"Fusiform gyrus,","Curator":"Maryann Martone,","Xref":"FMAID:62183","Abbrev":"IPul","AfferentProjections":["Fusiform gyrus"],"PMID":"6315779,15739240,8254107,1112928,8847417,6323553,12209852,401837,10379830","TopoDefiningCriteriaPMID":"ISBN:0-683-01455-2","AfferentProjectionsPMID":["10215937"],"Created":"2007-03-05","EditorialNote":"A few papers mention this nucleus in the cat.  Needs review","NeuronamesID":"315","Umlscui":"C0228346","SuperCategory":"Nucleus of CNS","Id":"birnlex_830","Is part of":"Pulvinar","Species":"Primate","Definition":"One of four subdivisions recognized in the primate pulvinar based on initially on topography, located ventrally between the medial and lateral geniculate bodies (Carpenter, A core text of neuroanatomy, 3rd ed., 1985, pg 238)","DefinitionPMID":"ISBN:0-683-01455-2","EfferentProjectionsPMID":"10215937,"}},{"Inferior ramus of arcuate sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","DefiningCriteria":"topography","CurationStatus":"uncurated","NeuronamesID":"2379","Umlscui":"C0262258","SuperCategory":"Sulcus","Id":"birnlex_1635","Is part of":"Arcuate sulcus","Abbrev":"iar"}},{"Inferior retina":{"PMID":"1968918,15174083,7636021,2794135,2893815,10531540","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_54318","Is part of":"Retina"}},{"Inferior rostral gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"1465682436","SuperCategory":"Regional part of brain","Id":"birnlex_1447","Is part of":"Frontal lobe","Species":["Human"]}},{"Inferior rostral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"Sulcus rostralis inferior","CurationStatus":"uncurated","NeuronamesID":"75","Umlscui":"C0694584","SuperCategory":"Sulcus","Id":"birnlex_1642","Is part of":"Rostral sulcus","Species":"Human","DefiningCitation":"http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID","Abbrev":"iros"}},{"Inferior salivatory nucleus of ABA 2009":{"PartiallyOverlapsWith":"Inferior salivatory nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153071","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Inferior temporal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":"gyrus temporalis inferior","CurationStatus":"uncurated","NeuronamesID":"120","SuperCategory":"Regional part of brain","Id":"birnlex_1577","Is part of":"Temporal lobe","Species":"Human","Definition":"Component of the temporal lobe, lateral aspect.  The rostral boundary is the rostral extent of the inferior temporal sulcus whereas the caudal boundary is designated as the temporo-occipital incisure on the cortical surface. The occipitotemporal sulcus is the medial boundary and the inferior temporal sulcus is the lateral boundary (Christine Fennema-Notestine)."}},{"Inferior temporal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","EditorialNote":"UMLS contains 2 CUIs for this class: C0228242 and C0228245.  The former is listed as \"human-only\" and thus best matches to the entity described in NeuroNames.","NeuronamesID":"112","CurationStatus":"uncurated","Umlscui":"C0228242","SuperCategory":"Sulcus","Id":"birnlex_800","Is part of":"Temporal lobe","Species":"Human"}},{"Inferior transverse frontopolar gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"1233666840","SuperCategory":"Regional part of brain","Id":"birnlex_1064","Is part of":"Transverse frontopolar gyri complex","Species":"Human"}},{"Inferior vestibular nucleus":{"MyeloDefiningCriteria":["Distinguished by longitudinally running fibers","giving it a reticulated appearance","and allowing all parts of the nucleus to be clearly outlined in Kluver Barrera stained sections"],"Synonym":["Descending vestibular nucleus"],"DefiningCriteria":"myelo-architecture","CurationStatus":"uncurated","NeuronamesID":"718","SuperCategory":"Regional part of brain","Id":"nlx_144004","MyeloDefiningCriteriaPMID":"3571524","Is part of":"Vestibular nuclear complex","DefinitionPMID":"3571524","Definition":"One of the nuclei comprising the vestibular nuclear complex, characterized by bundles of longitudinal fibers running through it.  Multiple cell groups are often identified within it."}},{"Infiltrative":{"Synonym":"infiltrating","CurationStatus":"uncurated","SuperCategory":"Structure","Id":"PATO_0002103","Definition":"A structural quality inhering in a bearer by virtue of the bearer's penetrating or permeating another substance or area."}},{"Inflexible":{"Synonym":["stiffness"],"SuperCategory":"Flexibility","Id":"PATO_0001545","Definition":"A physical quality inhering in a bearer by virtue of its inability of being turned, bowed, or twisted without breaking."}},{"Infliximab":{"RelatedTo":["Tumor necrosis factor","Tumor necrosis factor receptor superfamily member 1B"],"Synonym":["Ig gamma-1 chain C region"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00065","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00065","Definition":"Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion Pharmacology: Used in the treatment of auto-immune disorders such as Crohn's disease and rheumatoid arthritis. Infliximab binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal. Mechanism of action: Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa Drug type: Approved. Biotech. Drug category: Immunomodulatory Agents. Immunosuppressive Agents"}},{"Influence of dendritic geometry":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001067","DefiningCitation":"ModelDB:3640","Definition":"The impact that the morphology or shape of the dendrites has on the propagation of electrical signals within a neuron."}},{"Informatics":{"CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100631","Definition":"Informatics is a field of study focusing on development and application of information technology."}},{"Information content entity":{"Created":"2007-10-05","EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","CurationStatus":"uncurated","SuperCategory":"Non-realizable information entity","Id":"birnlex_11001","Definition":"an information content entity is an entity that is generically dependent on some artifact and stands in relation of aboutness to some entity"}},{"Information entity":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Generically dependent continuant","Id":"birnlex_11007"}},{"Information exchange":{"CurationStatus":"uncurated","SuperCategory":"Specification","Id":"nlx_158025","Keywords":"Resource:CINERGI","Definition":"A specification for how to expose a particular kind of data through a particular service protocol in a particular interchange format. The specification defines 1) an abstract content model for the information that defines the entity or entities of interest, their properties, and the logical data type to specify property values, possibly including controlled vocabularies; 2)  implementation of the content model using a specific encoding scheme for transmission between agents; 3)  the service protocol or protocols that will be used for accessing information. (CINERGI)"}},{"Infracerebellar nucleus":{"IsPartOfPMID":"923675","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144469","Is part of":"Cerebellum","DefinitionPMID":"923675"}},{"Infracerebellar nucleus of ABA 2009":{"PartiallyOverlapsWith":"Infracerebellar nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153009","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infralimbic area layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Infralimbic area  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153591","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infralimbic area layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Infralimbic area  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153642","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infralimbic area layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Infralimbic area  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153410","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infralimbic area layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Infralimbic area  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153311","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infralimbic area layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Infralimbic area  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153509","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infralimbic area of ABA 2009":{"PartiallyOverlapsWith":"Infralimbic area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153767","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Infundibular stem":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","Synonym":["Infundibulum of posterior lobe of pituitary gland","hypophyseal Infundibulum","Infundibular stalk","Infundibular stem of neurohypophysis"],"CurationStatus":"uncurated","NeuronamesID":"388","Umlscui":["C0447641"],"SuperCategory":"Regional part of brain","Curator":"Bill Bug","Id":"birnlex_1248","Is part of":"Neurohypophysis","Abbrev":"InfS"}},{"Ingestion":{"Created":"2006-06-01","Synonym":["Oral Supplementation","Oral"],"CurationStatus":"uncurated","Umlscui":"C0232478","SuperCategory":"Agent delivery process","Id":"birnlex_2128"}},{"Inhalant":{"CurationStatus":"uncurated","SuperCategory":"Agent delivery process","Id":"nlx_63864"}},{"Inhibitory":{"CurationStatus":"uncurated","SuperCategory":"Quality of related physical entities","Id":"oen_0001143","Has role":"Electrophysiology concept","Definition":"A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell."}},{"Inhibitory neurotransmitter":{"CurationStatus":"uncurated","SuperCategory":"Neurotransmitter","Id":"nlx_mol_20090603","Definition":"A neurotransmitter that generally activates receptors that have reversal potentials more negative than threshold for action potential firing. "}},{"Inhibitory postsynaptic current":{"RelatedTo":"Inhibitory postsynaptic potential","Synonym":["Inhibitory post-synaptic current","IPSC"],"CurationStatus":"uncurated","SuperCategory":"Transmembrane ionic current","Id":"oen_0001286","Xref":"nlx_mol_100202","Definition":"Any synaptic current which reduces the likelihood of an action potential.  Typically this is mediated by an increase in chloride conductance or potassium conductance.  Inhibitory postsynaptic current is usually synonymous with an evoked inhibitory post synaptic current. , Any synaptic current which reduces the likelihood of an action potential.  Typically this is mediated by an increase in chloride conductance or potassium conductance.  Inhibitory postsynaptic current is usually synonymous with an evoked inhibitory post synaptic current., Any synaptic current which reduces the likelihood of an action potential.  Typically this is mediated by an increase in chloride conductance or potassium conductance.  Inhibitory postsynaptic current is usually synonymous with an evoked inhibitory post synaptic current."}},{"Inhibitory postsynaptic potential":{"Synonym":["Inhibitory post-synaptic potential","IPSP"],"CurationStatus":"uncurated","SuperCategory":"Membrane potential","Id":"oen_0001261","Xref":"nlx_qual_20090502","Definition":"A temporary change in postsynaptic membrane potential, resulting from presynaptic release of neurotransmitter that has the effect of moving the membrane potential farther from threshold, reducing the probability of transmitter release, or limiting the effectiveness of excitatory inputs.  Typically this is an increase in postsynaptic potential, or hyperpolarization, but depolarizing or nonpolarizing potentials can also be considered inhibitory if they reduce the likelihood of action potential firing.  Hyperpolarization can be the result of several types of ionic changes including an increase of negative charged ions into the cell, an increase in positively charged ions out of the cell, or a decrease of positively charged ions into the cell.  Normally, Chloride is the negative charge carrier and the activation of chloride conductances underlies an inhibitory postsynaptic potential."}},{"Initial Segment":{"SuperCategory":"Regional Part Of Axon (sao280355188)","Id":"sao256000789","Definition":"Portion of the axon proximal to the neuronal cell body, at the level of the axon hillock. The action potentials that propagate along the axon are generated at the level of this initial segment (Gene Ontology)."}},{"Injection":{"Created":"2006-06-01","CurationStatus":"uncurated","Umlscui":"C0021485","SuperCategory":"Agent delivery process","Id":"birnlex_2135"}},{"Inner ear":{"Created":"2007-08-20","CurationStatus":"uncurated","Umlscui":["C0022889"],"SuperCategory":"Regional part of body","Id":"birnlex_1196","Is part of":"Ear"}},{"Inner granular layer of cerebellar cortex":{"Created":"2007-08-20","CurationStatus":"uncurated","Umlscui":["C0228471"],"SuperCategory":"Cell layer","Id":"birnlex_790","Is part of":"Granular layer of cerebellar cortex"}},{"Innovation Norway":{"Synonym":"Innovasjon Norge","CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_156799","DefiningCitation":"http://innovasjonnorge.no/no/contact-us/"}},{"Inorganic cation":{"Synonym":"inorganic cations","CurationStatus":"uncurated","Id":"CHEBI:36915"}},{"Inositol 1 4 5 Trisphosphate Receptor":{"SuperCategory":"Intracellular Calcium Channel","Id":"sao2115096416"}},{"Input Availability Flag":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4020","SuperCategory":"DICOM term","Id":"nlx_150160","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Flag that indicates the availability of Composite SOP Instances in the Attribute \"Input Information Sequence\" (0040,4021) of the General Purpose Scheduled Procedure Step."}},{"Input InformationSequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4021","SuperCategory":"DICOM term","Id":"nlx_150161","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"List of Composite SOP Instances that forms the input information needed to perform the scheduled procedure step. See also Input Availability Flag (0040,4020). "}},{"Input Resistance":{"Synonym":["R<sub>in<\/sub>","R<sub>N<\/sub>","Maximum R<sub>in<\/sub>","R<sub>input<\/sub>","Rin"],"CurationStatus":"uncurated","Comment":"NeuroElectro Term 2","SuperCategory":"Cellular physiology characteristic","Id":"oen_0001023","Has role":["NeuroElectro Term","Passive membrane property"],"Definition":"Input resistance at steady-state (steady-state of voltage response to current injection)"}},{"INRA Rennes":{"Synonym":"Institut National de la Recherche Agronomique Rennes","CurationStatus":"uncurated","SuperCategory":"Institute","Id":"nlx_81090","Is part of":"INRA - French National Institute for Agricultural Research; Paris; France","DefiningCitation":"www.rennes.inra.fr/"}},{"Insecta":{"Created":"2007-08-03","Synonym":["insect"],"CurationStatus":"uncurated","Umlscui":"C0021585","SuperCategory":"Hexapoda","Id":"birnlex_275"}},{"Insensitive toward":{"Synonym":["resistant"],"SuperCategory":"Sensitivity toward","Id":"PATO_0000513","Definition":"A quality of lacking sensitivity toward an external stimulus."}},{"Inserted into":{"Synonym":["inserted"],"SuperCategory":"Relational spatial quality","Id":"PATO_0000624","Definition":"A relational spatial quality in which the bearer entity becomes joined together with an additional entity."}},{"Insoluble in":{"Synonym":"insoluble","SuperCategory":"Solubility","Id":"PATO_0001538","Definition":"A solubility quality that arises from the inability of a substance to dissolve in a liquid."}},{"Insomnia":{"SuperCategory":"Sleep pattern","Id":"PATO_0000442","Definition":"A sleep pattern quality inhering in a bearer by virtue of its inability to sleep."}},{"Instance Availability":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0056","SuperCategory":"DICOM term","Id":"nlx_150162","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The availability of the referenced Instance."}},{"Instance Creation Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0012","SuperCategory":"DICOM term","Id":"nlx_150163","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Date the SOP Instance was created."}},{"Instance Creation Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0013","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150164","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"The time the SOP Instance was created."}},{"Instance Creator UID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0014","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150165","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UI","Definition":"Uniquely identifies the device which created the SOP Instance."}},{"Instance Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0013","SuperCategory":"DICOM term","Id":"nlx_150166","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"A number that identifies this image. Note: This Attribute was named Image Number in earlier versions of this Standard."}},{"Institution":{" limit":"100","Created":"2006-04-04","CurationStatus":"graph_position_temporary[[Category:Object aggregate]]This table is also available in {{#ask: [[Category:Institution]]","SuperCategory":"Object aggregate"," format":"csv{{#ask: [[Category:Institution]]","Id":"birnlex_2085","Definition":"The organization to which an individual researcher or groups of researchers belong and where the research is usually conducted, usually a university or medical facility."}},{"Institution Address":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0081","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150167","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"Mailing Address of the institution where the equipment is located."}},{"Institution Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0082","SuperCategory":"DICOM term","Id":"nlx_150168","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A sequence that conveys the healthcare facility identification. Only a single Item shall be permitted in this Sequence."}},{"Institution Name":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0080","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150169","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Institution where the equipment is located."}},{"Instrument manufacture":{" limit":"1000","Synonym":"Instrument manufacture resource","CurationStatus":"uncurated","SuperCategory":"Material service resource"," format":"CSV","Id":"nlx_res_20090426","Definition":"A resource that provides the manufacture of a piece of hardware. An example is producing a made to order microarray chip."}},{"Instrument operator":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Investigator","Id":"birnlex_2137"}},{"Instrument role":{" limit":"1000","CurationStatus":"uncuratedThis table is also available in {{#ask: [[has_role::Category:Instrument_role]] ","SuperCategory":"Role"," format":"csv{{#ask: [[has_role::Category:Instrument_role]] ","Id":"nlx_60039","Definition":"The role of the entity (usually inanimate) that an agent uses to perform an action or start a process"}},{"Instrument supplier":{"RelatedTo":"Instrument","Synonym":["Instrument vendor"],"CurationStatus":"uncurated","SuperCategory":"Material resource","Id":"nlx_res_20090448","Definition":"A resource that provides scientific instruments such as microscopes, amplifiers or dissection tools. For example, Grass Instruments is a site that sells amplifiers and other equipment useful for electrophysiology."}},{"Insufficient":{"Synonym":"Inadequate","SuperCategory":"Sufficiency","Id":"PATO_0001628","Definition":"Lacking enough functionality."}},{"Insula":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","AtlasImage":"Insula2.jpg,Insula.jpg,","ConnDefiningCriteriaPMID":"6167896,2860583,9391023,1719041,12819943","Synonym":["Insular cortex","central lobe","insular gyrus","insular lobe","insular region","insulary cortex","island of Reil"],"CurationStatus":"graph position temporary","TomoDefiningCriteria":["Buried in lateral sulcus","covered by opercular parts of frontal","parietal"],"Curator":"Maryann Martone","Has role":["Interoception","Awareness","Visceral Sensation"],"ConnDefiningCriteria":["Receives connections from sensory thalamic nuclei","reciprocal connections with amygdala","parietal lobe","temporal lobe","frontal lobe","basal nuclei"],"CytoDefiningCriteria":["In monkeys","the insula is divided into three cytoarchitectonic areas: (1) a rostroventral agranular eld that is divided into two architectonically distinct zones: the periallocortex surrounding the primary olfactory cortex"],"CytoDefiningCriteriaPMID":"9391023","Created":"2006-10-04","EditorialNote":"I added the synonyms from Brain Info, but I'm still debating whether insular gyrus is a synonym for insular cortex.  I think so, but perhaps needs review.","TopoDefiningCriteriaPMID":"8957561","SynonymPMID":"21789500","DefiningCriteria":"topography","NeuronamesID":"93","Umlscui":"C0021640","SuperCategory":"Regional part of brain","Id":"birnlex_1117","Is part of":"Neocortex","HasRolePMID":"14730305,19096369,2860583,8957561","Definition":"Gray matter of the insular region of the neocortex. In gyrencephalic animals, it is part of the insular lobe and lies in the depths of the lateral fissure and covered by portions of the frontal, parietal and temporal lobes. It includes Brodmann areas 13-16."}},{"Insulin":{"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"CHEBI:5931","Has role":["Hormone"],"Definition":"A hormone composed of 51 amino acids and has a molecular weight of 5808 Da. It is produced in the islets of Langerhans in the pancreas. "}},{"Insulin Glargine recombinant":{"RelatedTo":["Insulin receptor","Insulin-like growth factor 1 receptor","Cathepsin D","Low-density lipoprotein receptor-related protein 2","Carboxypeptidase E","Protein NOV homolog","Insulin-degrading enzyme","HLA class II histocompatibility antigen","DQ(6) alpha chain","HLA class II histocompatibility antigen","DQ(1) beta chain","Retinoblastoma-associated protein","Neuroendocrine convertase 2","Neuroendocrine convertase 1","Insulin-like growth factor-binding protein 7"],"Synonym":["Insulin glargine"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00047","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00047","Definition":"Lantus is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Pharmacology: Used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat. Mechanism of action: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism. Drug type: Approved. Biotech. Drug category: Hypoglycemic Agents"}},{"Insulin Granule":{"PMID":"3013544","Synonym":"Insulin secretory granule","CurationStatus":"uncurated","SuperCategory":"Transport Vesicle","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/3013544","Id":"nlx_27557","Is part of":"Pancreatic Beta Cell","DefiningCitation":["Orci"],"DefinitionPMID":"12879249","Definition":"Membrane-bound secretory granules which contain insulin and occur inside pancreatic beta cells."}},{"Insulin like growth factor 1":{"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_mol_1007001","Has role":"Growth Factor,","Abbrev":"IGF1"}},{"Insulin Lyspro recombinant":{"RelatedTo":["Insulin-like growth factor 1 receptor","Cathepsin D","Low-density lipoprotein receptor-related protein 2","Carboxypeptidase E","Protein NOV homolog","Insulin-degrading enzyme","HLA class II histocompatibility antigen","DQ(6) alpha chain","HLA class II histocompatibility antigen","DQ(1) beta chain","Retinoblastoma-associated protein","Neuroendocrine convertase 2","Neuroendocrine convertase 1","Insulin-like growth factor-binding protein 7"],"Synonym":["Humalog","Insulin Lispro","Humalog (Eli Lily)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00046","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00046","Definition":"Monomeric form of regular insulin hexamer. Absorbed more rapidly than regular insulin. Has a lysine28, proline29 substitution in the B chain Pharmacology: Used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat. Mechanism of action: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism. Drug type: Approved. Biotech. Drug category: Hypoglycemic Agents"}},{"Insulin recombinant":{"RelatedTo":["Insulin receptor","Insulin-like growth factor 1 receptor","Cathepsin D","Low-density lipoprotein receptor-related protein 2","Carboxypeptidase E","Protein NOV homolog","Insulin-degrading enzyme","HLA class II histocompatibility antigen","DQ(6) alpha chain","HLA class II histocompatibility antigen","DQ(1) beta chain","Retinoblastoma-associated protein","Neuroendocrine convertase 2","Neuroendocrine convertase 1","Insulin-like growth factor-binding protein 7"],"Synonym":["Insulin precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00030","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00030","Definition":"51 residue peptide hormone, covalently linked by disulfide bonds. The protein is synthesized in a special non-disease-producing special laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for human insulin production. Pharmacology: Used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat. Mechanism of action: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism. Drug type: Approved. Biotech. Drug category: Hypoglycemic Agents"}},{"Insulin, porcine":{"RelatedTo":["Insulin receptor","Insulin-like growth factor 1 receptor","Cathepsin D","Low-density lipoprotein receptor-related protein 2","Carboxypeptidase E","Protein NOV homolog","Insulin-degrading enzyme","HLA class II histocompatibility antigen","DQ(6) alpha chain","HLA class II histocompatibility antigen","DQ(1) beta chain","Retinoblastoma-associated protein","Neuroendocrine convertase 2","Neuroendocrine convertase 1","Insulin-like growth factor-binding protein 7"],"Synonym":["Insulin precursor"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Insulin","Curator":"ab","Id":"DB00071","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00071","Definition":"Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure Pharmacology: Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat. Mechanism of action: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism. Drug type: Approved. Biotech. Drug category: Hypoglycemic Agents"}},{"Insulin-like peptide":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5114"}},{"Insulin-like peptide 5":{"Created":"2007-09-19","SuperCategory":"Insulin-like peptide","Id":"nifext_5115"}},{"Insurance Plan Identification":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_1050","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150171","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"TBD (retired)."}},{"Insusceptible toward":{"Synonym":"insusceptible","SuperCategory":"Susceptibility toward","Id":"PATO_0001153","Definition":"A quality of lacking susceptibility toward an external stimulus."}},{"Intebrain":{"Synonym":"Diencephalon","DefiningCriteria":"topography","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_158512","Is part of":"Cerebrospinal axis","Definition":"The caudal and ventral topographic division of the forebrain. The interbrain in turn has two great topographic divisions, dorsally the thalamus and ventrally the hypothalamus. This basic division of the macrodissected adult human brain( has been recognized at least since Varolio (1573, p. 13, his \"pars posterior medullae spinalis\"), and it received its current name for vertebrates from Baer (1837, p. 107; in the original German, \"Zwischenhirn\"). This English form of diencephalon (Sharpey et al., 1867) has been used routinely, for example by Sharpey et al. (1867, p. 577), Johnston (1906, p. 25), Strong & Elwyn (1943, p. 12), and Williams & Warwick (1980, p. 953)."}},{"Integral membrane protein":{"Created":"2007-09-06","CurationStatus":"uncurated","SuperCategory":"Molecule role","Id":"nifext_2567","Definition":"A protein with a moiety (either a covalently linked lipid or a transmembrane domain) that is integrated into the hydrophobic core of the bilayer.www.nature.com/nrm/journal/v6/n3/glossary/nrm1591_glossary.html"}},{"Integrative zone":{"RelatedTo":"Action potential","CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001159","Definition":"The initial segment of the axon where the decision is made to initiate an action potential."}},{"Integrin":{"SuperCategory":"Protein","Id":"sao1846292151"}},{"Intended Recipients of Results Identification Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_1011","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150172","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Identification of the physicians who are intended recipients of results. One or more items shall be included in this sequence. If more than one Item, the number and order shall correspond to the value of Names of Intended Recipients of Results (0040,1010)."}},{"Intensifier Size":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1162","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150173","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Diameter of X-Ray intensifier in mm."}},{"Intensity":{"SuperCategory":"Qualitative","Id":"PATO_0000049","Definition":"A quality inhering in a bearer by virtue of possessing or displaying a distinctive feature in type or degree or effect or force."}},{"Inter-Golgi Transport Vesicle":{"SuperCategory":"Transport Vesicle","Id":"sao1382918459","Definition":"A vesicle that mediates transport of cargo within the Golgi complex (for example, between cisternae of the Golgi stack) (Gene Ontology)."}},{"Interaction":{"Synonym":"Interaction type,","CurationStatus":"uncurated","SuperCategory":"Entity","PublicationLink":"http://www.biopax.org/release/biopax-level3.owl#Interaction","Id":"Interaction","Xref":"BioPAX Interaction","Definition":"A biological relationship between two or more entities. Rationale: BioPAX interactions are atomic from modeling perspective, i.e. it is not possible to define sub-interactions. For representing non-atomic continuants with explicit subevents, pathway class should be used. Interactions does not have to be temporally atomic though, for example genetic interactions cover a large span of time. Usage: Interaction is a highly abstract class and in almost all cases it is more appropriate to use subclasses of interaction. It is partially possible to define generic reactions by using generic participants. A more comprehensive method is planned for BioPAX L4 for covering all generic cases like oxidization of a generic alcohol. Synonyms: Process, relationship, event. Examples: protein-protein interaction, biochemical reaction, enzyme catalysis. Taken from BioPAX"}},{"Interanterodorsal nucleus of the thalamus":{"EditorialNote":"Not sure whether this is equivalent to the massa intermedia.  Needs review.","Synonym":"interanterodorsal nucleus of thalamus","CurationStatus":"graph position temporary","NeuronamesID":"1273","SuperCategory":"Regional part of brain","Id":"nlx_144468","Is part of":"Thalamus","Species":"Rodent","Definition":"a group of nerve cells that bridges the midline of the thalamus between the anterodorsal nucleus of the thalamus of the left and right sides. According to Crosby (1962), it is more developed and consistently present in rodents than in primates (adapted from Brain Info)."}},{"Interanterodorsal nucleus of the thalamus of ABA 2009":{"PartiallyOverlapsWith":"Interanterodorsal nucleus of the thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153179","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interanteromedial nucleus of the thalamus of ABA 2009":{"PartiallyOverlapsWith":"Interanteromedial nucleus of the thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153693","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interbrain of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Diencephalon","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153673","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Brain stem of ABA 2009","Species":"Mouse"}},{"Intercalated amygdalar nucleus of ABA 2009":{"PartiallyOverlapsWith":"Intercalated amygdalar nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153608","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Intercalated amygdaloid nuclei":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","EditorialNote":"The intercalated amygdaloid nuclei may be better characterized as a cell group (NIF class) rather than a nucleus, because we describe them in terms of groupings of individual cells rather than masses of gray matter.","Synonym":["Massa intercalata","Massa intercalata of amygdala","intercalated nucleus of the amygdala","intercalated nuclei of amygdala"],"NeuronamesID":"232","CurationStatus":"uncurated","Umlscui":"C0262259","SuperCategory":"Regional part of brain","Id":"birnlex_2683","Is part of":"Amygdala","Definition":"Discrete clusters of cells intercalated among the major amygdaloid nuclei.  They stain darkly in Nissl stains and have been identified in all mammals.  The main groups lie between the lateral-basolateral nuclear coplex and the central and medial nuclei.  Additional cell groups have been described by some in other locations (Millhouse, O. E. The intercalated cells of the amygdala. J Comp Neurol 247: 246-271, 1986).,  Groups of cells located between the lateral basolateral amygaloid nuclear complex and the central nucleus of the amygdala.  They stain darkly in Nissl stains and have been identified in all mammals.  (Millhouse, O. E. The intercalated cells of the amygdala. J Comp Neurol 247: 246-271, 1986)"}},{"Intercalated Disk":{"SuperCategory":"Cell Cell Contact Zone","Id":"sao1152983960","Definition":"Contact site between adjacent cells in cardiac muscle fibers. When observing tissue through a microscope, this is an identifying feature of cardiac muscle.It holds the myofibrils together and permits easy transfer of excitation (depolarization)."}},{"Intercellular Gap Junction Channel":{"SuperCategory":"Junction Complex","Id":"sao-1778046445","Definition":"Junctional complex consisting of two connexons that come together to form a communicating pore between two cells"}},{"Intercellular Junction":{"SuperCategory":"Supra Cellular Structure","Id":"sao1395777368"}},{"Intercellular Junction Site":{"Comment":"The Cell_Cell_Contact_Zone and the Intercellular_Junction are not the same.  The junction only refers to the bridging complex and not the larger region where the junction resides.  The intercellular_Junction is part of a larger cell-cell contact zone.  The cell-cell contact zone may also contain additional junctions and cellular machinery related to the function of the junction.","SuperCategory":"Site","Id":"sao1922892319","Definition":"The site of cell-cell contact containing a morphologically identified junctional complex joining the two cells."}},{"Interchange format":{"CurationStatus":"uncurated","SuperCategory":"Standard specification","Id":"nlx_157907","Keywords":"Resource:CINERGI","Definition":"A specification for how an information model may be serialized for transmission between systems. (CINERGI)"}},{"Interchromatin Granule":{"SuperCategory":"Nuclear Subcomponent","Id":"sao1049471211","Definition":"A class of nuclear body measuring 20-25 nm in diameter and distributed throughout the interchromatin space, linked together by thin fibrils. They are believed to be storage centers for various snRNAs, snRNPs, serine/arginine-rich proteins and RNA polymerase II. A typical mammalian cell contains 25-50 clusters of interchromatin granules. Interchromatin granule clusters do not contain the heterogeneous nuclear RNA-binding proteins (hnRNPs) (Gene Ontology)."}},{"Interdependent self-construal":{"PMID":"21359209","CurationStatus":"uncurated","SuperCategory":"Cognitive process","PublicationLink":"http://www.plosone.org/article/info:doi/10.1371/journal.pone.0016901","Id":"nlx_90639","DefinitionPMID":"21359209","Definition":"A self-concept in which the self is conceptualized in terms of its relationship to others, blurring the distinction between self and others and allows the self to be easily modulated by dynamic social context. "}},{"Interdigitated":{"SuperCategory":"Shape","Id":"PATO_0001960","Definition":"A shape in which parts or projections are interlocked; for example, the fingers of two hands that are clasped."}},{"Interfascicular nucleus raphe of ABA 2009":{"PartiallyOverlapsWith":"Interfascicular nucleus raphe","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153629","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interfascicular Oligodendrocyte":{"SuperCategory":"Oligodendrocyte","Id":"sao1952867392","Definition":"White matter oligodendrocytes that may be aligned in rows (Peters, Palay and Webster, 1991)."}},{"Interferon Alfa-2a, Recombinant":{"RelatedTo":["Interferon-alpha/beta receptor beta chain"],"Synonym":["Interferon alfa-2a","Oral interferon alfa","rIFN-alpha-2a","Roferon A (Hoffmann-La Roche Inc)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00034","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00034","Definition":"Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences. Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. Mechanism of action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. Drug type: Approved. Biotech. Drug category: Antineoplastic Agents. Antiviral Agents"}},{"Interferon Alfa-2b, Recombinant":{"RelatedTo":["Interferon-alpha/beta receptor beta chain"],"Synonym":["Interferon alfa-2b","rIFN-alpha-2b"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00105","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00105","Definition":"Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. Mechanism of action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. Drug type: Approved. Biotech. Drug category: Antineoplastic Agents. Antiviral Agents. Immunomodulatory Agents"}},{"Interferon alfa-n1":{"RelatedTo":["Interferon-alpha/beta receptor beta chain"],"Synonym":["Interferon alpha-2","Interferon alpha-A","LeIF A"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00011","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00011","Definition":"Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. Mechanism of action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. Drug type: Approved. Biotech. Drug category: Antiviral Agents. Immunomodulatory Agents"}},{"Interferon alfa-n3":{"RelatedTo":["Interferon-alpha/beta receptor beta chain"],"Synonym":["interferon alfa-n3","Alferon (Interferon Sciences Inc,)","Alferon LDO"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00018","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00018","Definition":"Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). Pharmacology: Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R. Mechanism of action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents. Antiviral Agents. Immunomodulatory Agents"}},{"Interferon alfacon-1":{"RelatedTo":["Interferon-alpha/beta receptor beta chain"],"Synonym":["CIFN","IFN Alfacon-1","Interferon Consensus","Methionyl","Recombinant Consensus Interferon","Recombinant methionyl human consensus interferon","consensus interferon","methionyl interferon consensus","methionyl-interferon-consensus","rCon-IFN","Advaferon"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00069","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00069","Definition":"Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This protein has a molecular weight of 19,434 daltons. Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. Mechanism of action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. Drug type: Approved. Biotech. Drug category: Antineoplastic Agents. Antiviral Agents. Immunomodulatory Agents"}},{"Interferon beta-1a":{"Synonym":["Fibroblast interferon","IFN-beta","Interferon beta precursor","Avonex (Biogen Inc)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00060","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00060","Definition":"Human interferon beta (166 residues), glycosylated, MW"}},{"Interferon beta-1b":{"RelatedTo":["Interferon-alpha/beta receptor beta chain"],"Synonym":["Fibroblast interferon","IFN-beta","Interferon beta precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00068","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00068","Definition":"Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW"}},{"Interferon gamma-1b":{"RelatedTo":["Interferon-gamma receptor beta chain"],"Synonym":["IFN-gamma","Immune interferon","Interferon gamma precursor","interferon gamma-1b","Actimmune"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00033","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00033","Definition":"Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. Pharmacology: IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring. Mechanism of action: Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes. Drug type: Approved. Biotech. Investigational. Drug category: Antiviral Agents. Immunomodulatory Agents"}},{"Intergeniculate leaflet of the lateral geniculate complex":{"CurationStatus":"uncurated","NeuronamesID":"1956","SuperCategory":"Regional part of brain","Id":"nlx_144470","Is part of":"Lateral geniculate body"}},{"Intergeniculate leaflet of the lateral geniculate complex of ABA 2009":{"PartiallyOverlapsWith":"Intergeniculate leaflet of the lateral geniculate complex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152996","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interlaminar Astrocyte":{"Comment":"We need to create an object property that allows us to assign taxonomy information to classes that are only seen in certain taxa","SuperCategory":"Protoplasmic Astrocyte","Id":"sao-1220620412","Definition":"Glial cell type unique to primates which extend long processes throughout cortical lamina forming pallisades."}},{"Interleukin":{"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_55101","Has role":["Cytokine"],"Definition":"A group of cytokines (secreted proteins/signaling molecules) that were first seen to be expressed by white blood cells (leukocytes), The term interleukine, (inter-) as a means of communication, (-leukin) deriving from the fact that many of these proteins are produced by leukocytes and act on leukocytes. The name is something of a relic though (the term was coined by Dr. Paetkau, University of Victoria); it has since been found that interleukins are produced by a wide variety of body cells. The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4+ T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. (Adapted from Wikipedia)"}},{"Interleukin-1":{"CurationStatus":"uncurated","SuperCategory":"Interleukin","Id":"sao950082944","Has role":"Cytokine","Abbrev":"IL-1","Definition":"A soluble factor produced by monocytes, macrophages, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. IL-1 consists of two distinct forms, IL-1 alpha and IL-1 beta which perform the same functions but are distinct proteins. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. The factor is distinct from INTERLEUKIN-2 (MSH)."}},{"Intermediate acoustic stria":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":["commissure of Held","intermediate acoustic stria (Held)"],"NeuronamesID":"599","CurationStatus":"uncurated","Umlscui":"C0175455","SuperCategory":"Regional part of brain","Id":"birnlex_768","Is part of":["Pontine tegmentum"],"Definition":"White matter structure containing axons arising from cochlear nuclear complex (Brodal, Neurological Anatomy, 3rd ed, 1985, pg 609)"}},{"Intermediate filament":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C0021770","SuperCategory":"Cellular component","Id":"GO:0005882","Is part of":"Cytoskeletal system","Definition":"A cytoskeletal structure that forms a distinct elongated structure, characteristically 10 nm in diameter, that occurs in the cytoplasm of eukaryotic cells. Intermediate filaments form a fibrous system, composed of chemically heterogeneous subunits and involved in mechanically integrating the various components of the cytoplasmic space. Intermediate filaments may be divided into five chemically distinct classes: Type I, acidic keratins; Type II, basic keratins; Type III, including desmin, vimentin and others; Type IV, neurofilaments and related filaments; and Type V, lamins."}},{"Intermediate hypothalamic region":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-09","CurationStatus":"uncurated","NeuronamesID":"375","Umlscui":"C0020669","SuperCategory":"Regional part of brain","Id":"birnlex_1015","Is part of":"Hypothalamus","Abbrev":"IHR"}},{"Intermediate lateral septum":{"PMID":"15211459,2476467","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_74965","Is part of":"Lateral septum"}},{"Intermediate nuclei of the lateral lemniscus":{"PMID":"16856136,7860778","CurationStatus":"uncurated","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_11408","Is part of":"Lateral lemniscus","Abbrev":"ILL"}},{"Intermediate oculomotor nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"485","CurationStatus":"uncurated","Umlscui":"C0175378","SuperCategory":"Regional part of brain","Id":"birnlex_803","Is part of":"Oculomotor nuclear complex","Abbrev":"I3"}},{"Intermediate orbital gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"1278177547","SuperCategory":"Regional part of brain","Id":"birnlex_1247","Is part of":"Orbital gyri complex","Species":"Human"}},{"Intermediate part of hypophysis":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","Synonym":["intermediate lobe of hypophysis","middle lobe of hypophysis","intermediate region of hypophysis"],"CurationStatus":"uncurated","NeuronamesID":"392","Umlscui":"C0175321","SuperCategory":"Regional part of brain","Id":"birnlex_906","Is part of":"Adenohypophysis","Abbrev":"IHP"}},{"Intermediate periventricular nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","NeuronamesID":"377","CurationStatus":"uncurated","Umlscui":"C0694604","SuperCategory":"Regional part of brain","Id":"birnlex_1564","Is part of":"Intermediate hypothalamic region","Abbrev":"IPe"}},{"Intermediate reticular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Intermediate reticular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152989","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Intermediate voltage electron microscope":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Transmission electron microscope","Id":"birnlex_2182","Definition":"Transmission electron microscope cabable of operating at an accelerating voltage in the range of 300-400 KeV"}},{"Intermediodorsal nucleus of the thalamus":{"CurationStatus":"uncurated","NeuronamesID":"1868","SuperCategory":"Regional part of brain","Id":"nlx_144471","Is part of":"Thalamus","Species":"Mouse"}},{"Intermediodorsal nucleus of the thalamus of ABA 2009":{"PartiallyOverlapsWith":"Intermediodorsal nucleus of the thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153302","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Internal angle":{"SuperCategory":"Convex angle","Id":"PATO_0001054","Definition":"Convex angle that is inside two adjacent sides of a polygon."}},{"Internal arcuate fiber bundle":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","EditorialNote":"NeuroNames uses the preferred term \"internal arcuate fibers\", but I'm trying to avoid plurals.  NN preferred term included as a synonym.","Synonym":["arcuate fibers medial lemniscus"],"CurationStatus":"uncurated","NeuronamesID":"792","Umlscui":"C0228533","SuperCategory":"Regional part of brain","Id":"birnlex_1091","Is part of":["Medulla oblongata"],"Abbrev":"ia"}},{"Internal capsule":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C0152341","SuperCategory":"Regional part of brain","Id":"birnlex_1659","Is part of":["Telencephalon","White matter"],"Abbrev":"ic","Definition":"White matter regional part of brain which is flanked by nuclear masses, consisting of both afferent and efferent fibers projecting between the cerebral cortex and the brainstem and spinal cord. It consists of three distinct parts: an anterior limb, posterior limb, and genu. (Adapted from MSH by Maryann Martone)."}},{"Internal Capsule of CIVM postnatal rat brain atlas":{"AtlasImage":["ic p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151549","Is part of":"Major White Matter Structures of CIVM postnatal rat brain atlas","Definition":"The internal capsule and the white matter tracts that flow from it (cerebral peduncles, longitudinal fasciculus, pyramids) are easily segmented on coronal T2-weighted images. These dense white matter tracts appear much darker that a majority of surrounding highly cellular nuclei. The rostral extent of the internal capsule is a dark, vertically oriented, speckled band that appears between the lighter bed nucleus of the stria terminalis medially and the more striated pallidum laterally. Moving caudally, this band becomes thicker, darker and concave medially as it courses lateral to the might lighter appearing diencephalon. Just rostral to the pituitary the internal capsule/cerebral peduncle is bisected by the fimbria and stria terminalis. The medial portion is a thick, dark band at roughly a 45-degree angle that dips slightly in to the hypothalamus. The lateral portion is a very dark triangular region surrounded by the lighter corpus callosum/external capsule laterally, the lighter stria terminalis medially and the speckled caudate/putamen ventrally. Further caudal, the cerebral peduncle becomes a very dark crescent just ventral and medial to the pale-appearing substantia nigra. These crescents coalesce in to a dark circular bundle as they traverse the lighter pontine nuclei and course towards the ventral surface of the brainstem to become the pyramids. The pyramids appear as two very dark circular bundles on the ventral surface of the brainstem and are easy to distinguish from the surrounding trapezoid bodies and medial lemnisci. The pyramids end where they turn dorsally and cross to form the dorsal corticospinal tract of the spinal cord."}},{"Internal capsule of WHS11":{"AtlasImage":"Internal capsule of WHS11.png,","PartiallyOverlapsWith":"Internal capsule","CurationStatus":"uncurated","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143694","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Telencephalon of WHS11","Species":"Mouse","DefinitionPMID":"20600960","Definition":"Delineation of internal capsule in Waxholm mouse brain atlas as seen in T2* volume.  As seen in sagittal: subtly lower intensity region between  caudate  putamen and thalamus.  Modified from Badea's segmentation"}},{"Internal medullary lamina of thalamus":{"Created":"2007-03-03","CurationStatus":"uncurated","Umlscui":"C0228322","SuperCategory":"Regional part of brain","Id":"birnlex_1621","Is part of":"White matter","Abbrev":"iml","Definition":"Predominantly white regional part of thalamus consisting of a Y shaped bundle of fibers that runs the anterior-posterior length of thalamus and divides the thalamus into roughly three regions (MM: 2006-10-26)"}},{"Internalization assay":{"RelatedTo":["receptor trafficking"],"CurationStatus":"uncurated","Comment":"Need to determine whether all internalization assays are receptor internalization assays.","SuperCategory":"Assay","Id":"nlx_152203","Definition":"Assay used to study the translocation of a receptor or molecule from the membrane or extracellular space to an endocytic vesicle"}},{"International affective picture system":{"Created":"5/10/2011 14:46","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00831","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/International_affective_picture_system","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146053","Definition":"a database of photographs used in emotion research."}},{"International Geo Sample Number":{"Synonym":"International GeoSample Number","CurationStatus":"uncurated","SuperCategory":"Identifying value","Id":"nlx_154746","DefiningCitation":"http://www.geosamples.org/aboutigsn","Abbrev":"IGSN","Definition":"A 9-digit alphanumeric code that uniquely identifies samples taken from our natural environment (for example: rock specimens, water samples, sediment cores) as well as related sampling features (sites, stations, stratigraphic sections, etc.).Examples:IGSN:HRV003M16   (Registered object: Malachite specimen from Angola, registered by the Mineralogical Museum of Harvard University)IGSN:WHO000BC7  (Registered object: Dredge CHAIN35-2 St18 D18, registered by the Woods Hole Oceanographic Institution) Syntax:The IGSN is a \"mostly unintelligent\" identifier: The first three digits of the IGSN represent a name space (a unique user code) that uniquely identifies the person or institution that registers the sample. The last 6 digits of the IGSN are a random string of alphanumeric characters. The IGSN follows the syntax of the URN (Uniform Resource Name) which is composed of a 'Namespace Identifier' (NID), a unique, short string, and the 'Namespace Specific String' (NSS). The length of the IGSN has been limited to 9 digits to keep it short enough for use on sample labels and for inclusion in data tables of publications (the number of characters is similar to data, for example, Sr isotope data typically use a 8 character string such as 0.703456). The IGSN is long enough for large institutions such as repositories or museums to register large numbers of samples (with 10 numbers plus 26 letters for the 6 random digits after the user code, a total of 36^6 "}},{"International Standard Book Number":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Identifying value","Id":"birnlex_2388","DefiningCitation":"http://isbntools.com/","Abbrev":"ISBN","Definition":"An ISBN is a 10-digit or 13-digit number that identifies a book for purposes of commerce and supply chains. The last digit of the ISBN is a check digit used to detect transcription errors. This last digit is sometimes an \"x\". 13 digit ISBNs began to appear on January 1 2005, and all ISBN systems are required to support 13 digits by January 1, 2007.The first number or numbers of a 10 digit ISBN identifies the country that issued the publishers prefix; this number is followed by a dash and the publisher prefix. 13-digit ISBN's start with either 978 or 979, and the 9 digits that follow correspond to the first 9 digits of a 10-digit ISBN.The dashes (or spaces) in the ISBN occur in different places depending on the number and are meaningful, but are so frequently omitted that you can't really use the dashes for much."}},{"International Standard Serial Number":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Identifying value","Id":"birnlex_2389","DefiningCitation":"http://www.issn.org/","Abbrev":"ISSN","Definition":"The ISSN is the standardized international code which allows the identification of any serial publication, including electronic serials, independently of its country of publication, of its language or alphabet, of its frequency, medium, etc. The ISSN number,therefore, preceded by these letters, and appears as two groups of four digits, separated by a hyphen , has no signification in itself and does not contain in itself any information referring to the origin or contents of the publication.ISSN numbers are assigned by the ISSN national Centres coordinated in a network. All ISSN are accessible via the ISSN Register. The ISSN is not \"just another administrative number\". The ISSN should be as basic a part of a serial as the title.* As a standard numeric identification code, the ISSN is eminently suitable for computer use in fulfilling the need for file update and linkage, retrieval and transmittal of data.* As a human readable code, the ISSN also results in accurate citing of serials by scholars, researchers, information scientists and librarians.* In libraries, the ISSN is used for identifying titles, ordering and checking in, claiming serials, interlibrary-loan, union catalog reporting etc.* ISSN is a fundamental tool for efficient document delivery. ISSN provides a useful and economical method of communication between publishers and suppliers, making trade distribution systems faster and more efficient, in particular through the use of bar-coding and EDI (electronic data interchange)."}},{"International standard specification":{" limit":"1000","Synonym":"consortium standard specification","Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Standard specification"," format":"CSV","Id":"birnlex_2362"}},{"Interneuron (FBbt Term)":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Neuron","Id":"nlx_147830","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00005125","hasDBXref":"CL:0000099","Definition":"A neuron that is neither a sensory receptor nor a motor neuron."}},{"Internode":{"SuperCategory":"Node Related Site","Id":"sao-206157942","Definition":"Part of nodal complex located underneath the compact myelin in between nodes of Ranvier"}},{"Internode Axon":{"CurationStatus":"uncurated","SuperCategory":"Regional Part Of Cell","Id":"sao830092290"}},{"Interoceptive modality":{"RelatedTo":"Interoception","EditorialNote":"I would consider \"Stimulus\" as a role and so am not equating interoceptive modality with interoception here","CurationStatus":"graph position temporary","SuperCategory":"Stimulus modality","Curator":["Jessica Turner"],"Id":"COGPO:00128","Definition":"The interoceptive modality is the sensory modality that pertains to the sense of interoception, or internal sensations."}},{"Interpeduncular nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":"nucleus interpeduncularis","SynonymPMID":"2426312","CurationStatus":"uncurated","NeuronamesID":"513","Umlscui":"C0175398","SuperCategory":"Regional part of brain","Id":"birnlex_1000","Is part of":"Midbrain tegmentum","Abbrev":"IP"}},{"Interpeduncular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Interpeduncular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153257","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interpeduncular nucleus of WHS11":{"AtlasImage":["Interpeduncular nucleus of WHS11.png"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"Interpeduncular nucleus","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143779","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Midbrain of WHS11","Species":"Mouse","Definition":"Delineation of the interpeduncular nucleus on the Waxholm mouse brain atlas, as seen in T2* weighted volume.  As seen in sagittal: at midline, bright region  bounded by the rostral-ventral pons where it meets the hypothalamus"}},{"Interpolar part of spinal trigeminal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","CurationStatus":"uncurated","NeuronamesID":"335458770","Umlscui":"C0175418","SuperCategory":"Regional part of brain","Id":"birnlex_2646","Is part of":"Spinal trigeminal nucleus","Abbrev":["ISp5"]}},{"Interposed nucleus of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Interpositus Nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153573","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cerebellar nuclei of ABA 2009","Species":"Mouse","Abbrev":"IP"}},{"Interpositus Nucleus":{"Synonym":["interposed cerebellar nuclei","interposed nucleus of the cerebellum"],"CurationStatus":"uncurated","EfferentProjections":["Magnocellular part of red nucleus","Magnocellular part of medial dorsal nucleus","Reticulotegmental nucleus","Inferior olivary complex"],"SuperCategory":"Regional part of brain","Is_part_of":"Deep cerebellar nuclear complex","Id":"nlx_anat_20081242","Is part of":"Deep cerebellar nuclear complex,","EfferentProjectionsPMID":["6189563","6850357","6189563","6189562"],"Abbrev":["Int"]}},{"Interpretation Approval Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0112","SuperCategory":"DICOM term","Id":"nlx_150174","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Date the report or amendment was approved."}},{"Interpretation Approval Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0113","SuperCategory":"DICOM term","Id":"nlx_150175","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Time the report or amendment was approved."}},{"Interpretation Approver Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0111","SuperCategory":"DICOM term","Id":"nlx_150176","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Identifies the approvers of the interpretation. Zero or more Items may be included in this Sequence."}},{"Interpretation Author":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_010C","SuperCategory":"DICOM term","Id":"nlx_150177","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Name of author of interpretation."}},{"Interpretation Diagnosis Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0117","SuperCategory":"DICOM term","Id":"nlx_150178","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A sequence that conveys the interpretation diagnosis. One or more Items may be included in this Sequence."}},{"Interpretation Diagnosis Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0115","SuperCategory":"DICOM term","Id":"nlx_150179","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"Diagnosis produced by the Physician."}},{"Interpretation ID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0200","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150180","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Healthcare provider generated number used to reference the interpretation."}},{"Interpretation ID Issuer":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0202","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150181","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Name of healthcare provider which issued the interpretation ID."}},{"Interpretation Recorded Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0100","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150182","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Date interpretation was dictated or entered."}},{"Interpretation Recorded Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0101","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150183","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Time interpretation was dictated or entered."}},{"Interpretation Recorder":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0102","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150184","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Name of the person who recorded the interpretation."}},{"Interpretation Status ID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0212","SuperCategory":"DICOM term","Id":"nlx_150185","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"An Enumerated Value element used to track production status of the interpretation."}},{"Interpretation Text":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_010B","SuperCategory":"DICOM term","Id":"nlx_150186","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"Text of the interpretation."}},{"Interpretation Transcriber":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_010A","SuperCategory":"DICOM term","Id":"nlx_150187","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Name of person who transcribed the interpretation."}},{"Interpretation Transcription Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0108","SuperCategory":"DICOM term","Id":"nlx_150188","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Date interpretation was transcribed."}},{"Interpretation Transcription Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0109","SuperCategory":"DICOM term","Id":"nlx_150189","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Time interpretation was transcribed."}},{"Interpretation Type ID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4008_0210","SuperCategory":"DICOM term","Id":"nlx_150190","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The type of interpretation."}},{"Interpretive braille reading":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Interpretive verbal activity","Id":"birnlex_1848"}},{"Interpretive listening":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Interpretive verbal activity","Id":"birnlex_1895"}},{"Interpretive verbal activity":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Verbal activity","Id":"birnlex_1805"}},{"Interpretive vision based reading":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Interpretive verbal activity","Id":"birnlex_1885"}},{"InterSePT Scale for Suicidal Thinking":{"Created":"2008-03-14","CurationStatus":"uncurated","SuperCategory":"Rating scale","Id":"birnlex_3029","Has role":"Mental state assessment","DefiningCitation":["Lindenmayer","J. P.","Czobor","P.","Alphs","L.","Nathan","A.","Anand","R.","Islam","Z.","Chou J.C.Y. & InterSePT Study Group. (2003). The InterSePT scale for suicidal thinking reliability and validity. Schizophrenia Research"],"Abbrev":"InterSEPT","Definition":"The InterSePT Scale for Suicidal Thinking (ISST) is an assessment of current suicidal ideation in patients with schizophrenia and schizoaffective disorders."}},{"Interstitial nucleus of Cajal":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"506","CurationStatus":"uncurated","Umlscui":"C0228418","SuperCategory":"Regional part of brain","Id":"birnlex_1008","Is part of":"Midbrain tegmentum","Abbrev":"ICjl"}},{"Interstitial nucleus of Cajal of ABA 2009":{"PartiallyOverlapsWith":"Interstitial nucleus of Cajal","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153026","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interstitial nucleus of the posterior limb of the anterior commissure":{"CurationStatus":"uncurated","NeuronamesID":"1084","SuperCategory":"Regional part of brain","Id":"nlx_35944","Is part of":"Telencephalon","Species":"Mammal,","Abbrev":"IPAC","Definition":"A group of cells extending caudally with the posterior part of anterior commissure ventral to the striatum  in the mouse  (Paxinos-2001) and the primate  (Fudge-2009) (from Braininfo.org)"}},{"Interstitial nucleus of the vestibular nerve of ABA 2009":{"PartiallyOverlapsWith":"Interstitial nucleus of the vestibular nerve","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153746","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Interthalamic adhesion":{"Synonym":"massa intermedia","CurationStatus":"uncurated","NeuronamesID":"301","SuperCategory":"Regional part of brain","Id":"nlx_144100","Is part of":"Thalamus","Definition":"Median gray matter mass that connects the two thalami;  present in a large percentage of humans (Heimer, L. The Human Brain and Spinal Cord, 2nd ed., 1995, pg 76n)."}},{"Interval Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0016","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150191","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"TBD (retired)."}},{"Intervention":{"Synonym":["experimental intervention"],"CurationStatus":"uncurated","SuperCategory":"Planned process","Id":"C16197","DefiningCitation":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Intervention","Definition":"Activity or measure that produces an effect or that is intended to alter the course of a disease in patient or population. This is a general term encompassing medical, social, behavioral, environmental and other acts that can have preventive and/or therapeutic impact."}},{"Intervention Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_003A","SuperCategory":"DICOM term","Id":"nlx_150192","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"Further description in free form text describing the therapy or other intervention."}},{"Intervention Drug Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0029","SuperCategory":"DICOM term","Id":"nlx_150193","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that identifies the interventional drug."}},{"Intervention Drug Dose":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0028","SuperCategory":"DICOM term","Id":"nlx_150194","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Intervention drug dose, in mg."}},{"Intervention Drug Information Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0026","SuperCategory":"DICOM term","Id":"nlx_150195","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence of Repeating Items that describes the intervention drugs used. Zero or more Items may be included in this sequence."}},{"Intervention Drug Name":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0034","SuperCategory":"DICOM term","Id":"nlx_150196","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Name of intervention drug."}},{"Intervention Drug Start Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0035","SuperCategory":"DICOM term","Id":"nlx_150197","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Time of administration of the interventional drug."}},{"Intervention Drug Stop Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0027","SuperCategory":"DICOM term","Id":"nlx_150198","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Time of completion of administration of the intervention drug."}},{"Intervention Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0036","SuperCategory":"DICOM term","Id":"nlx_150199","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of items describing interventional therapies or procedures."}},{"Intervention Status":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0038","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150200","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Temporal relation of SOP Instance to intervention."}},{"Intra Ocular Pressure":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_000B","SuperCategory":"DICOM term","Id":"nlx_150201","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FL","Definition":"Value of pressure. Value in mmHg. Zero length means the pressure was not measured."}},{"Intracellular Amplifier":{"SuperCategory":"Amplifier","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","Id":"nlx_17117","Has role":"Instrument role","Definition":"Intracellular amplifiers are sometimes referred to as electrometers. They are used to measure potentials within the cytoplasm of a cell. They are typically low gain, very high input impedance amplifiers that incorporate special features to facilitate the unique requirements of intracellular recording."}},{"Intracellular Calcium Channel":{"SuperCategory":"Calcium Channel","Id":"sao1728785226"}},{"Intracellular electrode recording assay":{"Synonym":["Intracellular electrode recording"],"CurationStatus":"uncurated","SuperCategory":"Micro-electrode recording assay","Id":"nlx_inv_090910","Has role":"Electrophysiology concept","Xref":"OBI_0000447"}},{"Intracellular electrode recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Micro-electrode recording protocol","Id":"birnlex_2273","Has role":"Electrophysiology concept","Xref":"OBI_0000447"}},{"Intracellular injection":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Injection","Id":"birnlex_2136","Definition":"Injection of a dye or some other indicator agent into a cell using a micropipette to delineate cell morphology or the distribution of a signal across a single cell. May be in fixed or live tissue."}},{"Intracellular injection protocol":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Microscopy contrast enhancement protocol","Id":"birnlex_2051"}},{"Intracellular Membrane":{"Synonym":"organelle membrane","CurationStatus":"uncurated","Comment":"Gene Ontology has organelle membrane as the preferred term;  intracellular membrane is more commonly used in neuroscience","SuperCategory":"Cellular Membrane","Id":"GO:0031090","Is part of":"Membrane bound organelle","Definition":" The lipid bilayer surrounding an organelle."}},{"Intracristal Space":{"SuperCategory":"Mitochondrial Space","Id":"sao508958414","Definition":"The space bounded by the cristae membrane"}},{"Intradimensional shift task":{"Created":"7/10/2009 14:06","CurationStatus":"uncurated","Contributor":"Agatha Lenartowicz","CAO_Id":"CAO_00832","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Intradimensional_shift_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146054","Definition":"A task in which multiple (typically two) stimuli are presented simultaneously and the subject must select the stimulus that matches the currently relevant rule. The rule represents the relevant task and#34;dimensionand#34;. The stimulus-response mappings within this dimension alternate or and#34;shiftand#34; among multiple (typically two) alternatives."}},{"Intrafusal fiber":{"CurationStatus":"uncurated","SuperCategory":"Muscle Cell","Id":"oen_0001161","Definition":"A specialized muscle fiber that lies within the muscle spindle and whose contraction activates spindle afferents."}},{"Intralaminar nuclear group":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-03","Synonym":["nonspecific thalamic system","nuclei intralaminares (thalami)","intralaminar nuclei of thalamus","intralaminar nuclear group of thalamus"],"CurationStatus":"uncurated","NeuronamesID":"300","SuperCategory":"Regional part of brain","Id":"birnlex_1530","Is part of":"Thalamus,","Abbrev":"ILG"}},{"Intralaminar nuclei of the dorsal thalamus of ABA 2009":{"PartiallyOverlapsWith":"Intralaminar nuclei of the dorsal thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153757","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Intralingual sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"Sulcus Intralingualis","NeuronamesID":"133","CurationStatus":"raw_import","Umlscui":"C0694595","SuperCategory":"Superficial feature part of occipital lobe","Id":"birnlex_4019","Abbrev":"ils"}},{"Intramuscular injection":{"Created":"2006-06-01","CurationStatus":"uncurated","Umlscui":"C0021492","SuperCategory":"Injection","Id":"birnlex_2049","Abbrev":"i.m."}},{"Intranuclear Membrane Space":{"SuperCategory":"Cellular Space","Id":"sao1908934319","Definition":"The space between the inner and outer nuclear membranes"}},{"Intraparietal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["interparietal fissure"],"NeuronamesID":"79","CurationStatus":"uncurated","Umlscui":["C1281069"],"SuperCategory":"Superficial feature part of parietal cortex","Id":"birnlex_4031","Abbrev":"itps"}},{"Intraperotineal injection":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Injection","Id":"birnlex_2144","Abbrev":"i.p."}},{"Intrasonic":{"SuperCategory":"Sound frequency","Id":"PATO_0001524","Definition":"A sound frequency in the range of 0-20 Hz."}},{"Intrathecal":{"CurationStatus":"uncurated","SuperCategory":"Three_dimensional_region","Id":"nlx_inv_090911  ","Definition":"Inside the spinal canal (the canal in successive vertebrae through which the spinal cord passes-Wordnet definition) . For example, intrathecal immunoglobulin production means production of this substance in the spinal cord;  intrathecal injection is an injection into the the spinal canal (intrathecal space surrounding the spinal cord), as in a spinal anaesthesia or in chemotherapy or pain management applications."}},{"Intrathecal injection":{"Created":"2006-06-01","CurationStatus":"uncurated","Umlscui":"C0021896","SuperCategory":"Injection","Id":"birnlex_2150"}},{"Intraventricular injection":{"CurationStatus":"uncurated","SuperCategory":"Injection","Id":"nlx_inv_1005004","Definition":"An injection into one of the ventricles, lateral ventricle, third ventricle, fourth ventricle."}},{"Intrinsic Current":{"CurationStatus":"uncurated","SuperCategory":"Non-selective current","Id":"oen_0001289"}},{"Intrinsic emission imaging protocol":{"Synonym":"Intrinsic emission microscopy","Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Multiphoton imaging protocol","Id":"birnlex_2265"}},{"Intrinsic neuron":{"Synonym":["local circuit neuron"],"CurationStatus":"pending final vetting","SuperCategory":"Defined neuron class","Comment":"Note that the use of interneuron is not consistent between the invertebrate and vertebrate communities* xref: BAMSC961","Id":"nlx_cell_1003113","Xref":"BAMSC961","Definition":"A neuron whose axonal projections do not leave the anatomical region in which its cell soma lies."}},{"Intrinsic neuron (FBbt Term)":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"local interneuron","SuperCategory":"Interneuron (FBbt Term)","Id":"nlx_147398","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003664","Definition":"A neuron arborizing exclusively within a given neuropil domain. Intrinsic (local) interneurons may be ipsilateral, restricted to one of side of a paired neuropil domain, or bilateral, extending a process across the midline and arborizing in both sides of a pair of bilaterally symmetric neuropil domains."}},{"Intrinsic neuron role":{"Created":"2007-08-26","Synonym":["intrinsic neuron","local circuit neuron"],"CurationStatus":"uncurated","Comment":["We are leaving off \"interneuron\" for now"],"SuperCategory":"Projection role of nerve cell","Id":"birnlex_2534"}},{"Intrinsic neuronal circuit":{"Created":"2007-08-25","CurationStatus":"uncurated","SuperCategory":"Circuit part of central nervous system","Id":"birnlex_2515"}},{"Intrinsic pb neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Intrinsic neuron (FBbt Term)","Has_synaptic_terminal_in":"protocerebral bridge","Id":"nlx_147400","Is part of":"Adult central complex","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003666","hasDBXref":"VFB:FBbt_00003666","Definition":"Interneuron that innervates only the protocerebral bridge."}},{"Intrinsic vbo neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Intrinsic neuron (FBbt Term)","Id":"nlx_147399","Is part of":"Adult central complex","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003665","hasDBXref":"VFB:FBbt_00003665","Definition":"Interneuron that innervates only the lateral accessory lobe (ventral body)."}},{"Introverted":{"SuperCategory":"Oriented","Id":"PATO_0001856","Definition":"An oriented quality inhering in a bearer by virtue of being turned inward upon itself.  For example, a tubular organ or part."}},{"Inulin":{"RelatedTo":"Cycloinulo-oligosaccharide fructanotransferase","Synonym":[", Inulin USP 27"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:15443","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00638","Definition":"A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function. (PubChem) Pharmacology: The inulin test is a procedure by which the filtering capacity of the glomeruli (the main filtering structures of the kidney) is determined by measuring the rate at which inulin, the test substance, is cleared from blood plasma. Inulin is one of the more suitable and accurate substance to measure because it is a small, inert polysaccharide molecule that readily passes through the glomeruli. The inulin clearance test is performed by injecting inulin, waiting for it to be distributed, and then measuring plasma and urine inulin concentrations by various assays. As nutraceutical agents inulins may have antitumor, antimicrobial, hypolipidemic and hypoglycemic actions. They may also help to improve mineral absorption and balance and may have antiosteoporotic activity. Mechanism of action: As a diagnostic agent, inulin is readily soluble and essentially indigestible. It readily passes through the blood and into the urine. It is neither secreted nor resorbed by the kidney making it an excellent indicator for renal clearance rates. The inulin clearance test has largely been succeeded by the creatinine clearance test as a measure of glomerular filtration rate. As a hypoglycemic agent, inulin is not digestible by human enzymes ptyalin and amylase, which are designed to digest starch. As a result, inulin passes through much of the digestive system intact. It is only in the colon that bacteria metabolise inulin, with the release of significant quantities of carbon dioxide and/or methane. Because inulin is not broken down into simple sugars (monosaccharides) by normal digestion, it does not elevate blood sugar levels, hence, helping diabetics regulate blood sugar levels. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Diagnostic Agents. Hypoglycemic Agents"}},{"Invaginated":{"SuperCategory":"Concave","Id":"PATO_0001748","Definition":"A shape quality in which a portion of the outermost boundary of an entity folds in space such that a portion that was originally convex is now concave."}},{"Invariant":{"Synonym":["Constant"],"SuperCategory":"Variability","Id":"PATO_0000438","Definition":"A variability quality in a bearer by virtue of lacking or not exhibiting variation."}},{"Invariant color":{"SuperCategory":"Variability of color","Id":"PATO_0001614","Definition":"A variability quality inhering in a bearer by virtue of lacking or not exhibiting variation of color."}},{"Invariant shape":{"SuperCategory":"Variability of shape","Id":"PATO_0001931","Definition":"A quality inhering in a bearer by virtue of lacking or not exhibiting variation of shape."}},{"Invariant temperature":{"SuperCategory":"Variability of temperature","Id":"PATO_0001313","Definition":"A variability quality inhering in a bearer by virtue of lacking or not exhibiting variation of temperature."}},{"Inversion Recovery":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9009","SuperCategory":"DICOM term","Id":"nlx_150202","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Inversion Recovery preparatory sequence. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL. May be present otherwise."}},{"Inversion Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0082","SuperCategory":"DICOM term","Id":"nlx_150203","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Time in msec after the middle of inverting RF pulse to middle of excitation pulse to detect the amount of longitudinal magnetization. Required if Scanning Sequence (0018,0020) has values of IR."}},{"Inversion Times":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9079","SuperCategory":"DICOM term","Id":"nlx_150204","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Times in ms after the middle of inverting RF pulse to middle of excitation pulse to detect the amount of longitudinal magnetization. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL and Inversion Recovery (0018,9009) equals YES. "}},{"Invertebrate":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C1004398","SuperCategory":"Bilateria","Id":"birnlex_131"}},{"Inverted":{"Synonym":["backward"],"SuperCategory":"Oriented","Id":"PATO_0000625","Definition":"An oriented quality inhering in a bearer by virtue of being reversed in position, order, or condition."}},{"Inverted Light Microscope":{"SuperCategory":"Microscope","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","Id":"nlx_86229","Has role":"Instrument role","Definition":"Used in applications such as low to medium magnifications (50X to 200X) such as in patch clamping and large cell injections where the object is in a small liquid bath with circulation and the illumination comes from above the sample. "}},{"Investigation administration role":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Role","Id":"birnlex_11014"}},{"Investigation design":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Information entity","Id":"birnlex_11008"}},{"Investigation record":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Report","Id":"birnlex_11040"}},{"Investigator":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Investigation administration role","Id":"birnlex_11015"}},{"Involute":{"SuperCategory":"Curled","Id":"PATO_0001962","Definition":"A shape inhering in a bearer by virtue of the edges of its surface are rolled inwards spirally on each side."}},{"Inwardly rectifying potassium channel":{"RelatedTo":"Potassium(+)","Synonym":"Kir channel","Created":"2007-09-06","SuperCategory":"Dimeric ion channel","Id":"nifext_2513"}},{"Inwardly rectifying potassium channel - type 1":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2891"}},{"Inwardly rectifying potassium channel - type 2":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2896"}},{"Inwardly rectifying potassium channel - type 3":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2913"}},{"Inwardly rectifying potassium channel - type 4":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2931"}},{"Inwardly rectifying potassium channel - type 5":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2940"}},{"Inwardly rectifying potassium channel - type 6":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2945"}},{"Inwardly rectifying potassium channel - type 7":{"RelatedTo":"Potassium(+)","Created":"2007-09-06","SuperCategory":"Inwardly rectifying potassium channel","Id":"nifext_2954"}},{"Iodixanol":{"Synonym":["Indixanol","Iodixanolum","Visipaque","Visipaque 270"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01249","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01249","Definition":"Visipaque is commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. Pharmacology: Iodixanol is a contrast agent commonly used during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. It is an iso-osmolar contrast agent, with an osmolality of 290 mOsm/kg H20, the same as blood. Mechanism of action: Organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur. Drug type: Approved. Small Molecule. Drug category: Contrast Media"}},{"Iohexol":{"Synonym":[", Exypaque","Histodenz","Nycodenz"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01362","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01362","Definition":"An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. (PubChem) Pharmacology: Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. Mechanism of action: Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iohexol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iohexol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs. Drug type: Approved. Small Molecule. Drug category: Contrast Agents. Contrast Media"}},{"Ion":{"Synonym":["ion","iones","ions","lon"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"CHEBI:24870","Definition":"A molecular entity having a net electric charge."}},{"Ion channel":{"CurationStatus":"uncurated","SuperCategory":"Macromolecule","Id":"nifext_2508"}},{"Ion Channel":{"CurationStatus":"uncurated","SuperCategory":"Macromolecule","Id":"nifext_2508"}},{"Ion channel (nifext 2508)":{"Created":"2007-09-06","CurationStatus":"uncurated","SuperCategory":"Object","Id":"nifext_2508"}},{"Ion channel kinetics":{"RelatedTo":"Ion channel","CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001065","DefiningCitation":"ModelDB:3631"}},{"Ion channel recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Micro-electrode recording protocol","Id":"birnlex_2274","Has role":"\tElectrophysiology concept"}},{"Ion Selective Electrode":{"CurationStatus":"uncurated","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","SuperCategory":"Chemical quantification instrument","Id":"nlx_57518","Has role":"Instrument role","Definition":"Ion selective electrodes can be used with a standard pH meter to detect pH or the activity of Calcium, Potassium or TPP."}},{"Ion-exchange liquid chromotography instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Gravity-driven liquid chromotography instrument","Id":"birnlex_2405"}},{"Ion-sensitive electrode recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Amperometric electrode recording protocol","Id":"birnlex_2289","Has role":"\tElectrophysiology concept"}},{"Ionic current model":{"Synonym":"Membrane current model","Created":"2007-10-10","CurationStatus":"uncurated","SuperCategory":"Physiological model","Id":"birnlex_2304"}},{"Ionotropic Glutamate Receptor":{"CurationStatus":"uncurated","SuperCategory":"Glutamate receptor","Id":"nlx_mol_20090501","Definition":"Cell-surface proteins that bind glutamate and trigger changes which influence the behavior of cells. Ionotropic glutamate receptors include AMPA, kainate, often referred to as AMPA/kainate or A/K receptors and N-methyl-D-aspartate receptors.  These receptors directly control ion channels, and are the most common mediators of fast excitatory synaptic transmission in the central nervous system.  NMDA receptors have also been implicated in the mechanisms of memory and of many diseases."}},{"Iontophoresis system":{"Synonym":"Ionophoresis system","SuperCategory":"Measurement device","Comment":"NIF","Id":"nlx_53859","Has role":"Instrument role","Definition":"Uses a small electrical potential to deliver charged particles to the tissue.  Iontophoretic electrodes typically have 3 or 5 glass pipettes, which are filled with drugs, one is left as the control solution (NaCl) for charge balance."}},{"Iophendylate":{"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01187","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01187","Definition":"A mixture of isomers used as contrast medium, mainly for brain and spinal cord visualization. Iophendylate is a myelographic oil-ester (U.S. Patent 2,348,231). Iophendylate, which was never shown to be safe, was initially introduced for use in small amounts (1-2cc) for locating spinal tumors. It next appeared on the world scene for high volume (12-15cc), routine use, in diagnosing disc herniations. A number of clinicians have published on the dangers of oil myelography. In 1942 Van Wagenen (a neurosurgical colleague of Warrens, at the University of Rochester) identified Iophendylate as causing chemical meningitis in 30 patients where \"space-displacing masses within the spinal canal were suspected\". Pharmacology: Iophendylate is a myelographic oil-ester initially introduced for use in small amounts (1-2cc) for locating spinal tumors. Later, it was found to cause adhesive arachnoiditis. Because these substances are hyperbaric once they were placed in the subarachnoid space they would migrate to the distal portion, where they remained, producing progressive scarring. Mechanism of action: Iophendylate has been shown to be both a radiographic and magnetic resonance (MR) contrast agent in patients with suspected cord abnormalities who underwent MR examination following myelography. The iophendylate appears as a linear band of high signal intensity along the dependent portion of the spinal canal on MR images obtained with a repetition time of 500 msec and an echo time of 30 msec (Radiology. 1986 Feb;158(2):457-60). Drug type: Approved. Small Molecule. Drug category: Contrast Media"}},{"IP neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Serotonergic neuron (FBbt Term)","Id":"nlx_146579","Is part of":"Brain (FBbt Term)","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001587","Definition":"Serotonergic neuron whose cell body is located in one of 2 (bilateral) clusters in the brain: in the larva these clusters occupy the ventral cortex (rind) adjacent to the esophagus aperture, in the adult they are located in the cortex of the inferior-medial protocerebrum."}},{"IP1 receptor":{"Created":"2007-09-19","Synonym":"IP1; PGI receptor; Prostaglandin I2 receptor; Prostanoid IP receptor\tProstacyclin receptor","CurationStatus":"uncurated","SuperCategory":"Prostanoid receptor","Id":"nifext_7284"}},{"IP3R Type 1":{"SuperCategory":"Inositol 1 4 5 Trisphosphate Receptor","Id":"sao383990749"}},{"IP3R Type 2":{"SuperCategory":"Inositol 1 4 5 Trisphosphate Receptor","Id":"sao1920358312"}},{"IP3R Type 3":{"SuperCategory":"Inositol 1 4 5 Trisphosphate Receptor","Id":"sao2003006393"}}]}